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ABSTRACT 
Transcatheter intervention for cardiac valve disease is an attractive alternative to open-
heart surgery, avoiding a thoracotomy and cardiopulmonary bypass, and associated 
morbidity. A limitation of transcatheter intervention is the inability to cut tissue – the 
hallmark of surgery, and what makes it so versatile. During transcatheter valve 
implantation, native diseased valve tissue is displaced rather than resected. However, 
this displacement can occasionally cause fatal complications. In transcatheter mitral 
valve implantation, septal displacement of the anterior mitral valve leaflet can obstruct 
the left ventricular outflow tract. In transcatheter aortic valve implantation, 
displacement of the left or right coronary cusps may obstruct the flow to the coronary 
arteries. 
This thesis explores the use of radiofrequency energy delivered through guidewires 
directed by catheters to enable closed-chest beating-heart valve leaflet laceration using 
marketed devices. We call this technique transcatheter electrosurgery. Two entirely 
novel procedures are developed that use transcatheter electrosurgery techniques to cut 
valve tissue prior to transcatheter valve implantation: LAMPOON (Laceration of the 
Anterior Mitral leaflet to Prevent left ventricular Outflow ObstructioN); and BASILICA 
(Bioprosthetic and native Aortic Scallop Intentional Laceration to prevent Iatrogenic 
Coronary Artery obstruction). Benchtop experiments, pre-clinical procedure 
development in swine, first-in-human “compassionate use” experience, and early 
feasibility clinical trials are described for each procedure.   
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CHAPTER 1. THESIS OVERVIEW 
This thesis is submitted as a ‘thesis incorporating publication’, in accordance with 
Kings College guidelines.  
Summary of Chapters 
This thesis explores the concept and background of transcatheter electrosurgery and 
describes two novel percutaneous cardiovascular interventions for valve disease from 
concept, to animal experiments, to first-in-human, to early feasibility prospective 
clinical trial.  
Chapter 1 provides an overview and specific aims of this thesis. 
Chapter 2 provides an overview of transcatheter electrosurgery with a literature review 
of current applications. Benchtop and simulation experiments exploring the technique 
are described.  
Chapter 3 describes LAMPOON, a technique to lacerate the anterior mitral valve leaflet 
to prevent left ventricular outflow tract obstruction during transcatheter mitral valve 
implantation. The chapter describes pre-clinical animal experiments, first-in-human 
findings, and the early feasibility clinical trial.  
Chapter 4 describes BASILICA, a technique to lacerate the aortic valve leaflets to prevent 
coronary artery obstruction during transcatheter aortic valve implantation. The chapter 
describes benchtop and animal experiments, first-in-human findings, and the early 
feasibility clinical trial. 
Chapter 5 explores future directions using this novel technology.  
Chapter 6 concludes the thesis. 
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Background and Significance 
Heart valve disease is a leading global health problem. The prevalence increases with age and, 
with an ageing population, the disease burden is increasing. Of people over the age of 75, 4.8% 
have moderate or severe aortic valve disease and 9.5% have moderate or severe mitral valve 
disease (1). Patients with heart valve disease suffer reduced functional capacity and increased 
mortality. Many are too frail to undergo open-heart surgery. Transcatheter valve implantation is 
a life-saving treatment for these people. Large multicentre randomized trials have 
demonstrated that transcatheter aortic valve implantation (TAVI) is comparable to or better 
than surgical valve replacement in patients at all levels of surgical risk(2-7). Transcatheter mitral 
valve implantation (TMVI) is significantly more challenging, as the mitral valve is a more 
complex structure in its shape, dynamic nature, and in its integral role as part of the left 
ventricle. Several devices are in early investigation(8).  
The problem: During surgical valve replacement, the patient’s existing valve is cut out and a 
new one sewn in. Transcatheter valves are implanted inside the patient’s existing heart valve, 
displacing the failing valve leaflets. Occasionally, this displacement may fatally obstruct blood 
flow. This catastrophic complication is screened for during pre-procedure CT-image planning 
and patients at risk are excluded from treatment. For TMVI, over 40% of screened patients are 
excluded because of the risk of the displaced anterior mitral valve leaflet obstructing the left 
ventricular outflow tract (LVOT)(9). The incidence of LVOT obstruction after TMVI is 11%, with 
an 62% 30-day mortality(10). In TAVI, bulky aortic leaflets near the coronary ostia is an exclusion 
criterion for treatment. Fewer than 1% of all cases suffer coronary artery obstruction after 
TAVR, but with close to 50% mortality(11,12). 
Scientific premise and rationale: The pathophysiology of obstruction in both TAVI and TMVI is 
the displaced native leaflet. There is currently no transcatheter technique or device that can 
resect existing valve leaflets. Electrosurgery is a technique used to cut or coagulate tissue using 
radiofrequency current through a blunt conducting implement. Interventional cardiologists have 
used this principle to direct current to the tip of a guidewire to cross blockages in vessels, 
between chambers of the heart, or between blood vessels(13-15). We propose to use 
radiofrequency energy to make a controlled cut in valve tissue, and thereby to prevent blood 
flow obstruction following TMVI and TAVI.  
Limitations: Prevention relies on accurate prediction of obstruction, and there are limitations 
to the current prediction models for LVOT obstruction with TMVI (16) and coronary artery 
obstruction with TAVI (11).    
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Specific Aims 
The proposed solution: Transcatheter resection of mitral and aortic leaflets may enable safe 
valve implantation and so increase the number of patients who can access this life-saving 
treatment. Transcatheter electrosurgery techniques, deploying electrical current directed 
through catheters and guidewires, have previously been limited to crossing lesions, occlusions 
or vessel walls. We propose that by simple modification of transcatheter electrosurgery 
techniques, a linear laceration can be achieved. 
I hypothesize that the mitral and aortic valve leaflets can be precisely lacerated using 
transcatheter electrosurgery. I hypothesize that this controlled laceration will prevent blood 
flow obstruction following transcatheter valve implantation. My specific aims are to: 
1. Determine if transcatheter laceration of the mitral valve leaflet prevents left 
ventricular outflow tract obstruction following TMVI 
1A) We will develop a transcatheter procedure in anesthetized pigs to precisely lacerate the 
anterior mitral valve leaflet in line with the LVOT; and 
1B) We will conduct an early feasibility phase 1 study of the procedure in 30 human subjects 
predicted on CT imaging to be at prohibitive risk of LVOT obstruction from TMVI and therefore 
excluded from available treatment. 
2. Determine if transcatheter laceration of the aortic valve leaflets can prevent 
coronary artery obstruction following TAVI 
2A) We will develop a transcatheter procedure in anesthetized pigs to precisely lacerate the left 
and right coronary cusps in line with the coronary arteries; and 
2B) We will conduct an early feasibility phase 1 study of the procedure in 30 human subjects 
predicted on CT imaging to be at prohibitive risk of coronary artery obstruction from TAVI and 
therefore excluded from available treatment. 
If positive, these studies will give patients currently ineligible for transcatheter valve 
implantation an option for treatment. These studies may trigger larger trials, potentially with 
dedicated devices. The ability to cut cardiac tissue in a closed chest and with a beating heart 
may allow other patient-specific interventional therapies in the future.  
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Research Design and Methods 
AIM 1 
To determine if transcatheter electrosurgical laceration of the anterior mitral valve leaflet 
prevents left ventricular outflow tract obstruction following TMVI, we will develop a novel 
procedure in animals and assess the impact on LVOT geometry. If successful, we will conduct a 
phase 1 early feasibility trial in patients.  
Laceration of the anterior mitral leaflet to prevent outflow obstruction (LAMPOON) – 
developing a novel procedure 
Procedures will be performed in anesthetized naïve pigs and guided by biplane X-ray 
fluoroscopy and intracardiac echocardiography, an established model for percutaneous cardiac 
structural intervention. A reproducible technique will be developed using transcatheter 
electrosurgery to cut the anterior mitral leaflet and create enough room in the LVOT for blood 
flow following TMVI. 
Phase 1 clinical trial 
The LAMPOON IDE trial will enroll patients with severe mitral valve disease and high risk of 
mortality with surgery and prohibitive risk of LVOT obstruction with TMVI. We aim to enroll 30 
patients, typical in similar early device studies, with the primary endpoint assessed at 30 days. 
AIM 2 
To determine if transcatheter electrosurgical laceration of the aortic valve leaflets prevents 
coronary artery obstruction following TAVI, we will develop a novel procedure in animals and 
assess the impact on aortic leaflet geometry. If successful, we will conduct a phase 1 early 
feasibility trial in patients. 
Bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic 
coronary artery obstruction (BASILICA) – developing a novel procedure 
Procedures will be performed in anesthetized naïve pigs and guided by biplane X-ray 
fluoroscopy and intracardiac echocardiography, an established model for percutaneous cardiac 
structural intervention. A reproducible technique will be developed using transcatheter 
electrosurgery to cut the left and right coronary cusps to create enough room for blood flow 
into the coronary arteries following TAVI. 
Phase 1 clinical trial 
The BASILICA IDE trial will enroll patients with severe aortic valve disease and high risk of 
mortality with surgery and high risk of coronary artery obstruction with TAVI. We aim to enroll 
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30 patients, typical in similar early device studies, with the primary endpoints assessed at 30 
days.   
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CHAPTER 2. TRANSCATHETER ELECTROSURGERY 
State of the Art Review 
Introduction 
Transcatheter electrosurgery is a technique to traverse or cut tissue, typically within 
blood-filled spaces, using alternating current directed by guidewires and catheters. The 
technique has been applied to traverse occluded arterial and venous lesions, traverse 
between intact as well as atretic cardiac chambers, and, as part of the work developed 
in this thesis, to cut heart valve leaflets. Alternating current in the radiofrequency range 
(approximately 500KHz) is concentrated at the target tissue to heat and vaporize tissue, 
also called ‘cutting’ (1). Electrosurgery should not be confused with electrocautery. 
Electrosurgery relies on transfer of current to the target tissue where the increased 
current density generates heat and vaporization. Electrocautery relies on direct transfer 
of heat from a hot implement to tissue, typically to arrest bleeding. Furthermore, 
electrophysiological catheter ablation differs from transcatheter electrosurgery in that 
radiofrequency energy is used to form non-conductive lesions rather than to vaporize 
tissue. 
Surgeons typically employ electrosurgery using an active electrode, the electrosurgery 
‘pencil’, in a dry air-filled field and under direct operator vision. By contrast, 
transcatheter electrosurgery uses a long guidewire within conductive media (blood) and 
under fluoroscopic or echocardiographic guidance. This has important technical 
implications for charge concentration to achieve cutting, inadvertent charge dispersion 
that impedes cutting, electrode degradation through carbonization, and undesired 
blood coagulation. 
This chapter explores the physics of transcatheter electrosurgery relevant to 
interventional applications. It concludes with a review of contemporary applications of 
the technique. 
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Basic physics of transcatheter electrosurgery 
This section summarizes the principles of charge concentration to heat and vaporize 
target tissue using transcatheter tools. An understanding of these mechanisms will help 
enable the operator to use these techniques safely and effectively.  
Tissue heating and dielectric properties 
The goal of transcatheter electrosurgery is to cut tissue, whether to modify structures or 
allow device traversal. 
Electrosurgery relies on tissue conducting alternating current between two electrodes. 
High frequency alternating currents (~500KHz, or ‘radiofrequency’) are used because 
they do not stimulate nerve and muscle tissue and thus avoid pain, muscle contraction, 
and myocardial fibrillation (2). 
Current conducting through tissue causes resistive heating. Heat is generated by 
collision of ions and corresponds to the work done by charge carriers (ions or electrons) 
to travel to a lower potential. At a certain threshold, the delivered energy breaks down 
polar molecules (for example, water) to create mobile charge particles (for example, 
protons and hydroxide ions). This process, called dielectric breakdown, causes an 
exponential rise in ion collision and therefore in tissue heating. 
The conductivity of tissue increases with its water content. Tissues with high water 
content include muscle, skin, kidney and liver. Tissues with intermediate water content 
include brain, lung and bone marrow. Tissues with low water content include fat and 
bone(1). Tissue permittivity and conductivity values are shown in Table 1. These values 
explain why calcified tissues are harder to vaporize using radiofrequency energy, as are 
synthetic non-conductive materials like certain sutures and graft materials. 
Table 2 shows the behavior of tissues heated to different temperature thresholds at sea 
level (1,3). Irreversible tissue denaturization occurs at 60°C. Intracellular water boils at 
100°C, causing the cells to rupture. In transcatheter electrosurgery, focal temperatures 
to 100°C will vaporize the tissue, effecting “cutting”. Heating of adjacent tissue is 
generally undesirable.  
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Radiofrequency waveforms: cutting versus coagulation 
Targeted tissue vaporization requires a rapid and focal increase in current density, and 
hence temperature rise. This is achieved using continuous alternating currents at high 
voltages over short treatment times (4). Interrupted waveforms, including all varieties 
of ‘blended’ waveforms, allow intercurrent cooling resulting in slower heating and are 
intended to cause coagulation (1) [Figure 1]. While coagulation may be desirable in 
surgical applications to stop bleeding, in the transcatheter endovascular setting blood 
coagulation may cause stroke and other thromboembolic events. Moreover, at slower 
temperature rises, tissues desiccate over wide distances, with loss of water content and 
reduced conductivity, making the tissue more difficult to vaporize. These properties are 
exploited in radiofrequency ablation for treating arrythmias(5). Steam pops, the audible 
sounds produced by intramyocardial tissue vaporization, are a complication of 
electrophysiological ablation and are avoided by controlling the temperature rise. 
Conversely, tissue vaporization is the goal of transcatheter electrosurgery.  
Current Density 
The rate of heating depends on current density in the tissue. The current density 
decreases exponentially with the contact area between the target tissue and the active 
electrode. This is the principle behind improved cutting with plasma arcs, discussed 
below. The current density also decreases exponentially with the distance between 
tissue and active electrode. This enables tissue adjacent to the active electrode to be 
vaporized while sparing deeper layers.  
Plasma Arcs 
Plasma arcs form when the medium between two electrodes ionizes due to a strong 
electric field. If ionized molecules bump into other molecules with enough energy, they 
ionize too, leading to avalanche multiplication, creating a plasma cloud. The impedance 
of the medium drops and current increases. Small area arcs concentrate current onto 
the tissue over an area a fraction of the area of the active electrode. Therefore, cutting 
with the electrosurgical knife in the plasma cloud at a short distance is more effective 
than when it touches tissue. At enough power, dramatic plasma arcs are created and 
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contribute to tissue vaporization. Some electrosurgery generators attempt to reduce 
power in response to sudden impedance drops, in order to suppress arcing. 
Clinical applications 
Prior to this thesis, there were two broad applications for transcatheter electrosurgery: 
radiofrequency perforation to recanalize occlusive lesions and radiofrequency 
perforation to traverse tissue between two cardiovascular chambers. Table 3 
summarizes the evidence for the common clinical applications of this technology. A 
novel application, radiofrequency laceration to make linear cuts in tissue, will be 
explored in the body of this thesis.  
Radiofrequency perforation to recanalize occlusive lesions 
Pulmonary atresia 
The first transcatheter use of radiofrequency energy was to perforate atretic pulmonary 
valves in patients with congenital heart disease and intact ventricular septum (6). 
Purpose built wires were connected to a radiofrequency generator and directed by 
catheters positioned below the atretic valve. The wire was electrified and advanced 
through the valve into the pulmonary artery and balloon dilatation performed. 
Several groups have since published their experience with radiofrequency perforation 
and balloon dilation in pulmonary atresia demonstrating both immediate success and 
satisfactory long-term outcomes with and without downstream surgery (7-11). It is now 
an acceptable first line treatment for this uncommon application (12). 
Vascular occlusion 
Radiofrequency perforation using both off-the-shelf and dedicated devices (PowerWire 
RF, Baylis Medical Company, Burlington, MA) have been used to recanalize peripheral 
and central vascular occlusions following failed conventional antegrade and retrograde 
attempts. These include subclavian vein occlusion (4,13), non-malignant superior vena 
cava obstruction(14), occlusions of the anterior and posterior tibial arteries, common 
iliac vein, and superior vena cava (11), acquired chronic total occlusion of the left 
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pulmonary artery (15), acquired right pulmonary artery atresia (16), interrupted aortic 
coarctation (17), and re-entry for ostial right coronary artery chronic total occlusion 
(18). Transcatheter electrosurgery has been used to successfully restore flow following 
iatrogenic occlusion of the right pulmonary artery, by bioprosthetic bovine jugular vein 
material, after transcatheter pulmonary valve replacement with a Melody valve 
(Medtronic, Minneapolis, MN) (21).  
The Safe Cross radiofrequency guidewire (DSM, Heerleen, Netherlands) combined 
optical coherence reflectometry and radiofrequency energy to tackle chronic totally 
occluded coronary lesions(19) and the PlasmaWire (RetroVascular, Asahi Intecc, Japan) 
uses bipolar radiofrequency guidewires either side of chronic totally occluded 
arteries(20). The former is no longer marketed, and the latter is not yet marketed. 
Radiofrequency perforation of tissue planes between cardiovascular chambers 
Atrial septal puncture 
Atrial septal perforation using radiofrequency energy has been performed through a 
coaxial injectable catheter and radiofrequency wire (Nykanen Radiofrequency 
Perforation Catheter, Baylis Medical Company) (22). A randomized control trial 
comparing radiofrequency and needle transseptal access found reduced procedure 
time, reduced procedure failure, and reduced plastic particulate matter with the 
radiofrequency system (NRG Transseptal needle, Baylis) (23). 
Atrial septal radiofrequency assisted perforation has been performed in newborns with 
hypoplastic left heart syndrome (24). Atrial septal puncture has also been achieved by 
electrifying a Brockenbrough needle (25-27), or a coronary guidewire advanced through 
a transseptal dilator and sheath (28). 
Ventricular septal puncture 
The ventricular septum has been perforated using radiofrequency energy to create a 
ventricular septal defect in a patient with double outflow right ventricle and restrictive 
ventricular septal defect (29). Radiofrequency perforation was used to access the left 
ventricular endocardium for a ventricular tachycardia ablation in a patient with 
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mechanical aortic and mitral valves (30). It has also been used to position an 
endocardial left ventricular lead for cardiac resynchronization therapy (31,32). 
Transcatheter electrosurgery and valve repair 
Pledget-assisted suture tricuspid annuloplasty (PASTA) uses off-the-shelf guidewires to 
traverse myocardial and annular tissue, and then exchange these guidewires for suture 
to effect transcatheter tricuspid annuloplasty resulting in a double orifice valve(33). The 
annulus is traversed with electrified guidewires at target sites on the septal and anterior 
wall. The guidewires are exchanged for sutures that are then plicated to create a double 
orifice valve. PASTA is especially interesting because suture exchange for electrified 
guidewires is an early step towards transcatheter surgery with suture delivery. 
The Mitralign system (Mitralign Inc, Tewksbury, MA), which is not commercially 
available, uses an insulated radiofrequency crossing wire through the mitral or tricuspid 
annulus at adjacent positions to eventually cinch the annulus to reduce regurgitation 
(34). 
Intervascular traversal and extra-anatomic bypass 
Transcaval access 
Transcaval access is an alternative large bore access route when femoral artery access is 
not suitable for TAVR or mechanical assist devices. A stiff coronary guidewire (Astato XS 
20 or amputated Confianza, Asahi Intecc) is insulated in a polymer jacket (Piggyback, 
Teleflex, NC) or other microcatheter and connected to an electrosurgery pencil and 
generator. The wire is electrified at 50W briefly during advancement out of the vena 
cava into the abdominal aorta, where it is snared and exchanged for a stiff wire over 
which the large bore sheath is advanced. TAVR is performed as if it were via usual 
transfemoral access. Arterial extravasation, if any, spontaneously decompresses via the 
hole in the adjoining vena cava. On exit, the hole in the aorta is closed with a nitinol 
cardiac occluder at the end of the case (35,36) or with a dedicated occluder device 
(Transcaval Closure Device, Transmural Systems, Boston) (37). In the prospective 100 
patient NHLBI Transcaval TAVR trial, transcaval access was successful in 99% (38). There 
were no late vascular complications out to 1 year(39). The experience was 
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independently validated in Europe (40). Transcaval access has also been used to 
percutaneously deliver large bore mechanical circulatory assist devices (5.0 Impella, 
Abiomed, Danvers, MA), averting surgical implantation (41). 
Reverse Potts shunt 
Transcatheter electrosurgery enables a non-surgical reverse Potts shunt to decompress 
severe (supra-systemic) pulmonary artery hypertension. A radiofrequency wire is 
advanced from the aorta into the left pulmonary artery, exchanged for a stiff wire and a 
covered stent allows a right-to-left shunt that bypasses the cerebral circulation (42). 
Glenn shunt 
Radiofrequency energy was used for guidewire traversal between superior vena cava 
and pulmonary artery to create a catheter-only, closed chest, large vessel anastomoses, 
equivalent to a bidirectional superior cavopulmonary anastomosis (Glenn shunt) (43-
45). A purpose-built transcatheter Glenn shunt device is under development. 
Transcatheter electrosurgery through synthetic material 
Transcaval TAVR has been performed through a polyester aortic graft(46) and 
radiofrequency assisted transseptal puncture through an atrial septal patch repair(28). 
TEVAR fenestrations have been performed through polyester grafts (Valiant, Medtronic 
Vascular, Santa Rosa, CA; Zenith TX2, Cook Medical, Bloomington, IN) (47). 
Tissue laceration using transcatheter electrosurgery 
The applications described above all require pinhole perforation with the tip of an 
insulated guidewire. For tissue laceration, controlled targeted directional 
radiofrequency delivery is required, with greater care to avoid charring and coagulation 
during potentially longer and higher energy applications. The next section describes 
simulation and benchtop experiments to optimize transcatheter electrosurgery for 
tissue laceration. The chapters following describe two procedures developed using 
transcatheter electrosurgery for precise heart valve laceration.  
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Conclusions 
Tissues vaporize when heated to 100 degrees Centigrade, which can be achieved by 
resistive heating using alternating current directed to the target tissue through 
guidewires and catheters. Sufficient charge concentration is required for tissue 
vaporization, while keeping charge focal to avoid collateral tissue denaturing or 
coagulation. Contemporary applications include recanalization of occluded vessels and 
traversal between cardiac chambers. There is potential to expand the use of 
transcatheter electrosurgery to further modify tissues, beginning with linear laceration. 
J.M. Khan Transcatheter Electrosurgery 26
TABLE 1. Known tissue dielectric properties. 
The tissue dielectric parameters are computed according to the 4-Cole-Cole Model (48) 
at frequency = 10.00 MHz 
Tissue Electrical Permittivity (ε) Electrical Conductivity (σ) 
Blood 280 1.10 
Bone Cancellous 71 0.12 
Bone Cortical 37 0.04 
Fat 14 0.03 
Heart 293 0.50 
Lung (Inflated) 124 0.23 
Muscle (Parallel Fiber) 149 0.67 
Muscle (Transverse Fiber) 171 0.62 
Skin (Wet) 221 0.37 
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TABLE 2. Known tissue effects of heating(1,3) 
Temperature Tissue effect 
49o C Tissue coagulates 
60o C Protein denatures 
70o C Cells desiccate 
100o C Cells rupture from vaporization of intracellular water 
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TABLE 3: Representative clinical applications of transcatheter electrosurgery 
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FIGURE 1 Cutting versus coagulation radiofrequency waveforms 
Schematic diagram of typical radiofrequency (RF) waveforms in cutting mode, intended 
to vaporize tissue, compared with coagulation mode, intended to stop bleeding. Cutting 
mode is typically activated using a yellow-colored button on electrosurgical pencils and 
is associated with continuous-duty radiofrequency energy that constantly heats tissue 
until it vaporizes. Coagulation mode, activated typically using blue-colored buttons on 
electrosurgical pencils, applies interrupted-duty waveforms. The interrupted waveforms 
cause rapid heating-cooling cycles that allow blood to coagulate. 
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Simulation and Benchtop testing 
The rate of heating depends on current density in the tissue. We performed simulations 
to demonstrate the key principals of charge concentration required for transcatheter 
electrosurgery, and to inform transcatheter electrosurgical techniques.  
Comparative electrosurgical properties of commercial guidewires 
Although electrosurgical equipment is commercially available from at least one vendor 
(Baylis Medical Company), we usually use other commercial off-the-shelf guidewires for 
transcatheter electrosurgery, off-label, because they provide mechanical features not 
available in approved products. We tested guidewires from different major 
manufacturers to determine suitability for transcatheter electrosurgery. Guidewires 
were categorized by core material (stainless steel versus nitinol), tip style (core-to-tip 
versus fused shaping ribbon), tip cover (bare spring coils versus spring coils covered in a 
polymer jacket), and hydrophilic tip coating to determine different total-guidewire 
conduction properties. 
There are a variety of electrosurgical generators available. The experiments below were 
all performed with the Valleylab ForceFx generator (Medtronic, MN). Different power 
settings may be required with other commercial generators, many of which have 
adaptive circuitry to modulate power output in response to dynamic impedance 
changes. 
Freshly explanted pig hearts were incompletely submerged in a saline bath. Guidewire 
tips were apposed to myocardial tissue and secured 5cm proximally. Guidewire distal 
shafts were manually denuded of insulating polymer coating and then clamped to an 
electrosurgery generator (Valleylab ForceFx). The guidewire shaft was suspended in air, 
resembling perfect insulation with only the tip in contact with saline and myocardial 
tissue. The minimal power required for instantaneous vaporization, judged by 
unimpeded rapid wire traversal, was noted [Table 1]. 
The results showed that guidewire polymer coating acts as electrical insulation. 
Guidewires with a polymer jacket coating the tip did not penetrate tissue even at 30W, 
whereas guidewires with uncoated bare spring coils penetrated tissue without 
hindrance at 7-13W. When the polymer jacket was excised with a scalpel to expose the 
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spring coils, the guidewires performed similarly to uncoated guidewires. Design 
parameters such as core material (steel versus nitinol), design (core-to-tip versus fused), 
and presence of shaping ribbon did not appear to influence electrosurgical performance 
because all tested metal systems appeared highly conductive. Guidewires with a high tip 
load appear more suitable for transcatheter electrosurgery as they are less likely to 
prolapse when attempting traversal.  
Empirical experience suggests that a guidewire tip voltage of 70V or greater is required 
for tissue traversal (12). Voltages at the guidewire tip in a saline bath were measured by 
oscilloscope at a fixed power output. As expected, the voltage decreased exponentially 
with increased wire exposure in saline. To test properties of different guidewires, all 
guidewires were tested with 2mm of the tip exposed through an insulating polymer 
jacket (Piggyback Wire Converter, Teleflex, NC). Guidewires achieved 70V tip voltage 
when 5-13W power was applied, which corresponds with the traversal tests. 
Current density simulation 
Methods 
The current density simulations were performed using the AC/DC module on Comsol 
Multiphysics (v5.2a, Comsol Inc. MA, USA) simulation software. The biological structures 
were represented as simplified geometries in the simulation setup to reduce the 
computational cost. A 60cm height and 25cm diameter cylinder was used as the blood 
pool. A 3mm height and 10cm diameter disk was placed at the bottom of the blood pool 
to be used as the ground path. The leaflet and the myocardial tissues were represented 
with a 2cm X 0.5cm X 5cm and a 3cm X 20cm X 20cm rectangular blocks, respectively. A 
0.014” guidewire with 0.001” PTFE insulation (representing an Astato XS 20 guidewire, 
Asahi Intecc, Japan) was used as the energized wire. A 3Fr microcatheter was used over 
the energized wire. A 100W power source was used with 100V and 1A voltage and 
current outputs at 700kHz to simulate commercially available electrosurgery units. The 
relative permittivity and the conductivity values were used as 79 and 63 mS/cm for the 
blood, 61 and 49mS/cm for the leaflet and the myocardial tissues, respectively (6). The 
conductivity and the relative permittivity values of dextrose were extrapolated for 
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700kHz and set as 72 and 0.5mS/cm, respectively (7). The dielectric constant of PTFE 
coating was set as 2.1 (8). 
Simulations were run for a comprehensive set of conditions to assess the effects of 
guidewire denudation length, the use of insulating microcatheters and the use of 
dextrose on the current density in blood and the myocardial tissue. First, the effect of 
the guidewire insulation length was studied for a unipolar electrode in blood and in 
contact with the myocardial tissue in blood. Then a pair of bipolar electrodes were 
simulated to compare the current density around and in between the guidewire 
electrodes between the unipolar and bipolar setups. Finally, leaflet laceration conditions 
were simulated on a kinked wire straddling the leaflet tissue. Kinked wire variations 
included intact insulation, insulation focally denuded from the inner surface of the kink, 
the impact of adjacent insulating microcatheters, and the impact of flooding the field 
with dextrose to displace conductive ions in solution. The current density values were 
plotted for each condition in arbitrary units. 
Impact of different electrosurgical guidewire configurations 
Extending an un-insulated electrosurgical guidewire beyond the tip of a catheter allows 
current to disperse and thereby reduces its ability to vaporize and traverse tissue. Figure 
1 demonstrates that current density decreases exponentially as the guidewire electrode 
is extended beyond the insulating catheter tip. Current density also decreases 
exponentially with increased distance from the guidewire electrode. Therefore, both 
limiting the area of exposed guidewire electrode and close approximation with the 
target tissue are important for generating enough current density to vaporize tissue. 
Exposing an electrosurgical guidewire to blood also reduces cutting efficiency. Figure 2 
depicts a catheter delivering an electrified guidewire into tissue though blood, 
compared with the same catheter abutting tissue to deliver the electrified guidewire. As 
always, current follows the path of least resistance. The wire spans a medium with 
higher conductivity (blood) and a medium with lower conductivity (aortic valve leaflet), 
resulting in preferential current flow into the high conductivity medium (blood). In this 
case, there will be no current concentration, and therefore little resistive heating and 
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‘cutting’ of the target tissue. However, if the guidewire is insulated using a 
microcatheter, current will concentrate in and vaporize the target tissue. 
All electrosurgery involves current flow between two electrodes. Figure 4 demonstrates 
current densities in unipolar and bipolar modes. In unipolar mode, current flows 
between an ‘active electrode’ at the target tissue and a broad ‘indifferent’ or ‘dispersive 
electrode’ at a remote site on the skin surface. In a bipolar setup, two active electrodes 
are in close proximity to each other. Bipolar modes generate a larger electric field and 
have traditionally been used for coagulation rather than vaporization, using lower 
energy between two closely positioned static electrodes (1,9). Using static active 
electrodes is undesirable in transcatheter electrosurgery because of electrode 
carbonization and collateral tissue heating and coagulation. Traditionally, unipolar 
modes have been used for tissue cutting, generating concentrated current at an active 
electrode tip as it moves through the target tissue. Precisely applied, unipolar 
radiofrequency can vaporize cells adjacent to the guidewire electrode and spare cells 
only a few layers deep as current decreases exponentially with the radial distance from 
the source (1,10). To date, few transcatheter electrosurgery applications employ bipolar 
mode. 
Simulating transcatheter electrosurgery laceration 
The above demonstrations describe electrosurgical traversal of tissue or valve leaflets 
using the tip of a guidewire. To slice or lacerate a valve leaflet is more challenging. We 
determined the simplest approach to electrosurgical leaflet laceration is to traverse the 
leaflet to straddle both sides and then apply traction during electrification. Traction 
causes the guidewire to bend at the “lacerating surface” where it contacts the leaflet 
edge being cut. We hypothesized that the lacerating surface is more effective if specially 
configured. Using the same parameters for current density simulations above, we tested 
different guidewire configurations for valve tissue laceration.  
Figure 4 simulates current density using the kinked mid-shaft of a guidewire, the “Flying 
V”, which serves as the lacerating surface. Using an unmodified guidewire having intact 
PTFE coating, there is insufficient charge conducted from guidewire to tissue. After 
focally denuding the inner surface at the guidewire kink, charge density around the 
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lacerating surface increases but there is still charge dispersal along the guidewire shaft. 
With insulating microcatheters positioned on either side, charge dispersal along the 
guidewire shaft is reduced, but most of the charge still disperses in blood adjacent to 
the tissue. After displacing blood with 5% dextrose, a non-ionic fluid, alternative current 
paths are minimized and charge concentrates in tissue without heating the surrounding 
blood pool. This allows focal vaporization of target tissue at lower power outputs and 
minimizes char, coagulation, and possible thromboembolism in blood. Concentrating 
current on target tissue by displacing ionic solution with a non-ionic solution is not 
unique to transcatheter electrosurgery. For example, during transurethral 
electrosurgical resection of the prostate, the urethra is irrigated with sterile non-
conductive solution (dextrose or glycerin) (11). 
In vitro laceration testing 
We tested the optimal configurations for the guidewire together with a variety of 
insulation strategies. 
A benchtop model with freshly explanted pig aortas in a saline bath was used to test 
different insulating conditions for electrosurgical laceration (Figure 5A&B). The pulling 
force was maintained at 5N and 30W of “pure cut” radiofrequency energy was delivered 
for 2s and tested in triplicate. These parameters were chosen as they produced 
replicable cutting results in vitro. The laceration distance was measured and compared. 
The results showed no significant cut when an unmodified guidewire was used, or when 
the midshaft was circumferentially denuded. With a partially denuded guidewire that 
was kinked to enforce the denuded segment onto the target tissue, a steady laceration 
was achieved. Additional insulation strategies with microcatheters (Piggyback, Teleflex, 
NC) and 5% dextrose flush demonstrated incremental benefit (Figure 5C). 
This experiment emphasizes the importance of inner curvature charge concentration via 
selective denudation, and of robust insulation with both micro-catheters and non-ionic 
fluid, to concentrate charge for tissue laceration. These essential concepts underlie the 
clinical techniques employed for mitral and aortic leaflet laceration. 
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Conclusions 
Charge concentration is required for target tissue vaporization. Using commercial 
equipment, this can be achieved using microcatheters, selective guidewire denudation, 
and displacement of blood with a non-ionic liquid such as 5% dextrose solution. 
Guidewires with uncoated spring coil tips and high tip load appear most suited to 
transcatheter electrosurgery applications.  
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TABLE 4: Observed power (Watts) required for commercial guidewires to 
traverse tissue under the described in vitro conditions.  
Guidewires (0.014”) that require low traversal power and that have high tip loads appear best 
suited for transcatheter electrosurgery (highlighted in green). Guidewire models that failed to 
traverse even at the highest tested energy (30W) are indicated with an asterisk (*). These non-
traversing models were tested again after manually stripping distal polymer insulation 
(highlighted in orange), at which point they successfully traversed the target tissue at 

















Chronic total occlusion guidewires 
7 Yes Confianza Pro-9 Asahi 300 hydrophilic except 
distal 1mm 
9 
7 Yes Approach CTO-6 Cook 300 hydrophilic 6 
8 Yes Astato XS 20 Asahi 300 hydrophilic except ball 
tip 
20 
8 Yes MIRACLEbros 6 Asahi 180 hydrophobic 6 
8 Yes ProVia 9 Medtro
nic 
300 hydrophilic 9 
8 Yes Progress 200T Abbott 190 hydrophobic 13 
9 Yes Samurai Boston 190 hydrophilic 1.2 
>30* No Pilot150 Abbott 190 hydrophilic 2.7 
>30* No Shinobi Plus Cordis 300 hydrophilic 4 
Extra support guidewires 
8 Yes Iron Man Abbott 190 hydrophobic 1 
8 Yes Grand Slam Asahi 180 hydrophobic 0.7 
8 Yes Platinum Plus Boston 180 hydrophilic 7 
12 Yes Mailman Boston 182 hydrophilic except 
distal 3cm 
0.8 
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Workhorse guidewires 
9 Yes Runthrough NS 
extra floppy 
Terumo 180 hydrophilic 0.6 
11 Yes Balance Middle 
Weight 
Abbott 190 hydrophilic 0.7 
11 Yes Kinetix Boston 185 hydrophilic except 
distal 1.27cm 
0.8 
13 Yes Choice Floppy Boston 182 hydrophobic 0.8 
>30* No Fielder Asahi 180 hydrophilic 1 
>30* No Whisper Abbott 300 hydrophilic 1 
Distal polymer manually stripped to expose conductive spring coils 
7 Yes Fielder Asahi 180 hydrophilic 1 
8 Yes Whisper Abbott 300 hydrophilic 1 
8 Yes Pilot 150 Abbott 190 hydrophilic 2.7 
8 Yes Shinobi Plus Cordis 300 hydrophilic 4 
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FIGURE 2 Insulating a guidewire shaft (with a catheter) concentrates charge at 
the tip and improves effectiveness. 
Current density simulations were performed using the AC/DC module on Comsol
Multiphysics simulation software using methods described in the manuscript. Figure 2 is 
a simulation depicting the electric field around a conductive guidewire as it 
progressively extends beyond an insulating catheter. The top row shows long-axis views 
and the bottom row shows the cross-sectional views of the field in arbitrary units. On 
the left, a guidewire is extending far beyond the tip of an insulating catheter, resulting 
in a modest electrical field around the guidewire tip. Moving towards the middle and 
right columns, the guidewire is extended only minimally beyond the tip of the insulating 
catheter, resulting in marked enhancement of the electrical field. This focused 
insulation significantly increases electrosurgical efficiency, for example, during tissue 
traversal.  
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FIGURE 3 Electrosurgical guidewires should contact tissue directly; blood contact 
reduces effectiveness.  
Simulation depicting a guidewire spanning blood and tissue. In the left column the 
guidewire is exposed in both blood and tissue, with most of the current following the 
path of least resistance and dispersing in blood. In the right column the guidewire is 
insulated from blood so current concentrates through tissue. The bottom rows show 
cross-sectional views at the level of blood and of tissue, respectively. 
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FIGURE 4 Unipolar versus Bipolar modes 
Simulation comparing current density achieved with an exposed unipolar guidewire tip 
with two exposed bipolar guidewire tips, one black and one white, at progressively 
larger separation distances. Note the electrical field lines. Bipolar electrosurgery is less 
effective at-a-distance. The scale shows relative current density. 
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FIGURE 5 Charge density at the “Flying V” is highest when combining inner-
surface denudation, insulating catheters, and dextrose flush 
Impact of focally denuding a kinked guidewire used for electrosurgical laceration of 
leaflet tissue, depicted on electromagnetic simulations. (A) Schematic diagram of an 
electrified Flying V in position across a leaflet to be lacerated. (B) Charge is dispersed 
throughout the length of the guidewire straddling a leaflet. (C) Focally denuding the 
inner surface of the kinked wire increases charge on the inner lacerating surface. (D) 
Apposing two insulating microcatheters further enhances charge concentration on the 
inner lacerating surface. (E) Flooding the field with non-conductive dextrose displaces 
blood ions and further concentrates charge onto leaflet, contributing to more effective 
electrosurgical laceration. 
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FIGURE 6 Optimizing charge density at the “Flying V” 
Benchtop setup and results of testing different guidewire charge concentration 
strategies in pig hearts. (A) the pig hearts are submerged in saline and the traversal wire 
is positioned in a typical transcatheter electrosurgery configuration with suitable 
guiding catheters and microcatheters attached to a force meter (B). Panel (C) shows 
progressive electrosurgery strategies compared using the distance lacerated in a given 
time. More effective strategies traverse a greater distance, including inner-surface 
denudation, closely apposed microcatheters, and flooding the ionic fluid field with non-
ionic dextrose. 
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CHAPTER 3. LAMPOON (incorporating three published 
manuscripts) 
Introduction 
The first specific aim of this thesis was to determine if transcatheter laceration of the 
mitral leaflet prevents left ventricular outflow tract obstruction following TMVI. The 
preceding chapters have summarized the current state of the art of transcatheter 
electrosurgery and explored the physics of transcatheter electrosurgery. This 
chapter describes the first of two novel techniques to lacerate valve tissue using 
transcatheter electrosurgery to prevent blood flow obstruction from transcatheter 
valve implantation. The chapter incorporates three published manuscripts, 
describing the procedure from pre-clinical development through to first-in-human 
experience and finally early feasibility investigation in a prospective clinical trial.  
Transcatheter mitral valve implantation is an emerging treatment for patients with 
mitral valve disease who are not candidates for surgical mitral valve replacement or 
repair. Left ventricular outflow tract obstruction is a common and devastating 
complication of transcatheter mitral valve implantation, caused by septal 
displacement of the anterior mitral valve leaflet. During mitral valve replacement 
surgery, surgeons resect that anterior mitral leaflet to avoid left ventricular outflow 
tract obstruction. Laceration of the Anterior Mitral leaflet to Prevent Outflow 
ObstructioN (LAMPOON) is a transcatheter technique to cut the anterior mitral 
valve leaflet using an electrified guidewire. The preserved chords and the implanted 
mitral prosthesis splay the split leaflet away from the left ventricular outflow tract, 
mimicking surgical chord-sparing leaflet resection, preventing obstruction.  
In line with the specific aims, we developed the novel LAMPOON transcatheter 
procedure in anesthetized pigs to precisely lacerate the anterior mitral valve leaflet 
in line with the LVOT. Also, in line with the specific aims, we conducted an early 
feasibility phase 1 study of the procedure in 30 human subjects predicted on CT 
imaging to be at prohibitive risk of LVOT obstruction from TMVI and therefore 
excluded from available treatment. 
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Role of transcatheter electrosurgery 
Leaflets can be cut mechanically with sharp implements. However, the advantage of 
soft catheters and guidewires is that it allows atraumatic navigation through the 
vasculature. Transcatheter electrosurgery imparts temporary “sharpness” to the 
guidewire when need for traversal and laceration. It enables the LAMPOON 
procedure to be minimally invasive, with percutaneous femoral access, without 
cardiac arrest, guided by echocardiography and fluoroscopy. Transcatheter 
electrosurgery is required first to traverse then lacerate the anterior mitral leaflet, 
which would otherwise either not be lacerated, or avulsed unpredictably. The 
principals learnt from benchtop experiments and simulations are applied to 
concentrate current on the anterior mitral valve leaflet to enable laceration without 
collateral damage.    
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Intentional Laceration of the Anterior Mitral Valve Leaflet to 
Prevent Left Ventricular Outflow Tract Obstruction During 
Transcatheter Mitral Valve Replacement: Pre-Clinical Findings 
An original research manuscript published in the journal JACC: Cardiovascular 
Interventions in 2016. 
Candidate’s contribution 
My colleagues and I conceived of the idea for LAMPOON. I personally devised the 
specific procedure steps, techniques, and inventory. I established how to effectively 
direct current through the mid-shaft of a guidewire. I then established how to 
reproducibly use this to cut the anterior mitral valve leaflet using a transfemoral 
transcatheter approach. I personally performed the animal and benchtop 
experiments. I am first author on the enclosed pre-clinical manuscript, which I 
drafted, designed the figures, and consulted the references. 
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ofOBJECTIVES The authors propose a novel transcatheter transection of the anterior mitral leaflet to prevent iatrogenic
left ventricular outflow tract (LVOT) obstruction during transcatheter mitral valve replacement (TMVR).
BACKGROUND LVOT obstruction is a life-threatening complication of TMVR caused by septal displacement of the
anterior mitral leaflet.
METHODS In vivo procedures in swine were guided by biplane x-ray fluoroscopy and intracardiac echocardiography.
Retrograde transaortic 6-F guiding catheters straddled the anterior mitral leaflet. A stiff 0.014-inch guidewire with polymer
jacket insulation was electrified and advanced from the LVOT, through the A2 leaflet base, into the left atrium. The wire was
snared and externalized, forming a loop that was energized and withdrawn to lacerate the anterior mitral leaflet.
RESULTS The anterior mitral leaflet was successfully lacerated in 7 live and 1 post-mortem swine under heparinization.
Lacerations extended to 89  19% of leaflet length and were located within 0.5  0.4 mm of leaflet centerline. The
chordae were preserved and retracted the leaflet halves away from the LVOT. LVOT narrowing after benchtop TMVR was
significantly reduced with intentional laceration of the anterior mitral leaflet to prevent LVOT obstruction than without
(65  10% vs. 31  18% of pre-implantation diameter, p < 0.01). The technique caused mean blood pressure to fall
(from 54  6 mm Hg to 30  4 mm Hg, p < 0.01), but blood pressure remained steady until planned euthanasia. No
collateral tissue injury was identified on necropsy.
CONCLUSIONS Using simple catheter techniques, the anterior mitral valve leaflet was transected. Cautiously applied
in patients, this strategy can prevent anterior mitral leaflet displacement and LVOT obstruction caused by TMVR.
(J Am Coll Cardiol Intv 2016;9:1835–43) © 2016 by the American College of Cardiology Foundation.m the aCardiovascular and Pulmonary Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute,
tional Institutes of Health, Bethesda, Maryland; bCenter for Structural Heart Disease, Division of Cardiology, Henry Ford Health
stem, Detroit, Michigan; and the cStructural Heart and Valve Center, Emory University Hospital, Atlanta, Georgia. This work was
pported by the Division of Intramural Research (Z01-HL006040), National Heart, Lung, and Blood Institute, National Institutes
Health. Dr. Greenbaum serves as a proctor for Edwards Lifesciences and St. Jude Medical, which manufactures transcatheter
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ABBR EV I A T I ON S
AND ACRONYMS
LAMPOON = laceration of the
anterior mitral leaflet to
prevent left ventricular outflow
tract obstruction
LVOT = left ventricular
outflow tract
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J.M. KhanT ranscatheter stent valves (bothpurpose-built and off-label) areimplanted to relieve mitral valve
failure—whether native, bioprosthetic, or
after annuloplasty—when the risk for mitral
valve surgery is prohibitive (1,2). These
transcatheter mitral stent valves may cause
acute left ventricular outflow tract (LVOT)
obstruction by displacing the anterior mitral
valve leaflet toward the septum. Formalcriteria have not been established, but as in surgery
(3,4), contributors to LVOT obstruction include angu-
lated mitral and aortic annular planes, long or redun-
dant anterior mitral leaflets, small ventricles, bulging
septa, and narrow leaflet-to-septum distance (5–7).
Preparatory or bailout transcoronary alcohol septal
ablation can debulk the septum (8,9) but risks impor-
tant myocardial and conduction system injury. More-
over, alcohol septal ablation is not feasible when
septal thickness is normal and typically requires a
delay of 4 to 6 weeks for remodeling before transcath-
eter mitral valve replacement (TMVR), in highly
symptomatic patients. The anterior mitral leaflet can
be resected during hybrid surgical TMVR but requires
cardiopulmonary bypass (10). We propose a trans-
catheter alternative.
We describe a simple catheter technique to prevent
LVOT obstruction by transecting the anterior mitral
valve leaflet, called laceration of the anterior mitral
leaflet to prevent LVOT obstruction (LAMPOON). The
procedure uses an electrified guidewire that traverses
the leaflet base, between 2 retrograde aortic cathe-
ters, and which then is pulled outward toward the
leaflet tip (Figures 1A and 1B). The split anterior mitral
leaflet no longer obstructs the LVOT after stent valve
implantation and is displaced around the implant by
intact chordae tendineae (Figures 1C to 1F). We
developed and tested the technique in vivo and
ex vivo in swine.
METHODS
LAMPOON TECHNIQUE. The technique has 2 steps:
leaflet traversal followed by leaflet laceration
(Figure 2). Traversal is intended to be performed
before, and laceration after, positioning of the trans-
catheter mitral valve. This would allow rapid valves. Dr. Babaliaros is a consultant for Edwards Lifesciences and Abbo
nter investigation of transcatheter aortic and mitral devices from E
al, and Boston Scientific. All other authors have reported that th
to disclose.
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Transcatheter Electrosurgimplantation during expected hemodynamic com-
promise from intended mitral leaflet laceration.
For leaflet traversal, dual retrograde 6-F guiding
catheters (Vista Brite Tip, Cordis Corporation, Miami
Lakes, Florida) were positioned using 0.035-inch
guidewires, 1 into the left atrium, taking care to
cross the main mitral orifice without chordal entan-
glement, and the other in the LVOT, abutting the
aortomitral curtain. The LVOT catheter was posi-
tioned immediately below the hinge point of the
aortomitral curtain, as confirmed by contrast angi-
ography in a projection that corresponds to a 3-plane
echocardiogram. Alignment along the center of the
anterior leaflet, corresponding to the commissure
between the left and noncoronary cusps of the aortic
valve, was achieved using contrast angiography in a
projection corresponding to a short-axis echocardio-
gram. Intracardiac echocardiography (AcuNav;
Siemens Healthcare, Erlangen, Germany) confirmed
this position. A closed-loop snare (10-mm Amplatz
GooseNeck, Medtronic, Minneapolis, Minnesota)
was positioned through the left atrial catheter
behind the atrial base of the anterior mitral leaflet.
Through the LVOT catheter, a stiff 0.014-inch guide-
wire (Astato XS 20, Asahi-Intecc, Nagoya, Japan)
was extended through an electrically insulating
0.035-inch polymer jacket (Piggyback Wire Convertor
145 cm, Vascular Solutions, Minneapolis, Minnesota)
and directed toward the snare. The proximal guide-
wire was connected via forceps to a monopolar elec-
trosurgery pencil and diathermy generator (Valleylab
Force FX, Medtronic, Minneapolis, Minnesota) set at
30-W continuous duty cycle (“cutting” mode). After
traversal, the Piggyback polymer jacket was with-
drawn, and the free end of the guidewire was exter-
nalized through the retrograde left atrial catheter,
positioned to protect against inadvertent tissue
injury. The result was a transcatheter guidewire loop
around the anterior mitral valve leaflet. No traction
was applied until the laceration procedure was initi-
ated, to avoid causing or exacerbating mitral valve
regurgitation. Correct traversal was confirmed by
angiography through the LVOT catheter and by
echocardiography.
Laceration entails traction on both ends of the
guidewire that has crossed the leaflet base, during
electrification. The intended result is longitudinaltt Vascular; and his employer has research contracts
dwards Lifesciences, Abbott Vascular, Medtronic, St.
ey have no relationships relevant to the contents of
6, accepted June 13, 2016.
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FIGURE 1 Illustrations of the Technique of Intentional Laceration of the Anterior Mitral Valve Leaflet to Prevent Left Ventricular
Outflow Tract Obstruction
(A) Two Judkins left catheters are positioned on either side of the A2 mitral leaflet base. An energized guidewire is advanced from the left
ventricular outflow tract (LVOT) catheter into the left atrial catheter snare. (B) The snared tip is externalized to form a guidewire loop around
the A2 leaflet. This is energized and pulled outward to lacerate the leaflet lengthwise into 2 halves. (C,E) A transcatheter mitral valve implant
tents the anterior mitral leaflet into the septum, obstructing the LVOT. (D,F) Splitting the leaflet by intentional laceration of the anterior
mitral valve leaflet to prevent LVOT obstruction instead causes the 2 tethered halves to displace along either side of the transcatheter valve,
preventing LVOT obstruction.
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1837transection of the anterior mitral valve leaflet, so that
2 remaining flaps are displaced medially and laterally
by the transcatheter mitral valve implant, without
causing LVOT obstruction. To facilitate radio-
frequency ablation energy delivery on the inner
(cutting) side of the guidewire, a 5- to 10-mm sectionJ.M. Khan Transcof the middle shaft of the 0.014-inch guidewire
insulation was denuded by noncircumferential
scalpel abrasion (Figure 3A) and then deliberately
kinked to confine the denuded section to the inner
curvature. The original insulating Piggyback is posi-
tioned to mark and abut 1 margin of the denuded
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FIGURE 2 Fluoroscopy Demonstration of Intentional Laceration of the Anterior Mitral Valve Leaflet to Prevent Left Ventricular Outflow
Tract Obstruction in a Left Oblique Projection
(A) Angiography through the left ventricular outflow tract (LVOT) catheter shows good positioning of this catheter at the base of the anterior
leaflet, below the aortic valve, with a loop snare positioned through the left atrial (LA) catheter. (B) The electrified guidewire is advanced
through the A2 mitral leaflet base into the LA snare. (C) A denuded kinked section of the guidewire, insulated and marked proximally with a
polymer wire convertor further insulated by the 2 guiding catheters, is electrified while the LA catheter is pulled back into the LVOT (position D)
during stage 1 of the 2-step electrosurgical laceration. (D) Stage 2 of the laceration. Both catheters are pulled in tandem during a burst
application of radiofrequency energy, lacerating the leaflet completely and freeing the catheter-guidewire loop.
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J.M. Khanshaft, locked in place, and then the kinked denuded
section is positioned at the intended laceration site.
The guiding catheter tips are apposed within 2 to 5
mm to provide mechanical and electric protection
during laceration. The guidewire-catheter relation-
ships are locked using torque devices, and the
guidewire is clamped to an electrosurgery pencil.
To lacerate, both locked guiding catheters areTranscatheter Electrosurgretracted during brief 2-step electrification. Retrac-
tion force was measured using a force meter (ZP-11,
Imada, Northbrook, Illinois). Afterward, the guiding
catheters are further apposed, and 1 guidewire limb is
pulled through to allow catheter removal.
ANIMAL PROCEDURES. Nonsurvival procedures on
Yorkshire swine (mean weight, 51  7 kg) were
approved by the institutional animal care and use
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FIGURE 3 Guidewire Electrosurgery
(A) A short midshaft section of the electrically insulating polytetrafluoroethylene coating of a 0.014-inch guidewire is stripped using a scalpel
and then kinked, with a polymer jacket wire convertor locked alongside. (B) Infrared images of a saline bath with a denuded guidewire loop
through 2 catheters, replicating in vivo intentional laceration of the anterior mitral valve leaflet to prevent left ventricular outflow tract
obstruction. The guidewire is clipped to an electrosurgery pencil and electrified, revealing a hot spot (bright yellow, arrow) only at the exposed
guidewire loop. (C) A close-up of the guidewire loop reveals no heating around the nearby metallic hemostat, suggesting freedom from electric
coupling.
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1839committee and conducted according to contemporary
National Institutes of Health guidelines. Bilateral
percutaneous femoral artery and vein introducer
sheaths were placed during isoflurane anesthesia
with mechanical ventilation, and animals received
intravenous heparin (150 IU/kg) to achieve an acti-
vated clotting time >350 s. Biplane x-ray fluoroscopy
(Artis Zee, Siemens Healthcare) and intracardiac
echocardiography (AcuNav 8.5-F, Siemens) guided
procedures. Euthanasia and necropsy were per-
formed hours after the procedure.
To test the consequences of wrong crossing
along the aortomitral curtain, an intentionally highJ.M. Khan Transctraversal and laceration was performed. To test
whether flowing blood would obscure thermal injury,
the procedure was also performed in another animal
under heparinization, immediately after euthanasia.
At the conclusion of these nonsurvival experi-
ments, animals were euthanized. In all animals, the
mitral and aortic structures were examined carefully
for thermal or mechanical injury. The laceration po-
sitions and lengths were recorded.
TAVR was not performed in these naive animals,
absent a suitable fixation mechanism, and instead
was performed ex vivo. Native LVOT length (from
aortic root to mitral annulus) and minimum LVOT
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FIGURE 4 Images of the Lacerated Anterior Mitral Leaflet After Intentional Laceration of the Anterior Mitral Valve Leaflet to Prevent
Left Ventricular Outflow Tract Obstruction
(A) Short-axis intraoperative intracardiac echocardiographic image of the mitral valve showing the anterior mitral leaflet (AML) split in 2 equal
halves. (B) The corresponding post-procedural surface rendering of contrast-enhanced computed tomography also displaying split and splayed
leaflets. See Online Video 1. AML ¼ anterior mitral leaflet; LCC ¼ left coronary cusp; NCC ¼ noncoronary cusp; PML ¼ posterior mitral leaflet.
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J.M. Khananteroposterior diameter were measured in explan-
ted hearts following in vivo LAMPOON. Transcatheter
heart valves (23-mm SAPIEN 3, Edwards Lifesciences,
Irvine, California) were implanted at the benchtop at
a 70:30 ventricular position across the annulus, and
LVOT geometry was measured with and without
LAMPOON modification.
IN VITRO HEATING. We performed infrared photog-
raphy (FLIR E40, FLIR, Portland, Oregon) to test
focal midshaft heating during electrification of the
insulation-stripped guidewire. A 2-catheter and
guidewire crossing system was partially submerged in
a saline bath including the electrosurgery indifferent
electrode and held in place by a steel clamp to
simulate potential electric coupling with a trans-
catheter mitral valve (Figure 3B).
IMAGING AND DATA ANALYSIS. Post-procedure
contrast-enhanced CT was performed on a 320-row
volume scanner (Aquilion One Vision, Toshiba,
Tokyo, Japan). Surface renderings were generated on
an image processing workstation (Vitrea version 6.7,
Toshiba).
Data are expressed as mean  SD. LVOT diameters
were compared, before and after simulated TMVR
with and without LAMPOON, using 1-way analysis of
variance and a Student t test with Dunnett’s correc-
tion for multiple comparisons (Prism version 6,
GraphPad Software, La Jolla, California).
RESULTS
IN VIVO FINDINGS. The LAMPOON procedure was
performed in 7 live animals and in 1 post-mortemTranscatheter Electrosurganimal under heparinization. A representative pro-
cedure is depicted in Figure 2. The procedure was
successful in all animals. The mean procedure time
was 55  22 min, including imaging but excluding
anesthesia and vascular access. LAMPOON caused
mean blood pressure to fall by 44% (from 54 6mmHg
to 30  4 mm Hg, p < 0.01), as expected, but blood
pressure remained steady until planned euthanasia
for approximately 4 hours. Retraction force was high
(50 N, 5.1 kg) with an intact and electrified lacerating
guidewire in vivo; retraction force was reduced
(to 15 N, 1.5 kg) using a denuded cutting surface sur-
rounded by an insulated polymer jacket.
In 1 animal, the traversal was intentionally per-
formed “low” to simulate avoiding a calcified basal
leaflet and traversed 52% of the length of the A2
leaflet. In another animal, the traversal was inten-
tionally performed “high” or above the aortomitral
curtain, across the transverse sinus, into the left
atrium, to test a serious complication. This caused a
small pericardial effusion without hemodynamic
change, and the animal was excluded from further
analysis. No other animal had pericardial effusion
after 2  1 h of survival.
Intracardiac echocardiography demonstrated cavi-
tation microbubbles, as expected, during both the
traversal and laceration steps of the procedure.
Intracardiac echocardiography also demonstrated not
only laceration but also splaying of the A2 mitral
leaflet and acute mitral valve regurgitation, as
expected, after LAMPOON (Figure 4A). Concomi-
tantly, in vivo computed tomography demonstrated
splitting and splaying of the A2 mitral valve leaflets
(Figure 4B, Online Video 1).
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FIGURE 5 Benchtop Assessment of Left Ventricular Outflow Tract Geometry Impact
The base of the left ventricle is viewed in cross section after the apex is cut away. (A) A naive heart with the anterior mitral leaflet intact. The trajectory of an intentional
laceration of the anterior mitral valve leaflet to prevent left ventricular outflow tract obstruction (LAMPOON) laceration is depicted by the dashed line. (B) Transcatheter
mitral valve replacement (TMVR) with intact anterior leaflet showing reduced left ventricular outflow tract (LVOT) area. (C) LAMPOON modification made to the
same heart, with the anterior leaflets displaced to the side by TMVR and reduced LVOT obstruction. Flow would be possible through uncovered stent struts. (D) Explant
after in vivo LAMPOON heart showing lacerated anterior leaflet. (E) TMVR in the explanted heart after LAMPOON showing displacement of the anterior leaflet away from
the LVOT. (F) Explanted heart after isolated in vivo LAMPOON viewed from the posterior wall, showing central laceration down the complete length of the anterior
leaflet. The intact subvalvular apparatus displaces the leaflet tips away from the LVOT. LVOT ¼ left ventricular outflow tract; MVO ¼ mitral valve orifice.
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of leaflets revealed jagged transections of the A2
anterior mitral leaflet in all animals (Figure 5F). All
transections were located between major chordal in-
sertions, as intended. The transection lengths were
19  3 mm in leaflets that were 21  4 mm long (89 
19% of leaflet length). The average intercommissural
distance was 32  6 mm; the average position of the
laceration was 0.5  0.4 mm from the center of the
anterior mitral leaflet, as intended. Leaflets were
0.9  0.1 mm thick and showed no visible eschar.
There was no necropsy evidence of injury to
the aortic root or aortic valve, nor disruption of the
mitral subvalvular apparatus, on any animal whether
LAMPOON was performed in vivo or post mortem
in situ.
IN VITRO AND EX VIVO FINDINGS. Infrared photog-
raphy demonstrated that heat during the application
of radiofrequency ablation energy emanated from aJ.M. Khan Transcsingle location, the denuded portion of the guidewire
suspended between insulated guiding catheters
(Figure 3B). A nearby stainless steel clamp, positioned
to simulate a potentially conductive metallic trans-
catheter heart valve, did not exhibit heating, which
would reflect radiofrequency coupling with the abla-
tion guidewire.
IMPACT ON LVOT OBSTRUCTION. Figure 5 demon-
strates LVOT obstruction after benchtop TMVR with
and without preparatory LAMPOON. Figure 5F shows
a typical post mortem result after in vivo LAMPOON.
The 2 halves of the A2 leaflet are parted by the
intact subvalvular apparatus. After benchtop TMVR,
the LVOT anteroposterior diameters fell from 17  3
to 5  4 mm (p < 0.01) without LAMPOON and to
11  2 mm (p < 0.01) with LAMPOON. This repre-
sented a 69  18% reduction in LVOT diameter
following TMVR compared with a 35  10% reduction
following LAMPOON (p < 0.01).
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J.M. KhanDISCUSSION
We demonstrate a new application for transcatheter
electrosurgery to mitigate a life-threatening compli-
cation of TMVR. Using simple catheter techniques, we
can split the anterior mitral valve leaflet, which
otherwise would be displaced anteriorly by the mitral
valve implant and cause LVOT obstruction. The split
leaflet edges are displaced around the transcatheter
valve by chordal structures.
The potential for LVOT obstruction is a key barrier
to TMVR and remains a devastating complication of
early and investigational TMVR for native and post-
annuloplasty mitral valve failure (1,11,12). Imaging
may predict risk for LVOT obstruction (5,6,9) but their
sensitivity and specificity remain uncertain. Never-
theless, it is clear that many patients are excluded
from clinical and investigational transcatheter mitral
valve therapy out of concern for iatrogenic LVOT
obstruction.
LAMPOON may be especially helpful applied pro-
phylactically in patients deemed at high risk for LVOT
obstruction: those with unfavorable left ventricular
geometry, acute aortomitral plane angulation, long
leaflets, and a prominent septal bulge (5,6,9). Without
LAMPOON, operators may feel compelled to implant
TMVR devices higher into the left atrium, which risks
embolization. LAMPOON may allow lower implant
position and more aggressive flaring of the implant,
measures that otherwise would increase the risk for
LVOT obstruction.
By comparison, intentional alcohol infarction to
reduce interventricular septal thickness would best
be performed in a separate procedure, is not suitable
for patients with thin interventricular septa, and risks
conduction injury and exacerbation of myocardial
dysfunction (13).
The procedure sequence in patients would first be
LAMPOON traversal and guidewire externalization,
followed by pre-positioning of the TMVR device into
the left atrium or unexpanded across the mitral
valve, followed by LAMPOON laceration, followed
by TMVR. Patients without baseline severe mitral
valve regurgitation might be expected to experience
severe hypotension between the laceration and
implantation steps, which with proper planning could
be achieved quickly.
STUDY LIMITATIONS. We use radiofrequency abla-
tion to traverse and then lacerate the anterior mitral
leaflet. Our traversal technique is the same as used
to obtain transcaval access to the aorta (14,15) and
relies on radiofrequency power concentration on the
guidewire monopole tip, further insulated by
the Piggyback polymer jacket. For laceration, weTranscatheter Electrosurgovercome the tendency of charge to concentrate on
the outer curvature of the intentionally kinked
guidewire shaft by selectively denuding the inner
curvature. During laceration, we minimize the length
of exposed denuded guidewire by closely approxi-
mating the 2 guiding catheters. Both in vitro and
in vivo, we observed no evidence of electric coupling
to nearby conductive structures, which might heat
the transcatheter mitral valve frame or hinder elec-
trosurgical laceration (16).
Many of the risks and limitations of LAMPOON are
related to incorrect catheter placement and to elec-
trosurgery. An eccentric or low crossing of the ante-
rior leaflet would result in suboptimal parting of the
leaflets. A high crossing may exit into the transverse
sinus, risking pericardial effusion, but the guidewire
can probably be withdrawn and the traversal repeated
in the desired position. Entanglement with chordae
could cause chordal injury or deleterious leaflet
draping over the prosthetic valve and must be avoi-
ded by proper left atrial catheter positioning. We
predict that 3-dimensional transesophageal echocar-
diography, of limited use in swine because of unfa-
vorable anatomy, will be superior to 2-dimensional
intracardiac echocardiography in guiding catheter
position in patients. The risk for thrombus and gas
embolism is mitigated by lower ablation energy and
anticoagulation (17). Thrombus may form on the free
edges of the lacerated leaflet, although we did not
observe it, and may require post-procedural anti-
coagulation. There is a risk for bystander injury to the
aortic valve, which is mitigated by proper insulation
of the electrified guidewire. The role of LAMPOON is
unclear for valve-in-valve TMVR, where chordal at-
tachments are absent. Bailout LAMPOON is not an
option in its current form, as the stent struts of the
implanted valve prosthesis would prevent leaflet
laceration.
This pre-clinical experience is limited to healthy
juvenile swine, which unlike human patients have
pristine noncalcified mitral leaflets and nontortuous
aligned aortas and aortomitral structures. These
structures may be more difficult to align and to
lacerate in patients. Post mortem distortion of cardiac
geometry probably confounds our ex vivo measure-
ments of LVOT obstruction with and without
LAMPOON. LAMPOON was not combined with TMVR
in vivo in these animals, absent suitable valve devices.
LAMPOON would appear better suited in combination
with specific TMVR devices that do not rely on the
intact anterior mitral leaflet for fixation. LAMPOON
may induce hemodynamic compromise of different
severity in human patients with pre-existing mitral
valve disease and abnormal left atrial compliance.
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PERSPECTIVES
WHAT IS KNOWN? TMVR risks life-threatening LVOT
obstruction by displacing the anterior mitral leaflet.
WHAT IS NEW? LAMPOON is a catheter technique to transect
the anterior mitral leaflet, to prevent iatrogenic LVOT
obstruction.
WHAT IS NEXT? On the basis of this series of pre-clinical
experiments, LAMPOON may be ready for cautious investigation
in selected patients at high risk for LVOT obstruction.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 9 , N O . 1 7 , 2 0 1 6 Khan et al.
S E P T E M B E R 1 2 , 2 0 1 6 : 1 8 3 5 – 4 3 Splitting the AML to Enable TMVR
1843CONCLUSIONS
LAMPOON has a promising role in therapy for pa-
tients ineligible for surgery and who have a risk for
developing LVOT obstruction with TMVR. Serious
risks can be mitigated by intraoperative echocardio-
graphic guidance, adequate anticoagulation, and safe
electrosurgical practice. Cautious application may be
warranted in patients requiring TMVR expected to
cause LVOT obstruction but who have no alternative
options.
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Intentional Percutaneous Laceration of the Anterior Mitral Leaflet 
to Prevent Outflow Obstruction During Transcatheter Mitral Valve 
Replacement: First-in-Human Experience 
An original research manuscript published in the journal JACC: Cardiovascular 
Interventions in 2017. 
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For this publication, I drafted the manuscript and figures, and planned and 
proctored the clinical cases. I designed the LAMPOON procedure steps for the first-
in-human cases and prepared the contingency plans. My co-first authors recruited 
and screened the patients and performed the procedures as the primary operators.  
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EdOBJECTIVES This study sought to use a new catheter technique to split the anterior mitral valve leaflet (AML) and
prevent iatrogenic left ventricular outflow tract (LVOT) obstruction immediately before transcatheter mitral valve
replacement (TMVR).
BACKGROUND LVOT obstruction is a life-threatening complication of TMVR, caused by septal displacement of the AML.
METHODS The procedurewas used in patientswith severemitral valve disease and prohibitive surgical risk. Patients either
had prior surgical mitral valve ring (n ¼ 3) or band annuloplasty (n¼ 1) or mitral annular calcification with stenosis (n¼ 1).
Iatrogenic LVOT obstruction or transcatheter heart valve dysfunction was predicted in all based on echocardiography
and computed tomography. Transfemoral coronary guiding catheters directed an electrifiedguidewire across the center and
base of the AML toward a snare in the left atrium. The externalized guidewire loop was then electrified to lacerate the
AML along the centerline from base to tip, sparing chordae, immediately before transseptal TMVR.
RESULTS Five patients with prohibitive risk of LVOT obstruction or transcatheter heart valve dysfunction from TMVR
successfully underwent LAMPOON, with longitudinal splitting of the A2 scallop of the AML, before valve implantation.
Multiplane computed tomographymodeling predictedhemodynamic collapse fromTMVRassuming an intactAML.However,
critical LVOTgradientswerenot seen followingLAMPOONandTMVR.Dopplerbloodflowwasseenacross transcatheterheart
valve struts that encroached the LVOT, because the AML was split. Transcatheter heart valve function was unimpeded.
CONCLUSIONS This novel catheter technique, which resembles surgical chord-sparing AML resection, may
enable TMVR in patients with prohibitive risk of LVOT obstruction or transcatheter heart valve dysfunction.
(J AmColl Cardiol Intv 2017;10:798–809) Published by Elsevier on behalf of the American College of Cardiology Foundation.m the aStructural Heart and Valve Center, Emory University Hospital, Atlanta, Georgia; bCenter for Structural Heart Disease,
nry Ford Health System, Detroit, Michigan; cCardiovascular and Pulmonary Branch, Division of Intramural Research, National
art Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland; and the dChildren’s Healthcare of Atlanta,
ory University, Atlanta, Georgia. Supported without industry funding by the clinical programs of the Structural Heart and Valve
nter, Emory University Hospital; the Center for Structural Heart Disease, Division of Cardiology, Henry Ford Health System; and
Division of Intramural Research (Z01-HL006040), National Heart Lung and Blood Institute, National Institutes of Health.
. Babaliaros is a consultant for Edwards Lifesciences and Abbott Vascular; and his employer has research contracts from
wards Lifesciences, Abbott Vascular, Medtronic, St Jude Medical, and Boston Scientific. Dr. Greenbaum is a proctor for Edwards
Transcatheter Electrosurgery 63
AB BR E V I A T I O N S
AND ACRONYM S
AML = anterior mitral valve
leaflet
CT = computed tomography
LA = left atrium
LAMPOON = laceration of the
anterior mitral leaflet to
prevent left ventricular
outflow tract obstruction
LVOT = left ventricular
outflow tract




THV = transcatheter heart
valve
TMVR = transcatheter mitral
valve replacement
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799T he anterior mitral valve leaflet (AML) is amobile structure that physically separatesinflow and outflow zones of the left ventricle
(1). Preserving the AML during surgical mitral valve
replacement can cause left ventricular outflow tract
(LVOT) obstruction, either when the prosthesis struts
protrude into the LVOTorwhen a long redundant ante-
rior leaflet prolapses into the LVOT (2,3). In a similar
manner, implantation of a transcatheter heart valve
(THV) inside the native or repaired mitral valve en-
forces an “open position” of the AML that may
encroach on the LVOT (4–7). This septal displacement
of the AML is exaggerated when the aortic and mitral
annular planes are acutely angulated rather than paral-
lel, when the interventricular septum bulges toward
the LVOT, when the AML is elongated, and when the
implant extends or flares into the left ventricle. In
this setting transcatheter mitral valve replacement
(TMVR) may cause life-threatening LVOT obstruction
(Figure 1A). Moreover, after TMVR an excessively
long AML may prolapse anteriorly into a narrowed
LVOT as in hypertrophic cardiomyopathy, or it can pro-
lapse posteriorly and interferewith bioprosthetic heart
valve opening or closing bymechanical or Bernoulli ef-
fects after surgical (3) or transcatheter mitral replace-
ment (8). Longer AMLs are more susceptible to these
effects (9). Although few data are available to guide
decision-making, one-half of TMVR candidates having
an intact AML (Mayra Guerrero, personal communica-
tion February 24, 2017; NCT02370511) are excluded
from an ongoing clinical investigation because of the
perceived risk of life-threatening LVOT obstruction.
One approach to prevent or treat TMVR-related
LVOT obstruction is pre-emptive transcoronary
alcohol septal ablation (10,11), which sacrifices
myocardium and risks conduction system injury and
pacemaker-dependence in patients with cardiomy-
opathy, which is unsuitable in patients with thin
interventricular septa, and which delays TMVR by
4 to 6 weeks to allow remodeling in highly symp-
tomatic patients. Another option is surgical AML
resection combined with TMVR during thoracotomy
and cardiopulmonary bypass (12–14), with attendant
risk and morbidity to patients already believed to be
at high risk for cardiac surgery.Lifesciences and St Jude Medical. Dr. O’Neill is a consultant for Edwards
Vascular, and St. Jude Medical; and serves on the Board of Directors of Ne
Lifesciences. Dr. Lerakis is a consultant for Edwards Lifesciences and Abb
Lifesciences; and a proctor for B. Braun. All other authors have reported that t
this paper to disclose. Drs. Babaliaros, Greenbaum, and Khan contributed eq
Manuscript received December 23, 2016; revised manuscript received Janua
J.M. Khan TranscAs an alternative, we have developed a
transcatheter adjunct to TMVR using off-the-
shelf equipment, and described its preclinical
use (15). This technique resembles David’s
(16) surgical anterior resection with chordal
sparing. We create a longitudinal split of the
middle scallop (A2) of the AML, immediately
before TMVR. As a result, chordal attach-
ments displace the split AML away from the
LVOT after the cylindrical THV is implanted,
and blood flows unobstructed across the THV
stent struts (Figure 1B).
We report the initial human experience
with this intentional laceration of the AML
to prevent left ventricular outflow tract
obstruction (LAMPOON) procedure.
METHODSPATIENTS. TMVR with LAMPOON was performed at
2 medical centers, Emory University Hospital and
Henry Ford Hospital. The institutional ethics review
boards of both approved this communication. Five
patients deemed inoperable and believed to have
prohibitive risk of TMVR because of intact native
mitral leaflets consented explicitly to this novel pro-
cedure, as clinical therapy, after consensus from the
local multidisciplinary structural heart teams.
PROCEDURE PLANNING AND IMAGE GUIDANCE.
Baseline electrocardiogram-gated contrast-enhanced
64-detector row cardiac computed tomography (CT)
angiography was obtained to measure annular and/or
annuloplasty dimensions to select a THV. Multiplanar
reconstruction (Vitrea, Toshiba, Tustin, California)
was performed to predict the following working pro-
jections: angle of TMVR deployment perpendicular to
the prosthesis or annulus, a left anterior oblique caudal
projection corresponding to a short-axis CT recon-
struction to depict LAMPOON traversal position along
the medial-lateral dimension, and an attainable right
anterior oblique caudal projection corresponding to a
3-chamber CT reconstruction to depict LAMPOON
traversal position along the leaflet base-to-tip
dimension.Lifesciences, Medtronic, Boston Scientific, Abbott
ovasc Inc. Dr. Thourani is a consultant for Edwards
ott Vascular. Dr. Kim is a consultant for Edwards
hey have no relationships relevant to the contents of
ually to this work.
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FIGURE 1 Views of the Anterior Mitral Valve Leaflet From the LVOT
(A) In this example, transcatheter mitral valve implantation displaces the native anterior
mitral valve leaflet causing LVOT obstruction. (B) After LAMPOON, LVOT obstruction is
reduced and blood flows across the unobstructed struts of the implanted transcatheter
heart valve. (C to E) Illustration of the LAMPOON procedure. (C) In 2 retrograde guiding
catheters are positioned across the aortic valve, 1 into the LVOT and another across the
mitral valve into the left atrium. The LVOT catheter directs an electrified guidewire across
the base of the anterior mitral valve leaflet under echocardiographic guidance into a snare
positioned through the left atrial guiding catheter. (D) Once the guidewire traverses the
mitral leaflet, it is ensnared and externalized. The inset depicts a denuded and kinked
section of the guidewire shaft that directs electrosurgery energy to the leaflet. (E) The
guidewire is electrified and the 2 guiding catheters withdraw it to lacerate the anterior
mitral leaflet lengthwise. LAMPOON ¼ laceration of the anterior mitral leaflet to prevent
left ventricular outflow tract obstruction; LVOT ¼ left ventricular outflow tract.
Online Video 1 is depicted in this figure.
Babaliaros et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 1 0 , N O . 8 , 2 0 1 7
LAMPOON: Splitting the Anterior Mitral Leaflet to Enable TMVR in Patients A P R I L 2 4 , 2 0 1 7 : 7 9 8 – 8 0 9
800
J.M. Khan Transcatheter ElectrosurgA predicted post-TMVR minimum LVOT area
(“threatened neo-LVOT”) area was obtained on a
separate workstation (Mimics, Materialise, Leuven,
Belgium). TMVR was simulated in systole using cyl-
inders corresponding to the known external length
and diameter of the planned THVs, implanted at the
intended depth relative to the mitral annulus (80/20
left ventricle/left atrium [LA]), and the minimum
projected area recorded assuming the AML would be
obstructive only where it contacts the TMVR device.
AML lengths were measured on CT and trans-
esophageal echocardiography (TEE). Long leaflet
length (>30 mm, compared with nominal height 18.0
to 22.5 mm of Sapien 3, Edwards Lifesciences, Irvine,
California) combined with acute aortomitral angle,
was considered an independent risk factor for LVOT
obstruction and THV dysfunction as part of the
multidisciplinary heart team evaluation, accepting
the difficulty modeling this based on static CT im-
ages. TMVR with LAMPOON was performed in a
biplane angiography system at 1 site, and single plane
in the other. All patients underwent general anes-
thesia and intraprocedural TEE.
LAMPOON TECHNIQUE. The LAMPOON procedure
has 3 steps (Online Video 1): leaflet traversal with a
guidewire, followed by leaflet laceration, immedi-
ately followed by TMVR. These are all guided by
fluoroscopy combined with TEE.
For leaflet traversal, 2 6-F coronary guiding cath-
eters (JL3.5) are advanced across the aortic valve
(Figure 1C) through 2 femoral artery sheaths. One
guiding catheter is positioned retrograde in the LVOT
abutting the base of A2 to direct the traversal guide-
wire, and the other retrograde into the LA across the
aortic and mitral valves.
In patientswithmitral stenosis,we found it helpful to
advance the retrogradeLA catheter over a 0.014wire rail
into the transseptal catheter. The rail eases LA catheter
repositioning should it prolapse into the left ventricle.
The rail is formed by advancing a balloon tip catheter
from a transseptal deflectable catheter (Agilis NxT
medium curl, St. Jude Medical, St. Paul, Minnesota) in
the LA through the main orifice of the mitral valve.
The rail is a kink-resistant guidewire (Runthrough NS
0.014-inch, Terumo Interventional Systems, Somerset,
New Jersey), and is externalized after snaring. Through
the retrograde LA catheter, a multiloop snare (Atrieve
18/30, Argon Medical, Plano, Texas) is positioned
alongside the rail and alongside the mitral coaptation
surfaces.
The electrosurgical traversal technique is derived
from the technique of transcaval crossing (17,18). The
traversal guidewire is a 0.014-inch  300 cm
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TABLE 1 Baseline Clinical Characteristics (n ¼ 5)
Age, yrs 64.8  13.2
Female, % 40
Severe pulmonary disease, % 60
Prior stroke, % 40
Atrial fibrillation, % 60
eGFR ml/min/1.73 m2 65.4  11.4
NT-proBNP baseline 432.3  346.9
STS PROM mitral valve replacement, % 8.2  3.6
NYHA CHF functional class 3.8  0.4
TMVR setting TMVR-in-ring ¼ 3
TMVR-in-band ¼ 1
TMVR-in-MAC ¼ 1
Primary lesion (valvular stenosis/regurgitation/mixed) 3/1/1
Ring or band nominal diameter, mm 30.0  2.8
Left ventricular ejection fraction 0.48  0.14
Right ventricular dysfunction, % 80
Echo septal thickness, mm 8.8  1.1
Echo septal thickness amenable to alcohol septal ablation, % 0
Values are mean  SD or %.
CHF ¼ congestive heart failure; eGFR ¼ estimated glomerular filtration rate; MAC ¼ mitral
annular calcification; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; NYHA ¼ New York
Heart Association; STS PROM ¼ Society of Thoracic Surgeons predicted risk of mortality;
TMVR ¼ transcatheter mitral valve replacement.
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801guidewire (Astato XS 20, Asahi Intecc USA, Santa Ana,
California) inside an insulating polymer jacket wire
convertor (Piggyback, Teleflex Vascular Solutions,
Minneapolis, Minnesota), inside the retrograde LVOT
guiding catheter. The external back end of the
guidewire is connected via hemostatic forceps to an
electrosurgery pencil and generator (ValleyLabFX,
Medtronic Covidien, Minneapolis, Minnesota), set to
“pure” cutting mode at 50 W. The traversal guidewire
is advanced from the LVOT catheter, penetrating the
base of the A2 scallop, during brief (<1 s) electrifica-
tion into the prepositioned left atrial snare
(Figure 1D). The wire is captured and externalized
through the retrograde LA catheter.
A short segment along the middle of the guidewire
shaft is noncircumferentially denuded of its polymer
insulation, and then kinked, using a scalpel. This
minor modification focuses electrosurgery energy
required for laceration on the “inner elbow” of the
guidewire (Figure 1D, inset). The radiopaque tip of
the Piggyback wire converter is locked behind the
denuded kinked segment for added fluoroscopic vis-
ibility and electrical insulation. The kinked segment
is positioned to straddle the AML.
For laceration, both free guidewire ends are firmly
pulled during electrification in a series of brief (<1 s)
steps. Pulling the guidewires helps to oppose the
guiding catheters, to protect the aortic valve, and to
initiate laceration at the base of the AML (Figure 1E).
Further tension on the guidewires completes the
splitting of the AML.
ANTEGRADE TRANSSEPTAL TMVR TECHNIQUE.
TMVR was performed via an antegrade transseptal
route using Edwards Sapien 3 devices. The rigid
TMVR guidewire was delivered into the left ventricle
after first crossing the major mitral orifice using a
balloon wedge endhole catheter, and atrial septos-
tomy performed using 12-to-16-mm balloon dilatation
catheters to ensure transseptal THV delivery. Tension
was applied to the LAMPOON catheter system under
fluoroscopy to ensure the TMVR guidewire was not
entrapped. The THV was positioned in the left atrium
or partway across the mitral valve before LAMPOON
laceration to facilitate rapid deployment in case of
early hemodynamic compromise.
TMVRwas performed immediately after LAMPOON,
using rapid right ventricular pacing and slow balloon
inflation. After the first inflation, the THV delivery
balloon was advanced slightly forward and reinflated
with at least 4 ml additional inflation volume to flare
the ventricular aspect of the THV stent. At the
conclusion of the procedure, the iatrogenic atrial
septal defect was closed based on operator discretion.J.M. Khan TranscPOST-PROCEDURE IMAGE AND DATA ANALYSIS.
Post-procedure invasive pressure and Doppler echo-
cardiography gradients were recorded across the
LVOT and THV, using peak-to-peak and peak-
instantaneous measurements as suggested by Geske
et al. (19) for hypertrophic cardiomyopathy. Post-
procedure neo-LVOT was evaluated by echocardiog-
raphy. TMVR encroachment on the LVOT was
measured in B-mode to determine the retrospective
“threatened” LVOT diameter as if LAMPOON had not
been performed, and in color Doppler mode to visu-
alize blood flow across the THV stent struts and
determine the “actual” LVOT diameter. Similarly,
post-procedure CT was evaluated to measure a
“threatened” LVOT area as if LAMPOON had not been
performed. Data were reported as mean  SD or as
median (range) as appropriate.
RESULTS
PATIENTS. Clinical characteristics of the 5 patients
are shown in Table 1. All were believed to have pro-
hibitive surgical risk and no therapeutic alternatives.
None were considered suitable for preparatory
alcohol septal ablation to debulk the LVOT.
The first 4 patients had undergone prior surgical
mitral annuloplasty. The first had a rigid annuloplasty
ring (primarily regurgitant lesion), the next 2 had
semi-rigid rings (1 primarily stenotic and the other
mixed regurgitant/stenotic), the fourth had a flexible
posterior annuloplasty band (primarily stenotic), and
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TABLE 2 Procedure Characteristics, Hemodynamics, and Imaging
(n ¼ 5)
TMVR size, Sapien 3, mm 26 (n ¼ 2);
29 (n ¼ 3)
Crossing power, W 50  0
Lacerating power, W 58  11
LVOT catheter Judkins left length, cm 3.9  0.7
Left atrial retrograde catheter Judkins left length, cm 3.7  0.3
Procedure time, min 214  24
Time from catheter to valve, min 133  19
Time from leaflet traversal to leaflet laceration, min 66  10
Time from laceration to TMVR, min (range) 3.0 (1–38)
Fluoroscopy time, min 116  39
Radiation dose-area product, Gy∙cm2 335  319
Contrast volume, ml 68  41
Iatrogenic atrial septal defect closed 4 of 5
Pressure, mm Hg Before After
Mitral valve gradient mean 9.2  4.2 4.6  4.0
LVOT gradient (range) 7.4  0.5 (7–8) 17.6  12.4 (8–39)
LA mean pressure 25.8  9.2 18.2  4.8
LA v-wave 50.2  15.9 30.0  6.4
PA systolic pressure 72.8  10.9 58.2  15.4
Computed Tomography Characteristics
Aortomitral plane angle, degrees, n ¼ 5 123  10
Neo-LVOT* predicted, mm2, n ¼ 2 67  4
Neo-LVOT* after TMVR, mm2, n ¼ 2,
assuming LAMPOON had not been performed
50  71
Echo Characteristics After TMVR
LVOT max native dimension B-mode after TMVR, mm 17.6  2.1
LVOT vena contracta after TMVR (includes stent-free), mm 11.8  3.5
LVOT stent-free length after TMVR, mm 4.4  4.5
LVOT obstruction threatened diameter,† % 76  24
LVOT obstructed actual diameter, % 34  15
LVOT gradient peak-instantaneous by echo,
pre-discharge, mm Hg
26  11
LVOT gradient peak-instantaneous by echo, 1 month,mmHg 17  10
Values are mean  SD (range). *Neo-LVOT is the minimum cross-sectional area of
the LVOT expected after implantation of the selected valve, based on 3-
dimensional computed tomography analysis. These assume there is no flow
across the struts of the implanted transcatheter heart valve. Neo-LVOT is reported
on the 2 patients with predicted stent encroachment rather than excessive anterior
mitral valve leaflet length. †Threatened diameter refers to the diameter
obstruction of the LVOT assuming there would be no flow across the struts of the
transcatheter heart valve.
LA ¼ left atrium; LAMPOON ¼ laceration of the anterior mitral leaflet to prevent
left ventricular outflow tract obstruction; LVOT ¼ left ventricular outflow tract;
PA ¼ pulmonary artery; other abbreviations as in Table 1.
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J.M. Khanthe fifth had native mitral annular calcification (MAC)
with stenosis.
Three (Patient #1, #2, and #4) were predicted to have
prohibitive risk of LVOT obstruction or THV dysfunc-
tion from long redundant AMLs, with mean AML
length 32  2 mm and average peak-to-peak catheter
resting LVOT gradient 7.4  0.5 mm Hg. Two (Patient
#3 and #5) were predicted to have life-threatening
LVOT obstruction after TMVR with a predicted neo-
LVOT of 67  4 mm2 on the basis of multiplanar CTTranscatheter Electrosurgmodeling. One required intra-aortic balloon pump at
baseline because of intractable heart failure. No others
required mechanical circulatory support.
LAMPOON PROCEDURE. Procedure details are
shown in Table 2. A representative procedure is
depicted in Online Video 2. Preparatory LAMPOON
successfully split the A2 scallop of the AML in all 5
patients. Figures 2 and 3 show representative radio-
graph, TEE, and CT images of a patient undergoing
LAMPOON and TMVR after prior surgical mitral
annuloplasty. Figure 4 shows radiograph and TEE
sequences of a patient undergoing LAMPOON and
TMVR for MAC causing mitral stenosis. Figure 5 shows
the split mitral leaflet in the interval between
LAMPOON and TMVR. Figure 6 shows CT images of a
patient treated for mitral stenosis caused by MAC,
causing pulmonary alveolar hemorrhage. After TMVR
with LAMPOON, the THV is seen spanning the entire
LVOT, and the pleural and pulmonary abnormalities
are dramatically improved.
The blood pressure and heart rate did not decline
in any patient during the 1-to-38-min interval be-
tween LAMPOON and TMVR. Hemodynamic details
are shown in Table 2. The average post-procedure
LVOT catheter gradient was 17.6  12.4 mm Hg
immediately after LAMPOON and TMVR in these pa-
tients otherwise expected to have intolerable LVOT
obstruction or THV dysfunction.
X-plane TEE guided medial-lateral and base-to-tip
positioning of the LVOT catheter before and during
leaflet traversal and laceration, complemented by
left anterior oblique caudal short-axis and right
anterior oblique caudal pseudo-3-chamber fluoro-
scopic projections. A true 3-chamber extreme left
anterior oblique cranial or extreme right anterior
oblique caudal projection was not attainable in any
patient.
POST-LAMPOON IMAGING. LAMPOON created a
new jet of severe mitral regurgitation across the
A2 scallop in all 5 cases (Figure 4F). After TMVR, blood
flow across the THV struts was evident from the left
ventricular inflow into the LVOT, which would not
have been possible if the AML had not been disrupted
(Figures 3A, 3C, 4G, and 4I). Echocardiography and CT
details are summarized in Table 2.
SURVIVAL AND COMPLICATIONS. Four patients
(80%) survived beyond 1 month (197 days [range 23 to
273 days] as of this report). Complications are
described in Table 3. One patient died 23 days after
TMVR with LAMPOON because of intractable right
heart failure that did not improve after TMVR. There
were no procedural strokes, clinically significant
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FIGURE 2 LAMPOON to Enable Transcatheter Mitral Valve Replacement Inside a Flexible Mitral Annuloplasty Band
(A) Left anterior oblique caudal short-axis fluoroscopic projection showing 2 retrograde catheters positioned before anterior mitral valve
leaflet traversal. The retrograde LVOT and LA catheters overlap in this view, as intended. The posterior mitral valve band provides a
fluoroscopic marker to position the LVOT catheter along the base of the A2 scallop. The LA catheter is directing the multiloop snare and is
supported by a transseptal rail through a transseptal sheath. (B) A 3-dimensional transesophageal echocardiograph of the same step, with a
LVOT catheter positioned at the base of the A2 scallop, and the LA catheter pointing a multiloop snare at the other side of the A2 scallop.
(C) Initiation of laceration. The kinked guidewire cutting edge is circled in green. The transcatheter heart valve is pre-positioned at the orifice
of the mitral valve. The LAMPOON guidewire is pulled outward to apply tension. (D) The LAMPOON guidewire is electrified during further
pulling to initiate laceration. (E) Completed laceration, with both retrograde catheters insulating the wire safely in the descending aorta.
The kinked guidewire cutting edge, adjacent to the radiopaque piggyback tip marker, is seen sheathed in the catheter. LA ¼ left atrium;
other abbreviation as in Figure 1. Online Video 2 is depicted in this figure.
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803paravalvular leaks, or major bleeding or vascular
complications of the LAMPOON and TMVR procedure.
In the first patient, the THV embolized immedi-
ately into the left atrium. In retrospect it was signif-
icantly undersized for the rigid annuloplasty ring.
After successful TMVR using a 29-mm Sapien 3 THV,
the embolized valve was secured against the LA
septum using a 35-mm Amplatzer septal occluder.
Patient #5 suffered mild hemolysis, evident from
low haptoglobin and elevated lactate dehydrogenase
levels, and not requiring treatment. Post-procedure
anemia resolved but haptoglobin remained depressedJ.M. Khan Transc4 months later. We suspect this is caused by mechan-
ical red blood cell injury (20) from flow across the
THV struts, because there is no paravalvular leak.
DISCUSSION
We have successfully lacerated the AML using a
straightforward percutaneous technique (LAMPOON)
immediately before TMVR in 5 patients. The tech-
nique resembles chordal-sparing AML resection that
has become a standard in surgical mitral valve
replacement (16,21). The technique succeeded in a
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FIGURE 3 Imaging Immediately After LAMPOON for TMVR-in-Band
These images are from the same patient as in Figure 2. (A) B-mode and color Doppler transesophageal echocardiography after LAMPOON and
TMVR shows the stent struts protruding into the LVOT, and blood flow across those struts indicating successful leaflet splitting. (B) Catheter
pressure measurements across the LVOT show a tolerable gradient of 16 mm Hg. (C) Left ventriculography and (D) contrast computed
tomography after TMVR shows the THV encroaches completely across the LVOT and would nearly completely obstruct it if not
for LAMPOON. AoV ¼ aortic valve; LV ¼ left ventricle; THV ¼ transcatheter heart valve; TMVR ¼ transcatheter mitral valve replacement;
other abbreviations as in Figures 1 and 2. Online Video 2 is depicted in this figure.
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J.M. Khanrange of different TMVR settings: mitral valve rigid
ring annuloplasty, mitral valve semi-rigid ring annu-
loplasty, mitral valve flexible posterior band annulo-
plasty, and native MAC. In patients deemed ineligible
for TMVR because of predicted catastrophic LVOT
obstruction or THV dysfunction, LAMPOON allowed
TMVR without THV dysfunction and generated LVOT
obstruction that was less than otherwise predicted.
The LAMPOON technique is important because 9%
to 22% of patients selected to undergo TMVR in
annuloplasty rings or native MAC experience critical
LVOT obstruction (14,22,23). At present at least one-
third of patients seem to be excluded fromTMVRout of
predicted risk of LVOT obstruction caused by the dis-
placed AML. LAMPOON may allow TMVR in most, or
perhaps all such excluded patients when using
commercially available (uncovered) aortic THV de-
vices off-label. Moreover, long or redundant native
mitral leaflets have occasionally interfered with THVTranscatheter Electrosurgfunction either by direct mechanical interposition or
by creating a low-pressure Bernoulli jet that impairs
THV closure. Three of 5 patients had such long and
redundant AMLs. The LAMPOON technique may pre-
vent this THV dysfunction by displacing the split
mitral leaflet. Finally, the LAMPOON strategy of split-
ting the AML, combined with TMVR devices that allow
flow across uncovered stent struts, should inform
development of future dedicated TMVR devices.
Remarkably, no patient exhibited a change in heart
rate or blood pressure in the short time interval be-
tween LAMPOON mitral laceration and TMVR. In each
case, echocardiography revealed acute exacerbation
of mitral regurgitation. Acute mitral regurgitation
caused by leaflet tethering is a recognized cause of
hemodynamic deterioration in antegrade trans-
venous transseptal transcatheter aortic valve
replacement (24), and unintentional guidewire
laceration of the AML, in a tip-to-base fashion, is a
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FIGURE 4 LAMPOON to Enable TMVR in Native Mitral Annular Calcification
(A to C) Leaflet traversal, (D to F) leaflet laceration, and (G to I) imaging after LAMPOON and TMVR. (A) Guidewire traversal across the base of the anterior
mitral leaflet. Four catheters are in place. An antegrade transseptal sheath, used for TMVR, is currently connected via a guidewire rail to control the retrograde
LA catheter, which is used to deliver the multiloop snare on the LA side of the anterior mitral leaflet. A retrograde catheter in the LVOT is directing the
traversing guidewire. There also is a pigtail catheter in the ascending aorta. (B, C) X-plane TEE immediately after leaflet traversal shows the mid-basal A2
position of the traversal system. Also evident are the 2 catheters and the LA snare. (D)The traversing guidewire tip has beenexternalized. Theguidewire shaft
is denuded, kinked, and exposed between the 2 catheters (green circle), and is electrified to slice the anterior mitral leaflet longitudinally. The THV is pre-
positioned for immediate deployment. (E, F) B-mode and color Doppler TEE after LAMPOON but before TMVR shows severe acute mitral valve regurgitation
across the split A2 leaflet scallop. (G) Left ventriculography after TMVR shows the THV encroaches nearly completely across the LVOT and would nearly
completely obstruct it if not for LAMPOON. (H, I)B-mode and color Doppler TEE after LAMPOONand TMVR shows the stent struts protruding into the LVOT,
and blood flow across those struts indicating successful leaflet splitting. TEE ¼ transesophageal echocardiography; other abbreviations as in Figures 1 to 3.
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FIGURE 5 LAMPOON-Induced Anterior Mitral Leaflet Split
Three sequential diastolic frames of a 3-dimensional echocardiogram performed imme-
diately after LAMPOON but before TMVR. The volume is rendered from a left-atrial
“surgeons view.” (A) A laceration cleft is evident (dotted green line) at the beginning of
diastole in the A2 scallop of the anterior mitral leaflet. (B) The medial half of A2 and the
whole of A3 open early in diastole and then (C) the lateral half of A2 along with the
whole of A1 open a fraction later in diastole. A1 to A3 and P1 to P3 represent the lateral to
medial scallops of the anterior and posterior mitral leaflets, respectively. Abbreviations as
in Figures 1 and 3.
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J.M. Khan Transcatheter Electrosurgrecognized lethal complication of this approach (25).
After LAMPOON, however, we observe a “grace
period” that may reflect adaptation to left atrial vol-
ume and pressure overload from longstanding mitral
stenosis or mitral regurgitation. Nonetheless, in every
case we had pre-positioned the TMVR device in the
left atrium to allow immediate implantation.
We did not observe severe mechanical complica-
tions of the LAMPOON procedure. One theoretical
complication is injury to the aorta or aortic valve; we
mitigated this risk by protecting the laceration wire
surface using rigid braided guiding catheters. Another
is mitral leaflet laceration through a lateral orifice of
the mitral valve, which might leave a residual chorda
that could prevent the split mitral leaflet from draping
around the TMVR device. Another theoretical risk is of
insufficiently basal traversal and laceration of the AML
that causes insufficient leaflet debulking. We do not
believe LAMPOON reduced stability of the THV
implant; THV embolization in the first case reflected
our mistaken selection of an undersized initial device.
We attribute the observed low-grade hemolysis in pa-
tient #5 to nonlaminar flow across the THV struts as it
spans across the LVOT. This would be classified as a
mild complication according to the Mitral Valve Aca-
demic Research Criteria (26). Guidewire electrification
may cause thromboembolism including cerebral
thromboembolism; we mitigated this risk by anti-
coagulation and by selecting ablative energies used in
cardiac electrophysiology procedures (27).
STUDY LIMITATIONS. Limitations of our work
include the lack of a control group. We do not know
with certainty that LVOT obstruction would have
been clinically important without LAMPOON. How-
ever, we have compelling circumstantial evidence,
such as the finding that the THV straddled the full
width of the LVOT cases #3 and #5. Based on available
evidence, it does not seem reasonable to offer TMVR
without leaflet or septal debulking in patients with a
low predicted neo-LVOT. Additional limitations are
that the nature and long-term implications of THV
flow disruption caused by redundant AMLs is not
understood; neither is flow following LAMPOON.
Given the infancy of this field, we have few data to
predict post-TMVR LVOT obstruction with confi-
dence, whether based on LVOT geometry or on spe-
cific AML configurations (length, aortomitral angle,
redundancy, laxity). Despite LAMPOON there was
appreciable but tolerable residual LVOT geometric
obstruction and gradient in most of our patients.
Relying on flow across THV struts may predispose toery 71
FIGURE 6 LAMPOON and TMVR in Mitral Annular Calcification
Computed tomography scans before (A to C) and after (D to F) TMVR with LAMPOON in a patient treated for mitral annular calcification
causing mitral valve stenosis. Noncalcified fibrous valve tissue (asterisk) is interposed between the THV and the mitral annular calcification
(D). The transcatheter heart valve is shown to span across the LVOT (E), suggesting there would have been complete LVOT obstruction had
LAMPOON not been performed. Follow-up chest images (F) show near-resolution of pulmonary alveolar hemorrhage and pleural effusion.
Abbreviations as in Figures 1 and 3.
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Although this procedure relies on off-the-shelf cath-
eter devices, the transcatheter valves were not
designed and are not indicated for implantation in
the mitral position, and are used off-label. In the
mitral position, these THV devices may not performJ.M. Khan Transcas well as they do in the aortic position and, for
example, may be subject to premature degeneration
or thrombosis. Finally, the LAMPOON technique adds
to the procedural complexity of antegrade transseptal
TMVR, and perhaps should be undertaken in coordi-
nation with more experienced operators.
atheter Electrosurgery 72
TABLE 3 Complications and Clinical Outcomes
Complications (n ¼ 5)
Valve embolization 1 (20)
Paravalvular leak grade None, n ¼ 4 (80%)




Left ventricular perforation or pseudoaneurysm 0
Hemolysis 1 (20)
Clinical outcomes (n ¼ 5)
Length of stay after TMVR, days 8.6  5.6
Intensive care unit length of stay, days 3.2  2.7
Survival to hospital discharge 5 (100)
Survival 30 days 4 (80)
Survival ascertainment, days 132 (23–208)
Values are n (%), n, mean  SD, or median (range).
Abbreviation as in Table 1.
PERSPECTIVES
WHAT IS KNOWN? TMVR risks life-threatening
LVOT obstruction by displacing the native anterior
mitral leaflet.
WHAT IS NEW? LAMPOON is a catheter technique
to transect the anterior mitral leaflet, to prevent
iatrogenic LVOT obstruction. In the 5 patients
described, there was no immediate hemodynamic
deterioration during the short interval between
LAMPOON and TMVR. LAMPOON allowed TMVR
without causing life-threatening LVOT obstruction or
transcatheter heart valve dysfunction in patients
believed otherwise ineligible for any treatment.
WHAT IS NEXT? We plan a cautious multicenter
investigation of LAMPOON in a larger number of
patients at high risk of LVOT obstruction and
prosthetic heart valve dysfunction after TMVR.
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J.M. KhanLAMPOON joins the family of transcatheter
electrosurgery procedures. Originally limited to
radiofrequency ablation of cardiac arrhythmias,
transcatheter electrosurgery now includes atrial
septal crossing by electrification of a Brockenbrough
needle (28), and guidewire electrification for traversal
of congenital cardiac lesions including pulmonic
atresia (29) and complete aortic coarctation (30),
transcaval transcatheter aortic valve replacement
(17,31), and coronary CTO traversal (32), among others.
CONCLUSIONS
By splitting the AML without surgery, LAMPOON
allowed successful TMVR in patients at risk of LVOT
obstruction or THV dysfunction. Remarkably
LAMPOON did not induce any short-term hemody-
namic deterioration. Operators should use caution
applying this new technique to patients. A clinical
investigation of the procedure (NCT03015194) begins
in 2017. The concept of disrupting the native anterior
leaflet, to allow blood flow across THV struts, may
inform further development of TMVR devices.Transcatheter ElectrosurgACKNOWLEDGMENTS The authors thank Lauren
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invBACKGROUND Left ventricular outflow tract (LVOT) obstruction is a leading cause of mortality and exclusion from
transcatheter mitral valve replacement (TMVR). Intentional laceration of the anterior mitral valve leaflet to prevent LVOT
obstruction (LAMPOON) is a transcatheter mimic of surgical chord-sparing leaflet resection.
OBJECTIVES The purpose of this prospective multicenter trial was to study LAMPOON with transseptal (Edwards
Lifesciences, Irvine, California) TMVR in annuloplasty rings or native mitral annular calcification (MAC).
METHODS Subjects at high or extreme surgical risk and prohibitive risk of LVOT obstruction from TMVR were included.
Eligibility was modified midtrial to exclude subjects with threatened LVOT obstruction from a Sapien 3 valve fabric skirt.
The primary endpoint was procedure survival with successful LAMPOON, with successful TMVR, without reintervention,
and with LVOT gradient <30 mm Hg (“optimal”) or <50 mm Hg (“acceptable”). Secondary endpoints included 30-day
mortality and major adverse cardiovascular events. There was universal source-data verification and independent
monitoring. All endpoints were independently adjudicated. Central laboratories analyzed echocardiogram and CT images.
RESULTS Between June 2017 and June 2018, 30 subjects were enrolled equally between the MAC and ring arms.
LAMPOON traversal and midline laceration was successful in 100%. Procedure survival was 100%, and 30-day survival
was 93%. Primary success was achieved in 73%, driven by additional procedures for paravalvular leak (10%) and high-
skirt neo-LVOT gradients observed before a protocol amendment. There were no strokes.
CONCLUSIONS LAMPOON was feasible in native and annuloplasty ring anatomies in patients who were otherwise
ineligible for treatment, with acceptable safety. LAMPOON was effective in preventing LVOT obstruction from TMVR.
Despite LAMPOON, TMVR using Sapien 3 in annuloplasty rings and MAC still exhibits important limitations. (NHLBI DIR
LAMPOON Study: Intentional Laceration of the Anterior Mitral Leaflet to Prevent Left Ventricular Outflow Tract
Obstruction During Transcatheter Mitral Valve Implantation; NCT03015194) (J Am Coll Cardiol 2019;73:2521–34)
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ABBR EV I A T I ON S
AND ACRONYMS
LAMPOON = intentional
laceration of the anterior mitral
leaflet to prevent left
ventricular outflow obstruction
LVOT = left ventricular outflow
tract
MAC = mitral annular
calcification
NHLBI = National Heart Lung
and Blood Institute
PVL = paravalvular leak
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J.M. KhanT ranscatheter mitral valve replace-ment (TMVR) is an option for pa-tients with mitral stenosis or
regurgitation who are not suitable candi-
dates for open surgical mitral repair or
replacement (1). Pending commercial devel-
opment of dedicated TMVR devices, trans-
catheter aortic valves have been implanted
in the mitral position in bioprosthetic mitral
valves (valve-in-valve), mitral annuloplasty
rings or bands (valve-in-ring), and in native
mitral annular calcification (MAC) (valve-in-
MAC) (2,3). Left ventricular outflow tract
(LVOT) obstruction is a dreaded complica-
tion of TMVR, occurring in up to 40% ofvalve-in-MAC, 5% of valve-in-ring, and 2% of valve-
in-valve cases (2), and with 62% in-hospital mortal-
ity (3). Fear of LVOT obstruction is a leading cause
for treatment exclusion, with 49% of screened pa-
tients for valve-in-MAC and 6% for valve-in-ring
excluded in the MITRAL (Mitral Implantation of
Transcatheter Valves) trial for predicted risk of
LVOT obstruction (4,5).SEE PAGE 2535TMVR-induced LVOT obstruction has 2 mecha-
nisms. Fixed obstruction occurs when the anterior
mitral valve leaflet is pushed toward the interven-
tricular septum by the mitral valve prosthesis,
creating a narrowed and elongated “neo-LVOT” (6).
Predicting the neo-LVOT area on pre-procedural
time-resolved computed tomography (CT) integrates
multiple risk factors for LVOT obstruction, including
acute angulation of the aortic and mitral annular
planes, a small left ventricle, a prominent septal
bulge, and ventricular deployment of the trans-
catheter valve (6,7). Observational registries suggest a
simulated neo-LVOT area of under 170 to 190 mm2
predicts high risk of LVOT obstruction (8,9). Dynamic
obstruction occurs when the narrowed neo-LVOT
generates Bernoulli forces that draw the anterior
mitral leaflet toward the interventricular septum
during systole (10). A long anterior mitral leaflet with
redundant chordae is a risk factor (11). A long anterior
mitral leaflet may also prolapse back into the trans-
catheter heart valve, interfering with valve closure
and causing acute valve failure (12).Scientific. Dr. Greenbaum has served as a proctor for Edwards Li
consultant and a scientific advisor for and is an equity holder i
onsultants/proctors for Edwards Lifesciences and Medtronic. Dr.
fesciences. Dr. Leshnower has served on the Speakers Bureau for
fesciences, Boston Scientific, and Materialise. All other authors ha
ents of this paper to disclose.
received January 12, 2019; revised manuscript received February
Transcatheter ElectrosurgPreventive strategies include either surgical
transatrial leaflet resection, which involves cardio-
pulmonary bypass, associated morbidity, and re-
ported 30-day mortality of 27% (13), or prophylactic
alcohol septal ablation (14,15), which causes septal
infarction, sacrifices myocardium and conduction
tissue, may not be anatomically feasible or effective
in all patients, and delays TMVR by 4 to 6 weeks.
Current expert opinion recommends that TMVR
should probably be contraindicated in most of these
patients who are at high risk of LVOT obstruction
(16).
Contemporary surgical mitral valve replacement
includes resection of the anterior mitral leaflet to
prevent LVOT obstruction and sparing of the sub-
valvular apparatus to preserve left ventricular func-
tion (17). Laceration of the anterior mitral valve leaflet
to prevent outflow obstruction (LAMPOON) is a
percutaneous transcatheter mimic of the surgical
standard. Animal studies (18) and early compas-
sionate use in humans (19) demonstrated that
LAMPOON and TMVR may be feasible in these “con-
traindicated” patients. The split anterior mitral leaflet
parts away from the LVOT and blood flow is main-
tained through the open cells of the transcatheter
heart valve despite threatened obstruction were the
anterior mitral leaflet intact.
METHODS
TRIAL DESIGN AND OVERSIGHT. The LAMPOON IDE
trial (NCT03015194) was a prospective, single-arm,
multicenter study of the LAMPOON procedure with
transseptal Sapien 3 valve (Edwards Lifesciences,
Irvine, California) TMVR in annuloplasty ring or band,
or native MAC. The U.S. Food and Drug Administra-
tion granted Investigational Device Exemption (IDE)
for the study. The institutional review board at each
site and at National Heart, Lung, and Blood Institute
(NHLBI) approved the study protocol. The NHLBI
Data Safety Monitoring Board provided study over-
sight. The NHLBI was the data coordinating center.
All subjects consented in writing.
The trial was designed by the investigators and
sponsored by the senior author (R.J.L.) on behalf of
the NHLBI. Edwards Lifesciences provided arms-
length financial support for the study as part of afesciences, Medtronic, and Abbott Vascular; and has
n Transmural Systems. Drs. Foerst and Rogers have
Yazdani, Paone, and Eng have served as proctors for
Medtronic. Dr. Wang has served as a consultant for
ve reported that they have no relationships relevant
22, 2019, accepted February 25, 2019.
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FIGURE 1 Study Flow Chart
Assessed for eligibility,
n = 87
Enrolled, n = 30
1, Death day 13
30 day Endpoint
Assessment, n = 29
Excluded, n = 57
6, Not at risk of LVOT obstruction
5, Ineligible for LAMPOON
    [2, mechanical AVR;
    3, skirt neo-LVOT < 150 mm2]
22, Ineligible for Sapien 3 TMVR
    [12, insufficient calcification;
    8, annulus too large for Sapien;
    2, dehisced annuloplasty ring]
8, Declined, unwilling to travel,
    or elected hospice
11, Died during evaluation
3, Alternative treatment
    [2, SMVR; 1 ViV TMVR]
2, No reason available
A total of 87 subjects were screened and 30 were enrolled. Reasons for exclusion are
listed. AVR ¼ aortic valve repair; LAMPOON ¼ intentional laceration of the anterior
mitral leaflet to prevent left ventricular outflow obstruction; LVOT ¼ left ventricular
outflow tract; SMVR ¼ surgical mitral valve replacement; TMVR ¼ transcatheter mitral
valve replacement; ViV ¼ valve-in-valve.
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2523Collaborative Research and Development Agreement
with NHLBI on transcatheter modification of the
mitral valve. Edwards Lifesciences was not involved
in study design or analysis, and did not review this
report before submission. The study investigators
have custody of all data and are responsible for the
findings.
To ensure data integrity, all case report forms were
independently verified with source data on-site,
clinical events were independently monitored, and
all echocardiography and computed tomography (CT)
images were analyzed by central laboratories. An in-
dependent Clinical Event Adjudication Committee
classified the primary and all clinical endpoints
including death and stroke, and determined related-
ness to the LAMPOON procedure and to TMVR.
SUBJECTS. Between June 2017 and June 2018, 30
adult subjects with severe mitral stenosis or regurgi-
tation and high or extreme risk for surgical mitral
valve replacement were enrolled at 5 centers in the
United States (Online Appendix). Reasons for exclu-
sion are shown in Figure 1. No subject was excluded
for excessive leaflet calcification. A central eligibility
committee confirmed eligibility for transseptal Sapien
3 valve in ring or band, or native MAC, based on CT
annular measurements for suitable anchoring. Only
candidates with prohibitive risk of LVOT obstruction
from TMVR were enrolled, based on neo-LVOT
area <200 mm2, or long redundant anterior mitral
leaflet. The complete selection criteria are listed in
the Online Appendix.
The study was amended after the first 5 subjects
were enrolled, after LVOT obstruction was observed
despite anterior leaflet laceration requiring rescue
alcohol septal ablation. These were attributed to
obstruction from the covered fabric skirt at the base
of the Sapien 3 valve (20). The selection criteria were
therefore changed to exclude candidates with a “skirt
neo-LVOT” <150 mm2 on baseline CT. All enrolled
subjects were included in the final analysis.
LAMPOON TECHNIQUE. The LAMPOON technique
has been described previously (18,19). Briefly, 2
transfemoral guide catheters are advanced retrograde
through the aortic valve and positioned in the LVOT
and left atrium, respectively, on either side of the
middle-scallop (A2) of the anterior mitral leaflet
(Figure 2A). The left atrial guide catheter is stabilized
using a transseptal rail. A stiff 0.014-inch guidewire
(Astato XS 20, Asahi, Japan) is sheathed in an insu-
lating polymer jacket (Piggyback Wire Convertor,
Teleflex, North Carolina), and advanced from the
LVOT to perforate through the center and base of the
anterior mitral leaflet using a short pulse ofJ.M. Khan Transcradiofrequency energy. The guidewire tip is snare-
retrieved from the left atrium to form a guidewire
loop through the base of the anterior mitral leaflet,
with both guidewire limbs exiting femoral arteries
and insulated in catheters (Figure 2B). Tension is
applied to the guidewire loop during further radio-
frequency energy application, lacerating the anterior
mitral leaflet from base to tip (Online Video 1). Using a
retrograde guide catheter trajectory, the laceration
aligns in front of the LVOT and down the midline of
the anterior leaflet. The anterior mitral leaflet splays
in diastole and coapts in systole (Figure 3A, Online
Video 2), in part because the chordae are preserved.
Immediately after laceration, transseptal TMVR is
performed using a Sapien 3 balloon-expandable
atheter Electrosurgery 78
FIGURE 2 LAMPOON Procedure
(A) Transesophageal echocardiography visualization of retro-
grade LVOT catheter contacting the middle of the anterior
mitral leaflet (arrow) and pointed toward a snare positioned by a
second retrograde catheter in the left atrium. (B) The focally
denuded lacerating guidewire straddles the anterior mitral
leaflet (arrowhead) during electrification to achieve laceration
(Online Video 1). Ao¼Aorta; LA¼ left atrium; LV¼ left ventricle.
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J.M. Khanvalve. During valve inflation, the 2 halves of the split
anterior mitral leaflet parted to either side of the
LVOT. Blood flows through the open cells of the
Sapien 3 valve frame in the LVOT, which would have
otherwise been obstructed by the anterior mitral
leaflet (Figure 3). At completion, we recommended
but did not require closure of the iatrogenic atrial
septal defect.
STUDY ENDPOINTS. Primary and key secondary
endpoints were independently adjudicated. TheTranscatheter Electrosurgprimary endpoint was technical success on exit from
the catheter laboratory for both LAMPOON and
TMVR, which was defined as successful LAMPOON
traversal and laceration, successful deployment and
correct positioning of the first intended transcatheter
heart valve, final LVOT gradient <30 mm Hg, freedom
from emergency surgery or reintervention, and
absence of procedural mortality.
Exploratory endpoints included in-hospital or 30-
day death, stroke, life-threatening bleeding, major
vascular complications, major cardiac structural
complications, stage 2 or 3 acute kidney injury,
myocardial infarction requiring intervention, severe
hypotension requiring vasopressors or unplanned
mechanical assist devices, ventilation $48 h, repeat
surgery or intervention, proper device placement,
device delivery failure, device structural failure, ma-
jor atrial septal defect, coronary obstruction, tampo-
nade, valve fracture, damage to native mitral
structures, LVOT gradient $10 mm Hg from baseline,
valve thrombosis, endocarditis, hemolysis, residual
mitral regurgitation, mitral valve gradient $5 mm Hg,
and paravalvular leak (PVL). Mitral Valve Academic
Research Consortium definitions (21) were used to
determine endpoint success. The complete list of
endpoints is provided in the Online Appendix.
IMAGING. Baseline and post-procedure contrast-
enhanced, time-resolved CT used retrospective
electrocardiogram-gated acquisitions. Images were
reconstructed at 5% to 10% intervals with <1.0-mm
slice thickness. Baseline and follow-up neo-LVOT
and skirt neo-LVOT area measurements were per-
formed using dedicated mitral valve CT analysis
software (3mensio, PIE Medical, the Netherlands).
The neo-LVOT area was measured in the last systolic
phase with the aortic valve fully open (typically 30%
phase). This was not the phase that gave the smallest
neo-LVOT area (typically 40% to 50% phase), used in
some observational studies (8,9). We noted that at
these later phases, the aortic valve is partially or
completely closed and the earlier phase selected for
this study would better represent gradient across the
LVOT after TMVR. A virtual valve with dimensions of
the intended Sapien 3 implant was simulated in a
70:30 ventricle to atrium position across the mitral
annulus. The smallest resulting cross-sectional area
along the axis of the LVOT, circumscribed by the
virtual valve and the interventricular septum, was
measured to predict the neo-LVOT area (Figures 4A
and 4B). The same was repeated by simulating only
the fabric covered portion of the Sapien 3 valve for
the “skirt” neo-LVOT, and excluding the ventricular
open cells as described previously (20) (Figures 4C and
4D). This simulates the neo-LVOT that would result
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FIGURE 3 LAMPOON Outcomes
(A) Successful laceration of the anterior mitral leaflet before TMVR depicted on 3-dimensional transesophageal echocardiography (Online
Video 2). (B) Color-flow across open cells of the Sapien 3 valve frame that without leaflet laceration would have completely obstructed the
LVOT. The arrowhead shows the vena contracta, indicating the “leaflet lampooned” diameter; the arrow points to the edge of the valve
abutting septum, indicating “leaflet intact” diameter. (C) A 3-dimensional computed tomography volume rendering after TMVR showing the
split anterior mitral leaflet (black-outlined brown) splayed by the Sapien 3 valve frame (white) in the context of annular calcification (blue).
(D) A 3-chamber perspective shows the valve frame contacted the interventricular septum across the LVOT (Online Video 3). Abbreviations
as in Figure 1.
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2525after TMVR and complete partition, or surgical exci-
sion, of the anterior mitral leaflet. Leaflet thrombosis
was defined as leaflet thickening with reduced mo-
tion on follow-up CT or echocardiography.
Transthoracic or transesophageal echocardiograms
were performed at baseline, intraprocedure,
discharge, and 30 days. The neo-LVOT diameter on
echocardiography was measured as the distance be-
tween the Sapien 3 stent frame and the interventric-
ular septum in a 3-chamber view. This was called the
“leaflet intact” LVOT diameter and approximated the
neo-LVOT diameter assuming the anterior leaflet
covered the Sapien 3 frame and ended at the valveJ.M. Khan Transcedge. On color Doppler, the vena contracta through
the neo-LVOT was measured in the same 3-chamber
view (Figure 3B). This was called the “leaflet lam-
pooned” LVOT diameter and approximated the
physiological neo-LVOT diameter after LAMPOON.
Echocardiograms and CT images were analyzed at
central laboratories.
STATISTICAL ANALYSIS. The sample size of 30 sub-
jects was not statistically derived. Baseline subject
and procedural characteristics were summarized as
mean  SD or median and interquartile range for
continuous variables and counts and percentages for
categorical variables. Wilcoxon signed-rank tests
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FIGURE 4 Neo-LVOT and Skirt Neo-LVOT Areas
Illustration of computed tomography-based prediction of neo-LVOT (A and B) and skirt neo-LVOT (C and D) area using 3-chamber projections
(top) and LVOT short-axis projections (bottom) and a simulated valve (purple outline). A Sapien 3 valve is superimposed, illustrating covered
and uncovered sections of the valve frame. LVOT ¼ left ventricular outflow tract.
Khan et al. J A C C V O L . 7 3 , N O . 2 0 , 2 0 1 9
LVOT Obstruction During Transcatheter MV Replacement M A Y 2 8 , 2 0 1 9 : 2 5 2 1 – 3 4
2526
J.M. Khanwere used to assess the difference in the observed
neo-LVOT areas before and after LAMPOON, and the
differences in New York Heart Association functional
class, 6-min walk distance, and Kansas City Cardio-
myopathy Questionnaire quality-of-life summary
scores between baseline and 30-day visits. Spearman
rank tests assessed relationships between predicted
neo-LVOT and skirt neo-LVOT and residual gradients.
Statistical analyses were performed using R sta-
tistical software version 3.5.1 (R Foundation for Sta-
tistical Computing, Vienna, Austria).
RESULTS
SUBJECT AND PROCEDURE CHARACTERISTICS.
Baseline subject characteristics are shown in Table 1.
Transcatheter ElectrosurgThe majority were women and presenting late in their
disease process, with end-organ failure and multiple
comorbidities. All were at high or extreme risk for
surgery. There were an equal number of subjects with
mitral annuloplasty rings or bands and native MAC.
The 29-mm Sapien 3 valves were implanted in 20
patients (67%), 26-mm in 7 (23%), and 23-mm in
3 (10%).
Table 2 details the LVOT obstruction risk for
enrolled subjects. A total of 25 (83%) were at risk of
fixed LVOT obstruction, defined as having a predicted
neo-LVOT area <200 mm2 (mean 81 mm2). The ma-
jority (88%) had extremely small predicted neo-LVOT
area (<150 mm2). A total of 5 (17%) subjects were at
risk of dynamic LVOT obstruction, with anterior
mitral leaflet length >24 mm (mean 28 mm). One
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TABLE 1 Baseline Subject Characteristics (n ¼ 30)
Age, yrs 76 (47–89)
Female 22 (73)
BSA, m2 1.8  0.2
End-organ failure
Severe pulmonary disease 8 (27)
Severe pulmonary hypertension 16 (55)
Home oxygen 6 (20)
Severe RV dilation or dysfunction 4 (13)
End-stage kidney disease on dialysis 4 (13)




Peripheral artery disease 4 (13)
Coronary artery disease 21 (70)
Prior myocardial infarction 6 (20)
Prior stroke or TIA 5 (17)
Atrial fibrillation 16 (53)
Prior endocarditis 4 (13)
Prior rheumatic fever 1 (3)
Pacemaker or ICD 9 (30)
$2 prior cardiac surgery 9 (30)
NYHA functional class III or IV 27 (90)
Frail 14 (47)
STS predicted risk of mortality, % 10.2  6.2
HAS-BLED score 2.8  0.9
NT-proBNP, pg/ml 515 [282–850]
Medication
Dual antiplatelet baseline 11 (37)
Dual antiplatelet discharge 2 (7)
Oral anticoagulant agent baseline 10 (33)
Oral anticoagulant agent discharge 26 (93)
TMVR setting
Complete ring 13 (43)
Incomplete ring/band 2 (7)
MAC 15 (50)
Primarily mitral stenosis 20 (67)
Primarily mitral regurgitation 10 (33)
Mean mitral valve gradient, mm Hg 9.6  4.3




Annular area 551.3  141.2
Antero-posterior distance 30.3  3.9
Intercommissural distance 21.5  3.6
Values are median (range), n (%), mean  SD, or median [interquartile range].
ASE ¼ American Society of Echocardiography; BSA ¼ body surface area;
CT ¼ computed tomography; ICD ¼ implantable cardioverter-defibrillator;
MAC ¼ mitral annular calcification; NT-proBNP ¼ N-terminal pro–B-type natri-
uretic peptide; NYHA ¼ New York Heart Association; STS ¼ Society of Thoracic
Surgeons; TIA ¼ transient ischemic attack; TMVR ¼ transcatheter mitral valve
replacement.
TABLE 2 LVOT Obstruction Risk
Aorto-mitral angle, o 117.3  9.8
Septal thickness, mm 12.9  3.6
Fixed LVOT obstruction subset 25
Predicted neo-LVOT, mm2 81  51
Neo-LVOT <200 mm2 25 (100)
Neo-LVOT <150 mm2 22 (88)
Neo-LVOT <100 mm2 15 (60)
Neo-LVOT <50 mm2 7 (28)
Predicted skirt neo-LVOT, mm2 230  56
Skirt neo-LVOT <200 mm2 7 (28)
Skirt neo-LVOT <150 mm2 2 (8)
Skirt neo-LVOT <100 mm2 0 (0)
Dynamic LVOT obstruction subset 5
Anterior mitral leaflet length on CT, mm 28  3.1
Systolic anterior motion at baseline 1 (20)
Values are mean  SD, n, or n (%).
CT ¼ computed tomography; LVOT ¼ left ventricular outflow tract.
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2527subject had prior prophylactic alcohol septal ablation,
but still had a predicted neo-LVOT area of 25 mm2 and
was enrolled in the study.
PROCEDURE OUTCOMES. Table 3 shows the adjudi-
cated primary and key secondary endpoints. TheJ.M. Khan TranscLAMPOON traversal and laceration was successful in
all 30 (100%) subjects, including in subjects with
heavily calcified anterior mitral leaflets, and where
laceration trajectory was through a complete anterior
calcium bridge. Full leaflet laceration was not ach-
ieved in 1 subject due to insufficiently basal traversal.
All (100%) survived the immediate procedure and 28
(93%) survived to discharge and 30 days (100% for
valve-in-ring; 87% for valve-in-MAC). The LVOT
gradient immediately after TMVR was <30 mm Hg in
27 patients (90%), and on exit from the catheter lab-
oratory was <30 mm Hg in 29 patients (97%;
“optimal”) and <50 mm Hg in 30 patients (100%;
“acceptable”). A total of 8 patients (27%) required
further intervention before exiting the catheter lab-
oratory: 4 had alcohol septal ablation to decrease
LVOT gradients; 2 had second valve implantations for
PVL and displacement during interatrial septum
traversal, respectively; 1 had on-table conversion to
surgery for severe PVL; and 1 had percutaneous
closure for PVL through a dehisced mitral ring. The
primary endpoint of success was met in the remaining
22 (73%) subjects.
There were 2 post-procedural deaths. One was
attributed to clostridium difficile colitis and toxic
megacolon following clindamycin for dental extrac-
tion, despite a technically successful procedure. The
other was a failed TMVR despite successful
LAMPOON, requiring surgical conversion for PVL,
with a stormy post-operative course, and death on
day 38.
There were no strokes. Cerebral protection
(Sentinel, Claret Medical, Santa Rosa, California) was
used in 1 subject who had left atrial appendage
thrombus at baseline; no debris was retrieved.
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TABLE 3 Adjudicated Clinical Outcomes
Primary endpoint (exit from catheter laboratory) 30
Successful LAMPOON traversal and laceration 30 (100)
Successful access, delivery, and retrieval of LAMPOON device system 30 (100)
Successful deployment of first TMVR valve 27 (90)
LVOT gradient <30 mm Hg (“optimal”) 29 (97)
LVOT gradient <50 mm Hg (“acceptable”) 30 (100)
Freedom from emergency surgery or reintervention related to
LAMPOON or TMVR
22 (73)
Procedure survival 30 (100)
Procedure success (all of the above) 22 (73)
Secondary endpoints (30 days) 30
All death 2 (7)
Related to LAMPOON 0 (0)
Related to TMVR but not LAMPOON 1 (3)
Not related to TMVR or LAMPOON 1 (3)
All stroke 0 (0)
Life-threatening bleeding 3 (10)
Major vascular complication 6 (20)
Major structural complication 0 (0)
AKI stage 2/3 3 (10)
Myocardial infarction requiring PCI or CABG 0 (0)
Surgery or repeat intervention 8 (27)
Hypotension requiring increase in vasopressors or mechanical support 12 (40)
Respiratory failure requiring prolonged (>48 h) intubation 1 (3)
Valve position failure 1 (3)
Valve structural failure 0 (0)
Major ASD 0 (0)
Coronary obstruction 0 (0)
Cardiac tamponade or pericardial drainage 1 (3)
Damage to native mitral apparatus 0 (0)
LVOT $10 mm Hg from baseline 2 (7)
Aortic regurgitation 2þ or more 0 (0)
Valve thrombosis 4 (13)
Endocarditis 0 (0)
Hemolysis 12 (40)
MR more than mild 1 (3)
MVG $5 mm Hg 18 (60)
PVL more than mild 7 (23)
Values are n or n (%).
AKI ¼ acute kidney injury; ASD ¼ atrial septal defect; CABG ¼ coronary artery bypass graft;
LAMPOON¼ intentional laceration of the anterior mitral leaflet to prevent left ventricular outflow
obstruction; LVOT ¼ left ventricular outflow tract; MR ¼ mitral regurgitation; MVG ¼ mitral valve
gradient; PCI ¼ percutaneous coronary intervention; PVL ¼ paravalvular leak;
TMVR ¼ transcatheter mitral valve replacement.
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J.M. KhanPlanned intra-aortic balloon pump support was
used in 43%, when the transcatheter valve was not
pre-positioned in the left atrium. Table 4 shows
echocardiogram and invasive hemodynamic changes
with LAMPOON-TMVR. Hypotension requiring in-
crease in vasopressor support during the procedure
and recovery was common (n ¼ 12; 40%), but only 6
subjects (20%) had hypotension during LAMPOON
catheter manipulation and laceration. Unplanned
mechanical support was required in 1 subject (3%)
after the Sapien 3 skirt caused LVOT obstruction.Transcatheter ElectrosurgPer-subject procedural hemodynamics are reported in
Online Figure 1.
LVOT OBSTRUCTION PREDICTION AND OUTCOMES.
The predicted neo-LVOT simulated on pre-procedural
CT correlated well with the observed neo-LVOT
measured on post-procedural CT (Pearson r ¼ 0.95)
(Online Figure 2).
Among subjects who were at high predicted risk of
LVOT obstruction with standalone TMVR, 29 (97%)
exited the catheter laboratory with an LVOT
gradient <30 mm Hg, and 28 (93%) had an LVOT
gradient of within 10 mm Hg of their baseline on
30-day echocardiography follow-up. Both subjects
who failed to meet these endpoints had a skirt neo-
LVOT area <150 mm2 and were enrolled before the
protocol was amended to require an adequate skirt
neo-LVOT.
A total of 3 of the first 5 subjects had LVOT
obstruction (gradient $30 mm Hg) immediately after
TMVR and underwent alcohol septal ablation. Of
these, 2 had a skirt neo-LVOT <150 mm2, and 1 had a
heavily calcified anterior leaflet patch after prior
repair for subacute endocarditis combined with a skirt
neo-LVOT of 183 mm2. Thereafter, the protocol was
amended to exclude subjects with a skirt neo-
LVOT <150 mm2, with no further cases of LVOT
obstruction. A fourth subject had an insufficiently
basal anterior mitral leaflet laceration, likely limiting
leaflet splay after laceration, with an LVOT gradient of
29 mmHg; she also underwent alcohol septal ablation.
Figure 5 shows post-TMVR LVOT gradient by
catheterization in relation to predicted neo-LVOT
area and to predicted skirt neo-LVOT area. The ma-
jority had a predicted neo-LVOT area of <150 mm2 but
did not develop LVOT obstruction after LAMPOON
TMVR. There was a nonsignificant trend toward high
LVOT gradient among subjects with lowest neo-LVOT
and with lowest skirt neo-LVOT.
LAMPOON increased the observed neo-LVOT area.
The “leaflet intact” LVOT diameter on echocardiog-
raphy at discharge was 0.4  0.3 cm, whereas the
“leaflet lampooned” LVOT diameter was 0.8  0.3 cm
(p < 0.01). On post-procedural CT, the skirt neo-LVOT
was 150 mm2 greater than the neo-LVOT (p < 0.001).
There was no systolic anterior motion or leaflet in-
folding causing TMVR dysfunction in the subjects
with long anterior mitral leaflet.
PARAVALVULAR LEAK AND HEMOLYSIS. A total of 7
subjects (23%) developed greater-than-mild para-
valvular leak after first valve deployment (3 valve-in-
MAC; 4 valve-in-ring). Details and treatment are
provided in Table 5. One subject (4%) had greater-
than-mild PVL at 30 days.ery 83
TABLE 4 Hemodynamics
Echocardiography Baseline Pre-Discharge 30-Day
Left ventricular end-diastolic volume, ml 65.8  29.6 65.0  27.6 68.8  32.4
Left ventricular end-systolic volume, ml 26.5  15.9 28.8  19.8 33.6  25.7
LVEF, % 60.8  9.7 56.6  14.8 55.0  15.2
Left atrium volume index 53.0  16.5 53.4  25.2 52.2  18.1
LVOT peak velocity, m/s 1.1  0.3 1.5  0.5 1.4  0.6
LVOT peak gradient, mm Hg 5.7  4.8 9.8  7.2 9.2  7.3
LVOT mean gradient. Mm Hg 2.4  1.4 4.8  4.0 4.4  3.9
LVOT VTI, m 0.2  0.1 0.3  0.1 0.3  0.1
Mean transmitral gradient, mm Hg 9.6  4.3 5.6  2.1 6.6  2.3
Mitral regurgitation severity
None 0 (0) 5 (17) 5 (19)
Trace 6 (21) 10 (34) 8 (30)
Mild 6 (21) 13 (45) 12 (44)
Moderate 6 (21) 1 (3) 0 (0)
Severe 11 (38) 0 (0) 2 (7)
Perivalvular regurgitation
None — 16 (59) 17 (63)
Trace — 3 (11) 4 (15)
Mild — 8 (30) 5 (19)
Moderate — 0 (0) 0 (0)
Severe — 0 (0) 1 (4)
Cath Hemodynamics Baseline Post-LAMPOON Post-TMVR
Heart rate, beats/min 69.6  10.8 76.4  15.5 73.4  10.5
Systolic arterial pressure, mm Hg 123.4  22.4 96.2  20.5 123.3  19.0
Diastolic arterial pressure, mm Hg 61.5  12.0 51.4  11.6 57.4  15.6
Mean arterial pressure, mm Hg 85.0  14.7 65.8  14.7 82.7  14.3
Right atrial pressure, mm Hg 13.9  6.1 — 13.1  6.3
Systolic pulmonary artery pressure, mm Hg 56.8  18.5 — 52.8  17.0
Diastolic pulmonary artery pressure, mm Hg 24.8  8.3 — 22.6  6.8
Mean pulmonary artery pressure, mm Hg 38.7  11.2 — 34.4  9.2
Mean left atrial pressure, mm Hg 26.7  11.0 — 18.1  4.7
Left atrial v-wave, mm Hg 45.2  16.8 — 25.4  8.6
Mean transmitral gradient, mm Hg 8.2  4.8 — 2.8  1.6
Cardiac output, l/min 5.1  1.7 — 5.4  1.5
Left ventricular end-diastolic pressure, mm Hg 18.3  6.0 — 17.9  5.0
LVOT peak-to-peak gradient, mm Hg 7.6  6.0 17.7  23.4 10.7  9.3
Calculated mitral valve area, cm2 1.5  0.7 — 2.8  0.9
Values are mean  SD or n (%).
LVEF ¼ left ventricular ejection fraction; LVOT ¼ left ventricular outflow tract; VTI ¼ velocity time integral.
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2529In total, 12 subjects (40%) developed hemolysis, 7
(23%) clinical requiring blood transfusion and 5 (17%)
subclinical. Hemolysis was associated with trace
(n ¼ 4), mild (n ¼ 7), and moderate (n ¼ 1) para-
valvular leak. No subject developed hemolysis in the
absence of paravalvular leak.
OTHER CLINICAL ENDPOINTS. Subjects improved in
New York Heart Association functional class and
Kansas City Cardiomyopathy Questionnaire (22)
Clinical and Overall Summary scores, but not 6-min
walking distance (Figure 6). N-terminal pro–B-type
natriuretic peptide did not improve from baseline to
30 days (515 pg/ml [first and third quartiles: 282 to
850 pg/ml] to 736 pg/ml [first and third quartiles: 318
to 1,427 pg/ml]). A total of 18 subjects (60%) had mean
mitral valve gradient $5 mm Hg, of whom 1 (4%) had
a mitral gradient $10 mm Hg on 30-day echocardi-
ography. Leaflet thrombosis was seen in 4 subjects
(13%) and resolved with anticoagulation. A total of 6
subjects (20%) had major vascular complications: 5
with groin hematomas and 1 with retroperitoneal
hematoma. Iatrogenic atrial septal defects were
electively closed during the index procedure in 25
(83%). All subjects had general anesthesia, and 22
(73%) were extubated in the catheter laboratory. Total
procedure-to-hemostasis time was 195  77 min;
LAMPOON-to-TMVR time was 22  27 min; fluoros-
copy time was 120  53 min; and contrast volume
used was 47  48 ml. Baseline and procedure char-
acteristics and outcomes are stratified by subjects
with mitral stenosis and mitral regurgitation in
Online Tables 1 and 2.
DISCUSSION
The LAMPOON IDE study enrolled 30 subjects at
prohibitive risk of LVOT obstruction equally between
valve-in-ring and valve-in-MAC arms. None were
eligible for standalone TMVR and most were deemed
ineligible for any other therapy. Most would have
been excluded from contemporaneous cohort and
registry reports of TMVR for valve-in-ring and valve-
in-MAC because of the baseline risk of LVOT
obstruction (3,4,23,24). The main findings were that
LAMPOON was feasible in 100% of subjects across a
variety of native and annuloplasty ring anatomies and
calcium patterns. There was 100% procedure survival
and 93% in-hospital and 30-day survival (100% valve-
in-ring, 87% valve-in-MAC) in a very sick cohort,
many presenting with end-organ failure, in whom
outcomes have historically been very poor. There
were no neurological events (Central Illustration).
THE LAMPOON TECHNIQUE. The LAMPOON tech-
nique, although technically challenging, wasJ.M. Khan Transcsuccessfully performed in all sites with proctorship
and without roll-in procedures for new sites. The
technique cannot be used with the transfemoral
approach in subjects with mechanical aortic valves.
Furthermore, LAMPOON, or other anterior leaflet
modification or resection strategies, is unlikely to
prevent LVOT obstruction when there is a small pre-
dicted skirt neo-LVOT area. Extent and pattern of
anterior mitral leaflet calcification was not a contra-
indication to LAMPOON. There was no collateral
damage to adjacent structures, particularly the aortic
valve, from LAMPOON.
One safety consideration raised by this study is
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Predicted Neo-LVOT vs Gradient
15010050 400
LVOT catheter gradient after TMVR is compared with predicted neo-LVOT area (diamonds)
and predicted skirt neo-LVOT area (circles). Red, orange, and yellow symbols indicate
subjects who underwent bailout alcohol septal ablation. Red indicates subjects with
inadequate skirt neo-LVOT. Orange indicates a subject with calcific anterior mitral leaflet
patch and inadequate skirt neo-LVOT. Yellow indicates a subject with insufficiently basal
LAMPOON. Abbreviations as in Figure 1.
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J.M. Khanhigh LVOT gradients after TMVR highlight the value
of appropriate screening, especially for skirt neo-
LVOT area in extremely small ventricles.
A second safety consideration is transient proce-
dural hypotension. Leaflet manipulation and lacera-
tion was associated with increased vasopressor
support in 20% of subjects. There was a high rate of
planned intra-aortic balloon pump use as, with
increasing comfort with the technique, operators
stopped pre-positioning the Sapien 3 valve before
laceration, increasing time from laceration to valve
deployment. Emergency mechanical support was
required in only 1 subject to relieve severe LVOT
obstruction. Reasons for the relative hemodynamic
stability observed with LAMPOON procedures may be
that the lacerated anterior leaflet still coapts in sys-
tole, and that patients with chronic mitral diseasear Leak
MAC Ring or Band
1 (severe), converted to
surgery
2, repeat TMVR-in-TMVR (1 immediate,
1 day 3)






Transcatheter Electrosurgmay tolerate a further acute exacerbation in the short
period between LAMPOON and TMVR.
TRANSCATHETER MITRAL VALVE REPLACEMENT.
TMVR in the setting of annuloplasty rings and in
native MAC has previously been demonstrated to be
feasible but with problems, particularly LVOT
obstruction and PVL. The 30-day survival in carefully
selected patients screened out for LVOT obstruction
in the MITRAL trial was 93% for valve-in-ring and 81%
for valve-in-MAC (4,5). The 30-day survival in the
TMVR Registry was 90% for valve-in-ring and 65% for
valve-in-MAC (2). In patients who developed LVOT
obstruction, who likely represent the cohort enrolled
in this study, 30-day survival was only 48% and 1-
year survival was 15% (3).
Although LAMPOON was largely technically suc-
cessful, there were important safety considerations
for TMVR not related to LAMPOON, namely clinically
significant PVL and hemolysis, and high residual
transmitral gradients. Large annuli (9% screen failure
rate) and insufficient mitral calcification (14% screen
failure rate) remain important exclusion criteria for
TMVR using aortic valves.
Moderate or severe PVL occurred in 23% after first
valve deployment, and the majority required further
intervention. Even trace PVL was associated with
hemolysis. It is possible that blood flow through the
open valve cells in the LVOT caused additional he-
molysis, but no patient developed hemolysis in the
absence of PVL, and so we were unable to test this
hypothesis.
High transmitral valve gradients were seen in this
study. Other groups reporting similar rates (82.4%
[24]) have used a threshold of mean mitral valve
gradient <10 mm Hg when assessing success of mitral
valve-in-valve, valve-in-ring, and valve-in-MAC
(23,24) based on American College of Echocardiogra-
phy guidelines (25) and guidelines for transcatheter
aortic valve failure (26). In a study comparing surgical
mitral valve replacement with TMVR, mean mitral
valve gradients at 30 days were similar (6.5 
2.5 mm Hg surgery vs. 7.1  2.5 mm Hg TMVR;
p ¼ 0.42) (27), and compares with mean gradients in
this study (6.6  2.3 mm Hg). However, studies with
dedicated TMVR devices have reported lower trans-
mitral gradients (28,29), reflecting a shortcoming of
using transcatheter aortic valve devices in the mitral
position.
Rates of leaflet thrombosis were similar to reported
case series (30), suggesting the value of anti-
coagulation in these patients and the heightened risk
of thrombosis in transcatheter mitral valve replace-
ment (31).
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Decreased IV III II I
Changes before and 30 days after LAMPOON TMVR in New York Heart Association (NYHA) functional class (p ¼ 0.004), 6-min walk test (nonsignificant p ¼ 0.15 based
on n ¼ 20 nonmissing pairs), and Kansas City Cardiomyopathy Questionnaire (Kansas City Cardiomyopathy Questionnaire)-15 Overall (p ¼ 0.007) and Clinical Summary
(p ¼ 0.050) scores. Abbreviations as in Figure 1.
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2531STUDY LIMITATIONS. CT-predicted neo-LVOT area
measurements are not standardized, and there is
variation between centers in choice of cardiac phase,
virtual valve depth, and orientation. Observational
registries support a neo-LVOT cut-off of 170 mm2
when a later cardiac phase is used (9) and 190 mm2
when a more ventricular implantation depth is used
(8). The confidence intervals around these measure-
ments remain broad. Therefore, using the methodol-
ogy in this study, 200 mm2 appears to be an
acceptable cut-off for high risk of LVOT obstruction.
The CT-predicted neo-LVOT area, although an
advance over previous linear measurements, remains
a 2-dimensional assessment of a 3-dimensional
structure that varies during the cardiac cycle.
Computational fluid dynamics models accounting for
this time-varying structure as well as variations in
flow and behavior of the anterior mitral leaflet will
help better predict risk of LVOT obstruction (32–34).
The 5 subjects enrolled were deemed at high risk of
LVOT obstruction from an excessively long anterior
mitral leaflet, but it is possible that these subjects
may not have developed systolic anterior motion of
the mitral leaflet after TMVR. The problem of the long
anterior mitral leaflet needs to be further studied,
both in causing LVOT obstruction as well as in-folding
interfering with transcatheter heart valve func-
tion (10,12).J.M. Khan TranscGiven the small sample size, no meaningful com-
parisons could be made between several procedure
parameters and their effect on LVOT gradient,
particularly nonbasal or eccentric lacerations, surgi-
cally implanted neo-chordae, anterior mitral leaflet
calcium volume and pattern, and degree of antero-
posterior valve oversizing. The merits of closing the
atrial septal defect were not tested in this study.
There was no control group in this study because
the subjects enrolled were not eligible for standalone
TMVR due to risk of life-threatening LVOT obstruc-
tion. No subject had severe left ventricular dysfunc-
tion, perhaps reflecting the low likelihood of these
patients developing LVOT obstruction from TMVR
due to increased ventricular size, and so the safety of
LAMPOON in this cohort was not tested.
We await 1-year outcomes to assess long-term
safety. Successful patient outcomes depended on
both successful LAMPOON and successful trans-
septal TMVR using an aortic transcatheter valve off-
label. The results of this study should be applied
with caution when combining LAMPOON with other
transcatheter valves. The lessons learned on cautions
and contraindications to LAMPOON and to TMVR are
summarized in Online Table 3.
FUTURE DIRECTIONS. Dedicated TMVR devices have
attempted several valve designs to reduce the risk ofatheter Electrosurgery 86
CENTRAL ILLUSTRATION Anterior Leaflet Laceration to Prevent Ventricular Outflow Tract Obstruction During







































in 30 subjects at prohibitive






on exit from catheter
laboratory in 97%
0% Stroke
93% 30 day survival
TMVR limitations persist
with large annuli and PVL
Khan, J.M. et al. J Am Coll Cardiol. 2019;73(20):2521–34.
(Top) View from left ventricular outflow tract with and without intentional laceration of the anterior mitral leaflet to prevent left ventricular outflow obstruction.
(Bottom) Summary trial results. LAMPOON ¼ intentional laceration of the anterior mitral leaflet to prevent left ventricular outflow obstruction; LVOT ¼ left ven-
tricular outflow tract; PVL ¼ paravalvular leak; TMVR ¼ transcatheter mitral valve replacement.
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PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: LVOT obstruction is a common complication of mitral
valve replacement that is associated with a high risk of fatality.
Similar to chord-sparing leaflet resection in patients undergoing
mitral valve surgery, deliberate laceration of the anterior mitral
leaflet achieved with the LAMPOON technique can prevent LVOT
obstruction and improve clinical outcomes in patients undergo-
ing TMVR.
TRANSLATIONAL OUTLOOK: Larger studies with longer-
term follow-up are necessary to confirm the safety and efficacy
of the LAMPOON approach in patients undergoing TMVR.
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2533LVOT obstruction (1). However, LVOT obstruction
remains a leading reason to exclude candidates for
investigational TMVR devices to treat severe native
mitral regurgitation (22% excluded for LVOT
obstruction in the Intrepid TMVR device early feasi-
bility study [29]; 21% excluded for anatomical reasons
in general in the Tendyne TMVR device early feasi-
bility study [35]). LAMPOON has been successfully
used with a Tendyne valve (Abbott, Chicago, Illinois)
(11) at risk of dynamic LVOT obstruction from a long
anterior leaflet and acute aortomitral angulation. The
utility of LAMPOON with other novel TMVR devices
remains to be tested. LAMPOON has also been used to
treat LVOT obstruction from systolic anterior motion
of the native mitral valve leaflet after TMVR (10).
Dedicated devices for LAMPOON, TMVR, and
increased experience should elevate this procedure to
an acceptable therapy for high-risk patients with
mitral valve dysfunction.
LAMPOON is an entirely percutaneous technique
and is the first endovascular procedure to our
knowledge to create a controlled cut in cardiac tissue.
The technique can be adapted and has been used in
other settings, such as to free the anterior mitral
leaflet from an Alfieri stitch prior to TMVR (36) and to
prevent coronary obstruction from transcatheter
aortic valve replacement (bioprosthetic or native
aortic scallop intentional laceration to prevent iatro-
genic coronary artery obstruction) (37).
The LAMPOON IDE study corroborates findings
from the first-in-human series (19), and provides
further support for percutaneous leaflet laceration
enabling TMVR in very sick patients at risk of LVOT
obstruction. Longer-term follow-up and future larger
studies will be further helpful in assessing safety and
efficacy in the long term.
CONCLUSIONS
In selected cases, LAMPOON overcomes the most
common contraindication to TMVR for valve-in-ringJ.M. Khan Transcor valve-in-MAC, which is risk of LVOT obstruction.
This cohort study demonstrates that LAMPOON is
technically feasible in a variety of native and annu-
loplasty ring morphologies. LAMPOON enabled TMVR
in patients deemed otherwise ineligible for therapy.
Candidates with a low skirt neo-LVOT do not benefit
from LAMPOON and remain contraindicated.
LAMPOON exhibits an acceptable safety profile and
did not cause death or stroke.
TMVR in annuloplasty rings and MAC remains
challenging, with high complication rates, especially
related to large mitral annuli and residual para-
valvular leak. Efficacy and functional improvement
with TMVR in these subgroups needs to be assessed
with longer-term follow-up, in larger studies, and in
less critically ill subjects.
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Supplement 
LAMPOON to prevent LVOT Obstruction during Transcatheter Mitral Valve 
Replacement (TMVR): Prospective Multicenter Trial Results 
Participating Sites 




Emory University Hospital Atlanta, GA Vasilis Babaliaros 15 subjects 
Henry Ford Hospital Detroit, MI Adam Greenbaum 
Marvin Eng 
8 subjects 
Carilion Roanoke Memorial 
Hospital 
Roanoke, VA Jason Foerst 4 subjects 
Inova Fairfax Hospital Fairfax, VA Shahram Yazdani 2 subjects 
University of Washington Seattle, WA James McCabe 1 subject 
Participating Personnel 
Emory University Hospital, Atlanta GA: Vasilis Babaliaros; Adam Greenbaum; 
Bradley Leshnower; Madeline Kohrumel; Lisa Warren; Afua Harris; Neil Holtz; Patrick 
Gleason; Frank Corrigan; Norihiko Kamioka; Stamatios Lerakis; Chandan Devireddy; 
James Stewart; Altayyeb Yousef; Anurag Sahu; Sharon Howell; Mary Mungai; Jennifer 
James; Patricia Keegan; James Lee; Kelby Parsons; Vicki Smith; Lauren Wheeler 
Roberts. Henry Ford Hospital, Detroit MI: Adam Greenbaum; Marvin Eng; Dee Dee 
Wang; Tongwa Aka; Rewaa Yas; Marianne Rollet; Ashish Solanki. Carilion Roanoke 
Memorial Hospital, Roanoke VA: Joseph Rowe; Vivian Wilson. Inova Fairfax 
Hospital, Fairfax VA: Shahram Shawn Yazdani; Eric Sarin; Nadim Geloo; Anna 
Villagomez. University of Washington, Seattle WA: James McCabe; Gabriel Aldea; 
Claire Schwaegler. 
Study Management:  Annette Stine (Study Manager); Adriana Byrnes. 
Independent Data Monitors: Artur Karapetyan; Valeriy Matveev; Olha Katynska. 
Data Manager: Sergei Avdiushko. 
Clinical Events Adjudication Committee (Medstar Heart and Vascular Institute): 
Hector Garcia-Garcia (Chair); Eugene McFadden; Alexandre Kajita; Yuichi Ozaki; 
Petros Okubagzi 
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NHLBI Data Safety Monitoring Board: Jamison Bourque (Chair); Thomas Aversano; 
Dean Follmann; David Malenka; Mary Marshall; Gregg Stone 
Central CT Laboratory (NHLBI): Marcus Chen 
Central Echo Laboratory (Henry Ford): Dee Dee Wang 
Statistical Analysis (NHLBI Office of Biostatistics Research): Xin Tian 
Study Selection criteria 
Inclusion Criteria  
• Adults age ≥ 21 years  
• Severe symptomatic native mitral valve failure after mitral annuloplasty repair or 
related to mitral annular calcification.  
• Unacceptably high or prohibitive risk for surgical mitral valve replacement and 
indicated for transcatheter mitral valve replacement (TMVR) as determined by the 
multidisciplinary institutional heart team, including at least one cardiovascular 
surgeon who has examined the patient  
• High or prohibitive risk of LVOT obstruction (predicted neo-LVOT less than 200 
mm2) or transcatheter heart valve dysfunction from long/redundant anterior mitral 
valve leaflet, as determined by the multidisciplinary institutional heart team.  
• Anatomic eligibility for LAMPOON based on core lab assessment of the baseline CT 
and echocardiogram.  
• Concordance of the study selection committee 
Exclusion criteria  
• Subjects unable to consent to participate, unless the subject has a legally authorized 
representative  
• Subjects unwilling to participate or unwilling to return for study follow-up activities.  
• Predicted neo-LVOT created by the Sapien 3 skirt, after LAMPOON, less than 150 
mm2  
• TAVR within 6 weeks  
• Intended concurrent structural heart procedure, such as aortic or tricuspid valve 
implantation  
• Pregnancy or intent to become pregnant prior to completion of all protocol follow-up 
procedures  
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Trial endpoints 
Primary endpoint 
The primary endpoint is “Technical success ACCEPTABLE” (measured at exit from the 
catheterization laboratory). All the following must be present: 
• Successful LAMPOON traversal and laceration; and 
• Peak LVOT gradient < 50 mm Hg; and 
• Absence of procedural mortality; and 
• Successful access, delivery, and retrieval of the LAMPOON device system; and 
• Successful deployment and correct positioning of the first intended device; and 
• Freedom from emergency surgery or reintervention related to the device or access 
procedure. 
The first two factors are modifications of the MVARC (mitral valve academic research 
consortium) consensus endpoint (GW Stone GW, et al, Clinical Trial Design Principles 
and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 2: 
Endpoint Definitions: A Consensus Document from the Mitral Valve Academic Research 
Consortium. J Am Coll Cardiol 2015;66:308-21.), specific for LAMPOON procedure. 
Co-Primary endpoint 
Based on feedback from the FDA, the co-primary endpoint is Technical Success 
OPTIMAL (measured at exit from the catheterization laboratory). This differs from 0 
only in the magnitude of the peak LVOT gradient. 
All the following must be present: 
• Successful LAMPOON traversal and laceration; and 
• Peak LVOT gradient < 30 mm Hg; and 
• Absence of procedural mortality; and 
• Successful access, delivery, and retrieval of the LAMPOON device system; and 
• Successful deployment and correct positioning of the first intended device; and 
• Freedom from emergency surgery or reintervention related to the device or access 
procedure. 
Exploratory Endpoints 
Exploratory endpoints include 
• LVOT obstruction measured as a pressure gradient on catheterization and 
echocardiography 
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• Incidence of LVOT obstruction > 20 mm Hg before discharge and at 30 days, 
including as an alternative LVOT gradient threshold to the primary endpoint 
• Predicted neo-LVOT area based on THV frame had LAMPOON not been performed 
• MVARC 30-day Device Success 
• MVARC 30-day Procedure Success 
• MVARC 1-year Patient Success 
• Mortality, all-cause, cardiovascular vs non-cardiovascular, peri- vs non-
periprocedural, LAMPOON and TMVR relatedness) 
• Neurological events as reported by the site clinicians only 
• Pre-discharge stroke, alone, and in combination with the primary endpoint 
• Myocardial infarction 
• Access and vascular complications 
• MVARC bleeding complications 
• AKIN acute kidney injury 
• Arrhythmia and conduction disturbances 
• Freedom from infection related to the TMVR at each time point 
• Freedom from hemolytic anemia related to TMVR/LAMPOON 
• Device related technical failure: Device Failure, Paravalvular Leak, Pericardial 
effusion, Conversion to open surgery, Device mal-positioning or migration or 
detachment, Device fracture, Unintended damage to native mitral valve apparatus 
• Aortic valve regurgitation change 
• Device thrombosis 
  
J.M. Khan Transcatheter Electrosurgery 93
Supplement Table 1. Baseline characteristics stratified by mitral regurgitation and mitral 
stenosis 






Age, years (median and range) 73.5 (47 - 84) 81.5 (49 - 89) 
Female 6 (60%) 16 (80%) 
BSA, m2 1.8 ± 0.1 1.8 ± 0.2 
TMVR SETTING     
Complete ring 6 (60%) 7 (35%) 
Incomplete ring/band 2 (20%) 0 (0%) 
MAC 2 (20%) 13 (65%) 
Mean mitral valve gradient 
(mmHg) 
6.3±3.4 11 ± 4.0 
CT ANNULAR MEASUREMENTS     
Annular area 523.2 ± 137.2 565.4±144.51 
Antero-posterior distance 21.7 ± 4.0 21.4 ± 3.5 
Inter-commissural distance 29.3 ± 2.7 30.9 ± 4.3 
LVOT obstruction risk     
Aorto-mitral angle, º 118.1 ± 14.8 116.9 ± 6.6 
Septal thickness, mm 11.1 ± 2.9 13.9 ± 3.6 
Fixed LVOT obstruction subset, 
n==25 
(n=6) (n=19) 
Predicted neo-LVOT, mm2 118.8 ± 45.1 68.8 ± 47.8 
Predicted skirt neo-LVOT, mm2 250.5 ± 49.7 224.1 ± 57.1 
Dynamic LVOT obstruction 
subset, n==5 
(n=4) (n=1) 
Anterior mitral leaflet length on 
CT, mm 
26.9 + 2.7 31.5 
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Supplement Table 2. Outcomes stratified by mitral regurgitation and mitral stenosis 
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LVOT peak velocity, 
m/s 
1±0.3 1.3±0.4 1.2±0.6 1.1±0.3 1.6±0.6 1.5±0.6 
LVOT peak gradient, 
mmHg 
7.5±8.4 6.9±4.4 7.2±7 5.1±2.7 11.3±8 10.3±7.5 
LVOT mean 
gradient. mmHg 
1.9±0.9 3.3±2 3.5±3.7 2.6±1.5 5.6±4.6 4.9±4 
LVOT VTI, cm 0.2±0.1 0.2±0.1 0.3±0.2 0.2±0.1 0.3±0.1 0.3±0.1 
Mean transmitral 
gradient, mmHg 
6.3±3.4 5.1±1.2 6.3±2.1 11±4 5.9±2.5 6.8±2.5 
Mitral regurgitation 
severity 
            
None 0 (0%) 1(10%) 2 (20%) 0(0%) 4 (21%) 3(18%) 
Trace 0 (0%) 4 (40%) 4 (40%) 6 (30%) 6 (32%) 4(24%) 
Mild 0 (0%) 4 (40%) 4 (40%) 6 (30%) 9 (47%) 8 (47%) 
Moderate 2 (22%) 1 (40%) 0 (0%) 4 (20%) 0 (0%) 0 (0%) 
Severe 7 (78%) 0 (0%) 0 (0%) 4 (20%) 0 (0%) 2 (12%) 
Peri-prosthetic 
regurgitation 
            
None ⸺ 5 (50%) 9 (90%) ⸺ 11 (65%) 8 (47%) 
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Trace ⸺ 2 (20%) 1 (10%) ⸺ 1 (6%) 3 (18%) 
Mild ⸺ 3 (30%) 0 (0%) ⸺ 5 (29%) 5 (29%) 
Moderate ⸺ 0 (0%) 0 (0%) ⸺ 0 (0%) 0 (0%) 






























































































NA 18.3±4.4 25.1±6.9 NA 18.1±4.9 









4.3±3.5 NA 2.7±1.7 10.0±4.3 NA 2.9±1.6 
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Cardiac Output, 
L/min 
4.9±1.8 NA 5.7±1.4 5.2±1.8 NA 5.3±1.6 





NA 15.9±5.0 18.1±5.8 NA 18.9±4.9 
LVOT peak-to-peak 
gradient, mmHg 




valve area, cm2 
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Supplement Table 3. Cautions and contra-indications to LAMPOON and TMVR 
Step Caution or Contra-
indication 
Comments 
LAMPOON Mechanical AVR (for 
conventional retrograde 
transaortic LAMPOON) 
Alternative access routes for 
LAMPOON are under development 
 Skirt neoLVOT <150mm2 Causes life-threatening LVOT 
gradients 
 No calcium free traversal 
target on anterior mitral 
leaflet 
Once a leaflet is traversed, even if 
heavily calcified, in our experience it 
can be lacerated through 
electrosurgery and possibly fracture 
TMVR LVOT obstruction Avoiding this complication is the 
rationale for procedures such as 
LAMPOON and transcoronary 
alcohol septal ablation 
 Large annulus 
• Intercommissural 
distance >34mm 
• Area >850 mm2 
TMVR using the largest-available 
marketed Sapien 3 29mm valve 
risks life-threatening paravalvular 
leak and embolization. 
Off-label solutions are under 
development  
 Insufficient calcium for 
anchoring 
Objective criteria are missing, but 
most operators there must be 
opposed regions of heavy 
calcification to allow the TMVR to 
anchor 
 Bulky protruding calcium 
mass in the annulus 
We have observed TMVR “kick-
back” during deployment, and zones 
of PVL, attributable to such rigid and 
bulky masses 
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 Calcium pattern suggesting 
caseous necrosis 
Caseous necrosis of the mitral 
annular calcification remodels 
during TMVR and can cause 
paravalvular leak 
 Very eccentric rigid ring  Eccentric annuloplasty rings can 
distort the TMVR device, can create 
zones of paravalvular leak, and can 
contribute to or exaggerate 
annuloplasty ring dehiscence during 
TMVR 
 Dehisced bioprosthetic ring  As above 
 Futility Irreversible pulmonary 
hypertension and end-stage 
cardiomyopathy are not amenable 
to TMVR 
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Supplement Figure 1. Procedure Hemodynamics 
Heart rate and mean arterial pressure is shown for all subjects at three procedure stages: 
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Supplement Figure 2. Correlation between predicted and observed neo-LVOT by CT 
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Chapter Summary 
LAMPOON is a technique to lacerate the anterior mitral valve leaflet using 
transcatheter electrosurgery. First, charge is concentrated at the centre (A2 scallop) 
and base of the anterior mitral valve leaflet via the tip of a guidewire insulated by a 
polymer jacketed microcatheter. During radiofrequency energy application, the 
focused current density causes tissue vaporization and permits guidewire traversal 
through the leaflet. The guidewire tip is snared and externalized, and the kinked and 
denuded inner surface of the guidewire mid-shaft is positioned through the 
perforated base of A2. Both limbs of the guidewire are insulated in guiding catheters 
that are flushed with non-ionic 5% dextrose during guidewire electrification. These 
modifications focus charge on the anterior mitral valve leaflet at the lacerating edge 
of the guidewire. The guidewire and catheters are gently pulled, guiding the 
guidewire loop down the centreline of the anterior mitral leaflet as the tissue 
adjacent to the lacerating edge is vaporized.  
The procedure was tested in seven anesthetized pigs and in one heparinised post-
mortem pig. The results showed controlled centreline laceration of the anterior 
mitral valve leaflet is feasible using transcatheter electrosurgery. Precise traversal 
at the base of A2, guided by echocardiography and cineangiography, and a chord-
free trajectory of the catheters was necessary for optimal splitting and splaying of 
the anterior mitral valve leaflet.  
The procedure was then performed on a compassionate basis in five patients with 
mitral valve failure in the setting of native mitral annular calcification or previous 
mitral valve annuloplasty suitable for anchoring a transcatheter aortic valve. All 
patients were considered inoperable by the heart team and had prohibitive risk of 
LVOT obstruction as predicted on pre-procedure cardiac CT. LAMPOON  traversal 
and laceration was successfully performed in all five patients. Following TMVR, no 
patient developed severe LVOT obstruction despite the high predicted risk. One 
patient developed haemolysis, possibly due to red blood cell shearing against the 
open stent cells of the transcatheter valve protruding into the LVOT. All patients 
survived to discharge and one patient died within 30 days from intractable right 
ventricular failure. The differences in procedure in humans compared to in swine 
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were that 3-D transoesophageal echocardiography provided superior procedure 
guidance in patients compared with 2-D intracardiac echocardiography in swine, a 
transseptal veno-arterial rail was required to position the left atrial snare catheter 
and ensure a chord free trajectory, and TMVR was performed after LAMPOON in 
patients. Unlike in naïve pigs, no patient developed hemodynamic compromise after 
LAMPOON. This could be because the leaflets coapted in systole after the linear 
laceration, and that patients had physiologically compensated for chronically 
elevated left atrial pressures and the acute exacerbation was tolerated in the brief 
time between LAMPOON and TMVR.  
LAMPOON was investigated in a prospective single-arm multicentre clinical trial 
with independent end-point adjudication and core laboratory analysis of images. 30 
subjects at high or prohibitive surgical risk and high risk of LVOT obstruction from 
TMVR were enrolled. LAMPOON traversal and laceration was successful in all 
patients. Four patients required alcohol septal ablation after TMVR due to increased 
LVOT gradients. Three of these patients had a small “skirt neo-LVOT”, an important 
concept realized during this trial and subsequently adopted as an exclusion 
criterion for enrolment. The fourth patient had insufficiently basal leaflet laceration. 
Seven subjects had moderate or severe paravalvular leak, all remote from the site of 
leaflet laceration, with five requiring further procedures to treat the paravalvular 
leak. At 30 days, there were no strokes and 93% survival.  
In developing this novel procedure and investigating it in a carefully designed 
clinical trial, the hypothesis that mitral valve leaflets can be precisely lacerated 
using transcatheter electrosurgery, and that controlled laceration may prevent 
blood flow obstruction following transcatheter valve implantation has been 
demonstrated. Accordingly, the first specific aim of this thesis has been addressed.    
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CHAPTER 4. BASILICA (incorporating two published manuscripts) 
Introduction 
The second specific aim of this thesis was to determine if transcatheter laceration of 
aortic leaflets prevents coronary artery obstruction following TAVI. This chapter 
describes the second of two novel procedures to lacerate valve tissue using 
transcatheter electrosurgery to prevent blood flow obstruction from transcatheter 
valve implantation. The chapter incorporates two published manuscripts, 
describing the pre-clinical and first-in-human experience, and the early feasibility 
prospective clinical trial.  
Transcatheter aortic valve implantation (TAVI) is an effective treatment for aortic 
stenosis. Rarely, the diseased aortic valve leaflets, whether native or from a failed 
bioprosthetic valve, obstruct the coronary arteries when displaced, which can be 
fatal. Bioprosthetic or native Aortic Scallop Intentional Laceration to prevent 
Coronary Artery obstruction (BASILICA) is a transcatheter technique that uses an 
electrified guidewire to lacerate the aortic valve leaflet prior to TAVI to prevent 
coronary artery obstruction. Using procedure steps similar to those described for 
the LAMPOON procedure, the target aortic leaflet is lacerated in line with the 
coronary ostium and splays after valve implantation.  
In line with the specific aims, we developed the novel BASILICA transcatheter 
procedure in anesthetized pigs to precisely lacerate the aortic valve leaflets in line 
with the coronary ostia. Also, in line with the specific aims, we conducted an early 
feasibility phase 1 study of the procedure in 30 human subjects predicted on CT 
imaging to be at prohibitive risk of coronary artery obstruction from TAVI and 
therefore excluded from available treatment. 
Role of transcatheter electrosurgery 
The transcatheter electrosurgery techniques in BASILICA are like those used in 
LAMPOON. They enable the procedure to be done percutaneously. A guidewire is 
directed by a catheter to the target at the base of the aortic leaflet. The guidewire is 
insulated in a polymer jacketed microcatheter with only the tip exposed to minimize 
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the surface area of the active electrode for charge concentration at the leaflet base. 
During brief electrification, the guidewire traverses the base of the leaflet. The 
guidewire is snared and retrieved and the Flying V lacerating surface created and 
positioned at the basal perforation site. Insulation around this lacerating edge is 
provided by 5% dextrose infusion through catheters which sheath both limbs of the 
guidewire. Gentle tension is applied to the catheters and guidewires, directing the 
lacerating edge from the base of the aortic leaflet to the tip, vaporizing the leaflet 
down the centreline. Careful transcatheter electrosurgery techniques are required 
to create a controlled laceration without unpredictable leaflet avulsion or collateral 
injury.  
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Transcatheter Laceration of Aortic Leaflets to Prevent Coronary 
Obstruction During Transcatheter Aortic Valve Replacement: 
Concept to First-in-Human 
An original research manuscript published in the journal JACC: Cardiovascular 
Interventions in 2018 
Candidate’s contribution 
My colleagues and I conceived of the idea for BASILICA. I personally devised the 
specific procedure steps, techniques, and inventory list. I established how to 
reproducibly use transcatheter electrosurgery to cut both left and right coronary 
cusps of the aortic valve using a transfemoral approach. I designed and performed 
all the animal experiments. I planned all clinical cases, including all procedure steps 
and contingency plans, and proctored or performed all cases. I drafted, designed the 
figures, and consulted all the references for this pre-clinical and first-in-human 
manuscript, on which I am first author.  
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BloOBJECTIVES This study sought to develop a novel technique called bioprosthetic or native aortic scallop intentional
laceration to prevent coronary artery obstruction (BASILICA).
BACKGROUND Coronary artery obstruction is a rare but fatal complication of transcatheter aortic valve replacement
(TAVR).
METHODS We lacerated pericardial leaflets in vitro using catheter electrosurgery, and tested leaflet splaying after benchtop
TAVR.Theprocedurewas tested in swine.BASILICAwas thenoffered topatients athigh riskof coronaryobstruction fromTAVR
and ineligible for surgical aortic valve replacement. BASILICA used marketed devices. Catheters directed an electrified
guidewire to traverse and lacerate the aortic leaflet down the center line. TAVR was performed as usual.
RESULTS TAVR splayed lacerated bovine pericardial leaflets. BASILICA was successful in pigs, both to left and right
cusps. Necropsy revealed full length lacerations with no collateral thermal injury. Seven patients underwent BASILICA on
a compassionate basis. Six had failed bioprosthetic valves, both stented and stent-less. Two had severe aortic stenosis,
including 1 patient with native disease, 3 had severe aortic regurgitation, and 2 had mixed aortic valve disease. One
patient required laceration of both left and right coronary cusps. There was no hemodynamic compromise in any patient
following BASILICA. All patients had successful TAVR, with no coronary obstruction, stroke, or any major complications.
All patients survived to 30 days.
CONCLUSIONS BASILICA may durably prevent coronary obstruction from TAVR. The procedure was successful
across a range of presentations, and requires further evaluation in a prospective trial. Its role in treatment of
degenerated TAVR devices remains untested. (J Am Coll Cardiol Intv 2018;11:677–89) Published by Elsevier on behalf of
the American College of Cardiology Foundation.N 1936-8798/$36.00 https://doi.org/10.1016/j.jcin.2018.01.247
m the aCardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes
Health, Bethesda, Maryland; bUniversity of Washington, Seattle, Washington; cCenter for Structural Heart Disease, Division of
rdiology, and Division of Cardiac Surgery, Henry Ford Health System, Detroit, Michigan; and the dStructural Heart and Valve
nter, Emory University Hospital, Atlanta, Georgia. Supported by the National Heart, Lung, and Blood Institute, National
titutes of Health (Z01-HL006040-7), and by the intramural programs of the participating centers. National Heart, Lung, and
od Institute has a collaborative research and development agreement with Edwards Lifesciences on transcatheter modification
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ABBR EV I A T I ON S
AND ACRONYMS
BASILICA = bioprosthetic or
native aortic scallop intentional
laceration to prevent iatrogenic
coronary artery obstruction
CT = computed tomography
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J.M. KhanT ranscatheter aortic valve replace-ment (TAVR) is an effective alterna-tive to surgical aortic valve
replacement in intermediate- and high-risk
patients with native aortic stenosis (1,2).
TAVR is also an effective treatment for fail-
ure of bioprosthetic surgical aortic valves, a
treatment known as valve-in-valve TAVR
(3,4). Coronary artery obstruction is a devas-tating complication of TAVR, with a >50% mortality
(5). Coronary artery obstruction occurs when the
transcatheter heart valve displaces the underlying
surgical or native aortic valve leaflets outward and
obstructs the coronary artery ostia, either by sealing
the sinus of Valsalva at the sinotubular junction or
by the leaflet itself covering the coronary ostia
because of low-lying coronary ostia and inadequate
sinus width (Figure 1). Coronary artery obstruction
is 4 times as common during valve-in-valve
TAVR as during TAVR for native aortic stenosis (6),SEE PAGE 690likely because most surgical prostheses are supra-
annular in design, lowering coronary heights relative
to the valve leaflets, and because valve suturing
draws the coronaries closer, decreasing sinus width.
The risk of coronary obstruction is highest during
TAVR for surgical bioprothesis designs intended to
maximize effective aortic orifice area (“stented” bio-
prostheses that have externally mounted leaflets,
and “stent-less” surgical bioprostheses) (5). Treat-
ment requires bail-out percutaneous coronary inter-
vention, which may not be possible with a valve
leaflet obstructing the coronary artery, or emergency
bypass surgery. Pre-emptive coronary protection
with a guidewire, with or without a coronary balloon
or stent prepositioned down the coronary artery, is
variably successful (7,8) in the short and intermediate
term. One-third of coronary obstruction events may
manifest after the TAVR is concluded (5).
We propose a solution based on the LAMPOON
procedure (9,10), which uses catheters to split thel valve. Dr. Dvir is a consultant for Edwards Lifesciences, Medtron
s Lifesciences and Abbott St. Jude Medical. Dr. Babaliaros is a cons
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received October 20, 2017; revised manuscript received Decemb
Transcatheter Electrosurgmitral valve leaflet and prevent obstruction of the left
ventricular outflow tract during transcatheter mitral
valve replacement. Here we report a technique to
split aortic valve leaflets, whether bioprosthetic or
native, to prevent coronary artery obstruction after
TAVR. The new technique is called bioprosthetic or
native aortic scallop intentional laceration to prevent
coronary artery obstruction (BASILICA).
We developed the technique in vitro and in ani-
mals, and then offered the procedure to patients
experiencing aortic valve failure who were ineligible
for conventional surgical aortic valve replacement,
and high or prohibitive risk of coronary artery
obstruction from TAVR.METHODS
We set out to demonstrate several key technical
principles. First, that an aortic leaflet scallop can be
traversed in situ by an electrified guidewire between
the sinus of Valsalva and the left ventricular outflow
tract. Second, that the traversed leaflet, whether
native or bioprosthetic, can be lacerated in situ by the
mid-shaft of an electrified guidewire. Third, that the
lacerated leaflets splay after TAVR to allow blood flow
across them toward otherwise obstructed coronary
ostia. Fourth, whether partial (mid-scallop vs. basal
leaflet) lacerations extend lengthwise when stretched
by an implanted valve, which may influence the
required spatial precision of the procedure. Fifth, that
both left and right coronary cusps can be lacerated
simultaneously in vivo.
IN VITRO. We tested radiofrequency-assisted
transcatheter perforation and laceration of exterior-
mounted bovine pericardial leaflets on a representa-
tive bioprosthetic heart valve (19-mm Trifecta valve,
Abbott St. Jude Medical, St. Paul, Minnesota) sub-
merged in a 0.9% saline bath with a remote dispersive
electrode (Online Figure 1). Two lacerations were
attempted on the bioprosthetic heart valve. One leaflet
was lacerated from base to tip and the second fromic, and St. Jude Medical. Dr. Greenbaum is a proctor
ultant for Edwards Lifesciences and Abbott Vascular;
theter aortic and mitral devices from Edwards Life-
ific. Dr. Eng is a proctor for Edwards Lifesciences.
r Edwards Lifesciences. Dr. Guyton’s employer has
Edwards Lifesciences, Abbott Vascular, Medtronic,
his employer has research contracts for clinical
ifesciences, Abbott Vascular, Medtronic, St. Jude
ave no relationships relevant to the contents of this















FIGURE 1 Illustrations of Coronary Obstruction and Prevention by BASILICA
In normal transcatheter aortic valve replacement performed in a capacious aortic root, blood flows unrestricted around valve leaflets into
coronary arteries. In patients with a crowded sinus and low-lying coronary arteries, coronary blood flow is obstructed by the bioprosthetic
valve leaflets after transcatheter aortic valve replacement. After BASILICA, blood flows through the open cells of the transcatheter heart valve
unimpeded into the coronary artery. BASILICA ¼ bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary
artery obstruction; LCA ¼ left coronary artery; RCA ¼ right coronary artery.
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679mid-point to tip. A third scallop was left intact and
served as a control.
Balloon expandable (20-mm Sapien 3, Edwards
Lifesciences, Irvine, California) and self-expanding
valves (23-mm Evolut Pro, Medtronic, Minneapolis,
Minnesota) were deployed in the bioprosthetic valve
to test splaying of split leaflet around the open cells of
the transcatheter heart valve and propagation of the
split in the leaflet. A second valve (25-mm Mitroflow,
Sorin Livanova, London, England) was cut with a
scalpel and leaflet splaying was also tested with
appropriately sized balloon expanding and self-
expanding valves.
ANIMALS. Animal experiments on naive Yorkshire
and Yucatan pigs were approved by the institutional
animal care and use committee and conducted per
contemporary National Institutes of Health guide-
lines. Anesthesia was induced and maintained with
mechanical ventilation and inhaled isoflurane, 2
femoral arterial sheaths of 6-F catheter and a 9-F
catheter femoral venous sheath were placedJ.M. Khan Transcpercutaneously, and heparin and amiodarone were
administered. The BASILICA procedure without TAVR
was performed using catheters directed under
biplane x-ray fluoroscopy and intracardiac echocar-
diography guidance. Pre-procedural cardiac magnetic
resonance imaging was performed at 1.5-T (Aera,
Siemens, Erlangen, Germany) to plan fluoroscopy
projection angles. Hemodynamics were recorded for 1
h after laceration until euthanasia. The length of
scallop laceration relative to the overall length of the
scallop was measured using calipers at necropsy. The
heart was carefully inspected for evidence of
bystander electrical or mechanical injury.
CLINICAL. Pat ients . Patients with high or prohibi-
tive risk for surgical aortic valve replacement and
high risk of coronary artery obstruction with TAVR
underwent TAVR with BASILICA at 3 medical centers
(University of Washington, Henry Ford, and Emory
University Hospitals). All consented to clinical treat-
ment on a compassionate basis, despite explicitly















FIGURE 2 Illustration of the BASILICA Procedure
A catheter directs an electrified guidewire through the base of
the left aortic cusp into a snare in the left ventricular outflow
tract (A). After snare retrieval (B), the mid-shaft of the guide-
wire is electrified to lacerate the leaflet (C). The leaflet splays
after transcatheter aortic valve replacement permitting cor-
onary flow (D). Abbreviation as in Figure 1.
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J.M. Khanmultidisciplinary heart teams. The institutional
ethics review boards of all participating institutions
approved this retrospective report.
The local heart teams determined coronary
obstruction risk based on manufacturer-describedTranscatheter Electrosurggeometry of the specific implanted bioprosthetic
valve; and computed tomography (CT) and angio-
graphic measurements of the coronary ostia heights,
sinus of Valsalva width, presence and type of bio-
prosthetic valve, and virtual transcatheter heart valve
to coronary distance (Figure 1) (5).
BASIL ICA procedure . The procedure was planned
using electrocardiogram-gated contrast-enhanced
CT, performed under general anesthesia, and guided
by fluoroscopy and transesophageal echocardiogra-
phy. Catheter access was obtained typically via 3
femoral arterial (2 typically ipsilateral for BASILICA,
and 1 for TAVR) and at least 1 venous (for temporary
transvenous pacing) introducer sheaths. Heparin
anticoagulation achieved an activated clotting time
>300 s.
A pair of coaxial catheters (typically a 5-F mammary
diagnostic catheter inside a 6-F extra backup shape-
guiding catheter) was positioned in the targeted
aortic leaflet scallop to direct a guidewire across it,
near the scallop hinge point, by echocardiographic
and angiographic guidance. These aimed at a snare
positioned immediately below the leaflet using a
separate retrograde catheter (Figure 2, Online Video 1).
To traverse the aortic leaflet scallop, a 0.014-inch
guidewire (Astato XS 20, Asahi-Intecc, Santa Ana,
California) sheathed in an insulated polymer jacket
(Piggyback Wire Convertor, Vascular Solutions Tele-
flex, Minneapolis, Minnesota) was electrified,
advanced, and snare-retrieved. The wire was electri-
fied using a short burst of “cutting” radiofrequency
energy (w30 W) by clamping to an electrosurgery
pencil (Valleylab FX, Covidien Medtronic, Minneap-
olis, Minnesota).
After externalization of the free guidewire end,
the guidewire straddles across the leaflet scallop
between 2 catheters. The scallop was lacerated by
applying radiofrequency energy at approximately 70
W while tensioning both free ends of the guidewire.
A pigtail catheter was pre-positioned in the left
ventricle to allow TAVR to be performed immedi-
ately afterward.
TAVR was performed using established techniques.
Coronary artery stent systems were positioned pro-
phylactically at the discretion of the operator.
Cracking of a failed bioprosthetic heart valve frame,
using a high-pressure balloon (11), was performed at
operator discretion to achieve an optimum hemody-
namic result. Coronary artery patency was assessed
using angiography and post-TAVR CT. Antiplatelet
and anticoagulation therapy were prescribed at
operator discretion. Complications were assessed ac-
cording to the Valve Academic Research Consortium-















FIGURE 3 Benchtop Simulation of BASILICA
Two different transcatheter heart valves (23-mm Sapien 3, A, B; 26-mm Evolut Pro, C, D) implanted in 25-mm Mitroflow before (A, C) and















FIGURE 4 Necropsy After BASILICA in an Animal
Animal necropsy viewed from the aorta showing a split left
coronary cusp in line with the left coronary artery ostium.
LCC ¼ left coronary cusp; NCC ¼ noncoronary cusp; RCC ¼ right
coronary cusp.
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681STATISTICAL ANALYSIS. In this small clinical series,
we express continuous variables as median and
interquartile range. We express categorical variables
as counts and percentages. We made no statistical
comparisons because of the small sample size.
RESULTS
IN VITRO. A guidewire (Astato XS 20, Asahi) perfo-
rated a bioprosthetic bovine pericardial valve leaflet
(Trifecta, Abbott St. Jude Medical) using a <1-s burst
of radiofrequency energy at 20 W in a saline bath.
Laceration with a continuous nonionic (5% dextrose)
flush through 2 guiding catheters required 5 s (half
leaflet) and 18 s (full leaflet) of radiofrequency energy
at 20 W. Laceration using mechanical force without
electrification was not possible in this valve.
A 20-mm Sapien 3 valve (Edwards Lifesciences)
was deployed on the benchtop inside the lacerated
Trifecta valve. The laceration mid-way down theJ.M. Khan Transcatheter Electrosurgery 111
FIGURE 5 BASILICA for Transcatheter Aortic Valve Replacement With Sapien 3 in Failed Mitroflow Valve
(A) Left coronary injection demonstrates a high risk of left coronary obstruction from the Mitroflow leaflet (double headed arrow). (B) Coaxial
catheters direct an electrified guidewire through the left coronary leaflet of the Mitroflow valve into the left ventricular outflow tract snare.
(C) Laceration with radiofrequency concentrated at the kinked mid-shaft of the Astato guidewire (arrow). (D) Left cusp injection with flow
through split leaflet and patent left coronary artery that would otherwise have been obstructed. Abbreviations as in Figures 1 and 4.
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J.M. Khanbioprosthetic scallop did not propagate, nor did it
result in satisfactory parting of the leaflet. The full-
length laceration did not propagate further and
resulted in satisfactory parting of the leaflet. The
intact leaflet completely draped the Sapien 3 stent
cells. The results with the cut Mitroflow valve were
similar (Figure 3). Flaring of the bioprosthetic stent
posts increased splaying of the split leaflet.
ANIMALS. Five consecutive pigs (38 to 47 kg) under-
went attempted BASILICA, 3 on the left coronary cusp
and 2 on both left and right coronary cusps (Online
Table S1). The procedure time reduced with further
experience, despite the increased complexity of dou-
ble BASILICA. BASILICA resulted in severe aorticTranscatheter Electrosurgregurgitation with a reduction in diastolic blood
pressure in all pigs. Two pigs required euthanasia
before 1 h was complete because of poor hemody-
namics, the first after inadvertent mitral chordal
laceration, and the other following double BASILICA.
Guidewire traversal required <1 s of radio-
frequency energy at 20 to 30 W for all 5 animals.
Guidewire laceration required 2 to 3 s of radio-
frequency energy at 30 W and <1 s at 70 W. Minimal
subjective mechanical force was required for both
traversal and laceration. Laceration was central and
extended from base to tip in all animals (mean
laceration length was 12 mm and mean cusp length
14 mm for the left, and 12 mm and 12.5 mm, respec-
tively, for the right) (Figure 4).
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FIGURE 6 BASILICA and Transcatheter Aortic Valve
Replacement With Sapien 3 for Native Aortic Stenosis
(A) An electrified guidewire traverses native left coronary cusp
leaflet into the left ventricular outflow tract snare. (B) Leaflet
laceration through exposed kinked guidewire shaft (arrow).
(C) Aortic root angiography showing coronary flow in a low-
lying coronary artery that may have been obstructed without
BASILICA. Abbreviations as in Figures 1 and 4.
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J.M. Khan TranscMajor complications occurred in the first attemp-
ted animal BASILICA for left and right coronary cusps,
respectively. These included mitral chord entrapment
and laceration resulting in severe mitral regurgita-
tion; misdirected wire traversal into the left atrium or
interventricular septum, the latter causing ventricu-
lar fibrillation requiring defibrillation; and partial
annular laceration without pericardial effusion from
annulus rather than leaflet traversal. Thereafter we
refined the BASILICA technique (assiduous posi-
tioning of the traversal wire and of the snare catheter
in the distal left ventricular outflow tract) and
observed no important complications. There was no
macroscopic evidence of collateral thermal damage in
benchtop or in vivo necropsy specimens.
CLINICAL. Seven patients underwent TAVR with
BASILICA (Figures 5 to 9). There were a range of
diseased aortic valve substrates: 1 had a porcine aortic
stent-less bioprosthetic valve, 1 had a stent-less
bovine pericardial valve, 4 had stented bovine peri-
cardial valves, and 1 had native aortic valve stenosis.
One of the 7 required laceration of 2 aortic leaflet
scallops and the rest of only the left.
Table 1 shows their clinical characteristics. All were
believed to be unsuitable for surgery by the multi-
disciplinary heart teams. Five had prior coronary ar-
tery bypass grafts that were believed not to protect
threatened vessels. Six had failed bioprosthetic aortic
valves and 1 had native aortic stenosis. All were
believed to be at high risk of left coronary obstruction
with median coronary height of 6.8 mm, left sinus of
Valsalva width of 24.3 mm, and virtual transcatheter
valve to coronary distance of 2.8 mm (Online
Figure 2). One patient also had a threatened right
coronary artery (Online Table S2).
Table 2 details the procedure. All attempted leaflets
were successfully traversed and lacerated. The
laceration was central and along most of the leaflet
length as depicted on transesophageal echocardiog-
raphy (Figure 8B). All patients had severe aortic
regurgitation after laceration. Heart rate and systolic
blood pressures were unchanged in all cases, and no
patient required pharmacologic or mechanical he-
modynamic support in the 8 to 30 min between
laceration and valve deployment, nor afterward.
No patient had coronary obstruction evident on
coronary and aortic root angiography, nor echocar-
diographic regional wall motion assessment. One of
the pre-positioned stents was entrapped by the
transcatheter heart valve and so was deployed in the
left main coronary artery in the absence of coronary














FIGURE 7 Double BASILICA and Transcatheter Aortic Valve Replacement With Sapien 3 for Failed Magna Valve
(A) Heavily calcified leaflets, especially the left coronary cusp. (B) Left coronary height is low at 3.4 mm. (C) Both left and right VTC are low at
3.3 mm. (D) An electrified guidewire traverses the left coronary leaflet of a Magna valve. (E) The left coronary leaflet guidewire has been
externalized to form a loop and a second electrified guidewire traverses the right coronary leaflet. (F) Loops formed around both left (white
arrow) and right (black arrow) coronary cusps, ready for sequential laceration. (G) After transcatheter aortic valve replacement a high-
pressure balloon is inflated to crack the bioprosthetic valve to improve hemodynamics. (H) The bioprosthetic valve has been fractured at the
site of the black arrow. (I) Angiography demonstrates good flow to both coronary arteries that may otherwise have been completely
obstructed. VTC ¼ virtual transcatheter valve to coronary distance; other abbreviations as in Figures 1 and 4.
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J.M. Khanthe body undeployed. Procedural hemodynamics
confirmed satisfactory valve gradients and no patient
with more than mild paravalvular leak. Three patients
had follow-up CT scans confirming good flow in the
coronary arteries.
Clinical outcomes and standardized TAVR end-
points are shown in Table 3 and Online Table S3 (12).Transcatheter ElectrosurgOne patient had transient sinus bradycardia requiring
temporary transvenous pacing. There were no other
complications. Four patients underwent precaution-
ary intensive care unit observation overnight; the
remainder were transferred directly to ward beds.
The median length of stay was 4 days. All patients
survived beyond 30 days.
ery 114
FIGURE 8 Transesophageal Echocardiography During BASILICA and Transcatheter Aortic Valve Replacement With Sapien 3 for
Failed Sorin Solo Freedom Valve
(A) Echocardiography view showing the traversal catheter is aligned at the base of the left coronary cusp (upward white arrow). A snare
catheter is positioned across the valve (downward white arrow). (B) The laceration in the left coronary cusp is seen (white arrow), adjacent
to the left coronary artery ostium. Abbreviation as in Figure 1.
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685DISCUSSION
We describe a new technique that allows trans-
catheter heart valve treatment in patients otherwise
ineligible for any therapy because of a high risk of
valve leaflet-induced coronary artery obstruction. We
have demonstrated through benchtop testing, animal
experiments, and experience from 7 patients that: 1)
BASILICA seems technically feasible in all valve types
and valve conditions, including single and double
leaflet laceration, porcine and bovine pericardial
bioprostheses, stented and stent-less bioprostheses,
and in 1 case of native aortic leaflet disease; 2) there
was no hemodynamic collapse after laceration
regardless of baseline aortic regurgitation (n ¼ 5) or
aortic stenosis (n ¼ 2); and 3) there was uniform
success in preserving coronary blood flow.
The current strategy of ad hoc percutaneous
intervention or up-front coronary protection using a
pre-positioned wire, with or without balloon or stent,
is problematic. Coronary obstruction may be delayed
despite normal flow at the end of the TAVR procedure
(13). There are few data to support the longevity of a
“chimney” coronary stent extending beyond the
coronary ostium with a valve leaflet draped across it.
The ostial left main stent is at risk of fatal restenosis
and thrombosis (14). Re-engaging a coronary artery is
challenging after TAVR, and becomes almost impos-
sible with an ostial “chimney” stent (14,15). As seen in
Patient #7, the stent can be entrapped and thenJ.M. Khan Transcrequires unnecessary deployment. Applying caution
in this initial human experience, the threatened cor-
onaries were still protected by wiring and placing a
stent mid-vessel after BASILICA. Although the 1
entrapped stent confirmed the preprocedural concern
for coronary obstruction and need for intervention to
allow safe TAVR, the inability to remove the stent
necessitated deployment despite otherwise success-
ful BASILICA. It is difficult to know at this early stage
whether pre-positioning a stent after successful
BASILICA is mandated or whether the harm out-
weighs the benefits. As experience with BASILICA and
its success increases, we would predict a transition to
no prophylactic coronary stent protection.
One application of BASILICA not yet performed but
worth considering is to treat failed TAVR devices,
which are likely to become more common as TAVR is
applied to lower-risk patients who are expected to live
longer. The risk of coronary obstruction in patients
with previous TAVR may be elevated in patients with
high implantation and supra-annular TAVR devices
engineered to have longer leaflets (such as Medtronic
Corevalve). Several transcatheter heart valves are
implanted with the top of the valve at the sinotubular
junction where coronary filling is dependent on dia-
stolic valve-leaflet closure. We speculate that
BASILICA may be helpful in this setting.
In this small series, we observed that split leaflets
continued to appose during diastole, and caused in-















FIGURE 9 Computed Tomography Images Following BASILICA and Transcatheter Aortic Valve Replacement With Sapien 3 and Evolut Pro
(Top) Sapien 3; (Bottom) Corevalve Evolut Pro. (A and B) A narrow neosinus (double-headed arrow) maintains flow to the right coronary
artery but the left sinus (B and C) is completely effaced. (D and E) The left coronary artery was at risk of occlusion but there is adequate filling
following BASILICA. Abbreviations as in Figure 1.
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J.M. KhanPatients did not require pharmacologic or mechanical
support during the short period before TAVR.
STUDY LIMITATIONS. Our experience remains
limited, and confined to the specific bioprosthetic
devices and single native valve described. The leaflets
may splay variably depending on the type of bio-
prosthetic and transcatheter heart valve combination
used, as may flow through the open cells of the
transcatheter heart valve. Despite successful
BASILICA, TAVR device commissures may limit flow
to the coronary arteries by accidentally unfavorable
rotational orientation.
We observed no hemodynamic deterioration be-
tween BASILICA laceration and TAVR in this small
series. Our patients had relatively preserved left
ventricular systolic function (Table 1). Although 2 of 7Transcatheter Electrosurghad primarily stenotic lesions and 3 of 7 primarily
mixed stenotic and regurgitant, the applicability to
patients with more profound ventricular dysfunction
requires further investigation. Likewise, despite
operator precautions, BASILICA may injure mitral
valvular structures.
The role of BASILICA combined with intentional
balloon fracture to expand the valve frame (11), re-
mains uncertain. Double-leaflet BASILICA poses extra
challenges particularly with vascular access. Heavily
calcified leaflets are probably unsuited to BASILICA,
as evidenced by the prolonged procedure time
because of difficulty traversing in Patient #4.
Although there were no evident strokes in this
initial series, lacerating a heavily calcified leaflet may
generate embolic debris that cause stroke and in this
setting, judicious use of cerebral embolic protectionery 116
TABLE 1 Clinical Characteristics
All
Patient #
1 2 3 4 5 6 7
Age, yrs 74 (70–76) 87 74 74 67 78 68 71
Female, % 86 1 1 1 0 1 1 1
STS PROM aortic
replacement, %
12.7 (6.3–14.1) 13.4 4.6 19.5 2.0 12.7 8.0 14.7
Frailty, % 67 1 1 1 0 1 0 NA
Coronary artery
disease, binary, %
71 1 1 0 1 0 1 1
Prior CABG, % 71 1 1 0 1 0 1 1
Prior stroke, % 14 0 0 0 0 0 0 1
Atrial fibrillation, % 57 1 0 1 0 1 0 1
eGFR, ml/min/1.73 m2 53 (41–61) 60 31 12 62 51 65 53
NT-proBNP baseline,
pg/ml
517 (289–709) 701 332 712 2,145 262 275 NA
NYHA CHF functional
class
3 (3–4) 4 3 4 3 3 3 3
Severe pulmonary
disease, %
29 0 0 0 0 1 1 0
LV ejection fraction, % 0.58 (0.45–0.60) 65 58 45 45 60 60 40
RV dysfunction, % 14 0 0 0 0 1 0 0









21 (21–23) 19 21 21 23 NA 21 23
Bioprosthetic valve
type





5 (3–11) 6 14 4 3 NA 13 2
Primary lesion Regurgitation, 3;
stenosis, 2;
mixed, 2



































































































AVR ¼ aortic valve replacement; CABG¼ coronary artery bypass grafting; CHF ¼ congestive heart failure; eGFR ¼ estimated glomerular filtration rate; LAA¼ left atrial appendage; LV ¼ left ventricle; MVR¼
mitral valve replacement; NA ¼ not applicable; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; NYHA ¼ New York Heart Association; RV ¼ right ventricle; STS PROM ¼ Society of Thoracic Surgery
predicted risk of mortality; TAVR ¼ transcatheter aortic valve replacement.
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687strategies, and brain magnetic resonance imaging,
may be appropriate. Protracted radiofrequency abla-
tion is widely used in the left atrium and left ventricle
with a low risk of coronary and cerebral thrombo-
embolism. By comparison we use shorter bursts
of vaporizing high duty-cycle “cutting mode” elec-
trosurgery, also with full anticoagulation. HumanJ.M. Khan Transccadaver experiments may shed light on the potential
for embolization during bioprosthetic and native
aortic valve manipulation.
Coronary flow was assessed angiographically by
assessing echocardiographic left ventricular wall
motion but a pressure wire or other intracoronary
imaging was not used.atheter Electrosurgery 117
TABLE 2 Procedure Characteristics and Hemodynamics
All
Patient #
1 2 3 4 5 6 7
Transcatheter heart valve Sapien 3, 6;
Evolut Pro, 1
Sapien 3 Evolut Pro Sapien 3 Sapien 3 Sapien 3 Sapien 3 Sapien 3
Transcatheter heart valve size, mm 23 (22–23) 20 23 23 23 26 20 23
Transcatheter heart valve
post-dilatation
14% 0 0 0 0 0 1 0
Invasive hemodynamics baseline
Aortic regurgitation severity
(0 ¼ none, 1 ¼ trace, 2 ¼ mild,
3 ¼ moderate, 4 ¼ severe)
4 (3–4) 4 4 4 3 2 2 4
Aortic valve peak-to-peak
gradient, mm Hg
43 (14–64) 12 8 43 72 56 135 15
HR 75 (71–80) 84 72 67 77 69 83 75
SBP 126 (96–148) 151 126 93 95 166 145 97
DBP 44 (39–50) 32 47 35 53 73 42 44
LVEDP 31 (22–34) 23 21 35 36 31 32 16
Invasive hemodynamics completion
Aortic regurgitation severity
(0 ¼ none, 1 ¼ trace, 2 ¼ mild,
3 ¼ moderate, 4 ¼ severe)
0 (0–1) 0 0 1 0 0 1 2
Aortic valve peak-to-peak
gradient, mm Hg
1 (1–7) 1 10 1 12 0 0 3
HR 81 (79–84) 80 82 85 79 62 87 40 (sinus brady,
paced at 80)
SBP 175 (151–179) 177 151 175 120 181 197 150
DBP 68 (64–72) 64 63 79 68 72 57 71
LVEDP 27 (26–30) 34 28 26 26 27 18 31
Echocardiography, baseline
Aortic regurgitation severity
(0 ¼ none, 1 ¼ trace, 2 ¼ mild,
3 ¼ moderate, 4 ¼ severe)
4 (3–4) 4 4 3.5 4 3 2 4
Aortic valve peak velocity, m/s 3.4 (3.2–4.6) 3.3 3.1 5.6 4.1 3.4 5.0 1.6
Aortic valve mean gradient, mm Hg 24 (22–48) 24.0 22.0 67.0 22.6 45.4 51.0 4.8
Indexed effective orifice area, m2/m2 0.62 (0.49–1.00) 1.0 1.6 0.48 0.31 0.49 0.62 1.0
LVEF, % 58 (45–60) 65 58 45 45 60 60 35
Echocardiography, pre-discharge
Aortic regurgitation severity
(0 ¼ none, 1 ¼ trace, 2 ¼ mild,
3 ¼ moderate, 4 ¼ severe)
0 (0–0) 0 0 1 0 0 0 0
Aortic valve peak velocity, m/s 2.9 (2.7–3.2) 3.3 2.7 3.6 2.6 3.1 2.9 1.6
Aortic valve mean gradient, mm Hg 18 (17–21) 17.0 16.0 28.2 17.6 21.0 20.0 4.8
LVEF, % 61 (56–65) 71 64 61 51 60 65 35
DBP ¼ diastolic blood pressure; HR ¼ heart rate; LVEDP ¼ left ventricular end diastolic pressure; LVEF ¼ left ventricular ejection fraction; SBP ¼ systolic blood pressure.
TABLE 3 Clinical Outcomes
All
Patient #
1 2 3 4 5 6 7
Length of stay after TAVR, days 4 (4–5) 4 4 6 1 5 5 3
ICU stay, days 1 (0–2) 2 2 0 0 1 1 0
Survival to hospital discharge 100% 1 1 1 1 1 1 1
Survival 30 days 100% 1 1 1 1 1 1 1
Survival ascertainment, days 116 (109–153) 154 154 151 116 109 109 95
NYHA functional class at latest follow-up 2.0 (1.5–2.0) 2 2 1 2 1 2 2
Values are median (interquartile range) or %. ICU ¼ intensive care unit; other abbreviations as in Table 1.
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J.M. Khan Transcatheter ElectrosurgFinally, there was no comparator and so coronary
artery obstruction was not certain but predicted using
prevailing standards, which have their limitations.
The potential risk and benefit of BASILICA should be
weighed before applying it to any patient, including
the risk of embolization and, in patients with severe
ventricular dysfunction, the risk of acute severe
aortic regurgitation.
We believe technical descriptions are no substitute
for live observation, and we recommend BASILICA
only be undertaken with appropriate training.ery 118
PERSPECTIVES
WHAT IS KNOWN? Coronary obstruction following TAVR
carries up to 50% mortality, and CT-predicted coronary
obstruction may deprive patients of TAVR as a therapeutic
option. Current methods of pre-emptive or bail-out coronary
stenting are suboptimal.
WHAT IS NEW? We describe a catheter technique (BASILICA)
to lacerate aortic leaflets that otherwise threaten to obstruct a
coronary artery during TAVR. After TAVR, which is performed
immediately after BASILICA, blood is able to flow across the
lacerated aortic leaflets into the coronary arteries.
WHAT IS NEXT? BASILICA may have value in the future as
more patients have bioprosthetic surgical and even transcatheter
aortic valves likely to degenerate. BASILICA warrants further
prospective evaluation in a larger number of patients.
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689CONCLUSIONS
Bioprosthetic and native aortic leaflet laceration
seems feasible and may reduce the risk of coronary
artery obstruction following TAVR in patients at high
risk. No patient had a drop in blood pressure
following BASILICA. The technique offers a promising
alternative to “chimney” stenting to provide durable
prevention against coronary obstruction from TAVR.
BASILICA needs careful prospective investigation,
which begins with a Food and Drug Administration–
approved trial in early 2018.
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Supplement  
Transcatheter laceration of aortic leaflets to prevent coronary obstruction during 
transcatheter aortic valve implantation: concept to first-in-human 
Methods 
Details about BASILICA Technique 
Radiofrequency energy was confined to the guidewire-leaflet contact point by four 
maneuvers. First, the guidewire was kinked in mid-shaft, to assure proper 
positioning and close tissue contact. Second, the guidewire was focally denuded at 
the inner curvature of the kink, by the operator at the tableside, to concentrate 
charge at the target.  Third, the insulating polymer jacket was positioned close to 
the kink.  Fourth, during radiofrequency energy application, non-ionic flush (5% 
dextrose) displaced blood, concentrated current at the lacerating surface, and 
suppressed guidewire carbonization and blood coagulation.   
Findings 
Supplement Figure 3: In vitro laceration of a bovine bioprosthetic heart valve 
The shaft of an Astato XS20 guidewire, sheathed in a polymer wire-convertor and 
guiding catheter, was positioned against a bovine bioprosthetic heart valve 
(Trifecta, Abbott St Jude Medical) and perforated the bioprosthetic leaflet using a 
<1s burst of radiofrequency energy at 20W. Next, we tested laceration, during 
continuous 5% dextrose flush through two guiding catheters.  Laceration at 20W 
required 5s to traverse a half-leaflet (shown in the figure below) and 18s to traverse 
a full leaflet. Mechanical laceration without electrification was not possible in this 
valve.  
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Supplement Figure 4: VTC distance 
The figure depicts the virtual transcatheter valve to coronary (VTC) distance in six 
of the patients. The VTC of patient 6 is shown in figure 7.  
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Supplement Table 4: Animal Findings 
Basilica pre-clinical PIG1 PIG2 PIG3 PIG4 PIG5 
Weight (kg) 41 40 47 38 49 
LCC attempted Yes Yes Yes Yes Yes 
RCC attempted No No No Yes Yes 
Procedure time (mins) 205 35 11 70 58 
Survival time (mins) 5 >60 >60 >60 10 
Complications 
     
Left false crossing X (4) X (1) 
   
Right false crossing 




   
X 
 
Mitral chord rupture X 
    
Annulus laceration 
   
X 
 
Cusp hematoma X X 
   
Hemodynamics 
     
Systolic BP pre 61 74 78 70 74 
Diastolic BP pre 35 48 44 50 45 
Heart rate pre 63 71 82 88 59 
Systolic BP post 30 63 75 80 57 
Diastolic BP post 17 29 29 30 21 
Heart rate post 41 68 104 107 65 
Necropsy 
measurements 
     
LCC length (mm) 14 15 15 12 16 
LCC tear (mm) 10 13 11 12 10 
RCC length (mm) 
   
10 15 
RCC tear (mm) 
   
10 14 
 
LCC= left coronary cusp; RCC = right coronary cusp; BP = blood pressure 
Supplement Table 5: Additional clinical and CT findings and procedure details 
Patient number ALL 1 2 3 4 5 6 7 








L-VTC on CT for selected valve, 
mm 
2.9 (1.7-3.6) 3.7 -0.9 0.7 2.9 3.5 3.3 2.6 
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R-VTC on CT for selected valve, 
mm 
3.5 (3.-3.7) 3.7 -0.9 3.6 NA 2.9 3.3 4.4 
L-coronary height on CT 5.8 (4.5-7.9) 6.9 5.8 5.5 8.9 9.3 3.4 2 












CT annulus average diameter, 
mm 




CT annulus area, mm^2 
307.6 (258.3-
367.4) 








CT leaflet calcification (0=None, 
1=mild, 2=moderate, 3=severe) 
None,3; Mild, 1; 
Moderate, 2; 
Severe, 1 
0 0 1 2 2 3 0 




Time to traverse leaflet (both if 
applicable), min 
33 (28-82) 43 23 32 140 33 121 23 
Time from traversal to 
laceration (both if applicable), 
min 
46 (32-52) 54 46 50 28 59 33 30 
Time from laceration to TAVI, 
min 
19 (15-22) 12 8 25 30 19 19 18 
Fluoroscopy Time, min 74 (68-91) 82 62 68 114 74 100 68 
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Fluoroscopy Dose-Area Product 
(Gy·cm2) 




Contrast volume (mL) 102 (90-170) 37 115 102 225 90 285 90 
LCA prophylactic stent or 
balloon positioned 
None, 1; Balloon, 
1; Stent, 5 





LCA stent deployed 14% 0 0 0 0 0 0 1 
RCA prophylactic stent 
positioned 
29% 0 0 1 1 0 0 0 
RCA stent deployed 0% 0 0 0 0 0 0 0 
Neuroprotection 































Intentional balloon rupture of 
bioprosthetic frame to increase 
orifice 




















General anaesthesia 100% 1 1 1 1 1 1 1 
Transoesophageal 
echocardiography 
100% 1 1 1 1 1 1 1 
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1 2 3 4 5 6 7 
Mortality 0% 0 0 0 0 0 0 0 
Myocardial infarction 0% 0 0 0 0 0 0 0 
Stroke or transient ischemic attack 0% 0 0 0 0 0 0 0 
Life threatening or major bleeding 0% 0 0 0 0 0 0 0 
Acute kidney injury 0% 0 0 0 0 0 0 0 
Vascular major complications 0% 0 0 0 0 0 0 0 
Conduction disturbances or arrhythmias 0% 0 0 0 0 0 0 
Transient sinus 
bradycardia 
Conversion to open surgery 0% 0 0 0 0 0 0 0 
Unplanned cardiopulmonary bypass or mechanical 
hemodynamic support 
0% 0 0 0 0 0 0 0 
Coronary obstruction 0% 0 0 0 0 0 0 0 
Ventricular septal defect 0% 0 0 0 0 0 0 0 
Mitral valve apparatus damage or dysfunction 0% 0 0 0 0 0 0 0 
Cardiac tamponade 0% 0 0 0 0 0 0 0 
Endocarditis 0% 0 0 0 0 0 0 0 
Valve thrombosis 0% 0 0 0 0 0 0 0 
Valve mal-positioning (including migration and 
embolization) 
0% 0 0 0 0 0 0 0 
Additional valve-in-valve deployment 0% 0 0 0 0 0 0 0 
 
VARC-2 = Valve Academic Research Consortium-2 Consensus Document (Kappetein, 
et al, 2012, reference #13). 
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The BASILICA Trial Prospective Multicenter Investigation of 
Intentional Leaflet Laceration to Prevent TAVR Coronary 
Obstruction 
An original research manuscript published in the journal JACC: Cardiovascular 
Interventions in 2019.  
Candidate’s contribution 
I am first author on the enclosed clinical trial manuscript, which I drafted, designed 
the figures, and consulted the references. I, together with RJL, designed the NHLBI 
BASILICA trial, prepared the trial protocol and drafted the case report forms. I was 
the Clinical Lead for the trial and member of the steering committee. I planned and 
proctored all the cases performed. 
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owOBJECTIVES The BASILICA (Bioprosthetic or native Aortic Scallop Intentional Laceration to prevent Iatrogenic
Coronary Artery obstruction during TAVR) investigational device exemption trial was a prospective, multicenter,
single-arm safety and feasibility study.
BACKGROUND Coronary artery obstruction is a rare but devastating complication of transcatheter aortic valve
replacement (TAVR). Current stent-based preventative strategies are suboptimal. Bioprosthetic or native aortic scallop
intentional laceration to prevent iatrogenic coronary artery obstruction during TAVR (BASILICA) is a novel transcatheter
technique performed immediately before TAVR to prevent coronary artery obstruction.
METHODS Subjects with severe native or bioprosthetic aortic valve disease at high or extreme risk for surgery, and at
high risk of coronary artery obstruction, were included. The primary success endpoint was successful BASILICA and TAVR
without coronary obstruction or reintervention. The primary safety endpoint was freedom from major adverse cardio-
vascular events. Data were independently monitored. Endpoints were independently adjudicated. A core laboratory
analyzed computed tomography images.
RESULTS Between February 2018 and July 2018, 30 subjects were enrolled. Primary success was met in 28 (93%)
subjects. BASILICA traversal and laceration was successful in 35 of 37 (95%) attempted leaflets. There was 100%
freedom from coronary obstruction and reintervention. Primary safety was met in 21 (70%), driven by 6 (20%) major
vascular complications related to TAVR but not BASILICA. There was 1 death at 30 days. There was 1 (3%) disabling stroke
and 2 (7%) nondisabling strokes. Transient hemodynamic compromise was rare (7%) and resolved promptly with TAVR.
CONCLUSIONS BASILICA was feasible in both native and bioprosthetic valves. Hemodynamic compromise was
uncommon. Safety was acceptable and needs confirmation in larger studies. BASILICA appears effective in
preventing coronary artery obstruction from TAVR in subjects at high risk. (J Am Coll Cardiol Intv 2019;12:1240–52)
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AB BR E V I A T I O N S
AND ACRONYM S
BASILICA = bioprosthetic or
native aortic scallop intentional
laceration to prevent iatrogenic
coronary artery obstruction
during TAVR
HALT = hypoattenuated leaflet
thickening
IDE = investigational device
exemption
KCCQ = Kansas City
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1241unresected diseased leaflets are displaced toward the
coronary artery ostia or sinotubular junction during
transcatheter valve deployment.
Predicting coronary obstruction is imprecise.
From the available data, those at highest risk are
female, with coronary ostial height of <10 mm, sinus
of Valsalva width of <30 mm, and those with pre-
vious aortic bioprostheses, particularly with exter-
nally mounted leaflets or stentless surgical valves,
and with virtual transcatheter heart valve to coro-
nary distance (VTC) of <4 mm (4,5).SEE PAGE 1253
Cardiomyopathy Questionnaire
NHLBI = National Heart, Lung,
and Blood Institute
NYHA = New York Heart
Association
TAVR = transcatheter aortic
valve replacement
VARC = Valve Academic
Research Consortium
VTC = virtual transcatheter
valve to coronary distancePreventive strategies have to date involved pre-
positioning a guidewire or stent in the threatened
coronary artery and, after TAVR, deploying the stent
in the ostium and “snorkeling” it alongside the TAVR
valve into the aorta (6). This may be a suboptimal
solution, as these stents are prone to extrinsic
compression, deformation, and thrombosis, causing
delayed thrombotic coronary occlusion with often
challenging percutaneous bailout (7).
Bioprosthetic or native aortic scallop intentional
laceration to prevent iatrogenic coronary artery
obstruction during TAVR (BASILICA) is a transcatheter
procedure performed immediately before TAVR. The
target aortic leaflet is split using focused radio-
frequency energy directed by catheters and guide-
wires. The BASILICA technique is derived from the
earlier LAMPOON (Intentional Laceration of the
Anterior Mitral leaflet to Prevent left ventricular
Outflow ObstructioN during transcatheter mitral valve
implantation) technique (8,9). Early in vitro, animal,
and clinical BASILICA experience in 7 patients (10)
showed that the split leaflets splay away from the
coronary ostia during TAVR and that flow is main-
tained through the open cells of the TAVR valve. The
purpose of this study was to systematically assess the
early safety and efficacy of the BASILICA procedure.
METHODS
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J.M. Khan TranscLaceration to prevent Iatrogenic Coronary
Artery obstruction during TAVR) investigational
device exemption (IDE) trial (NCT03381989)
was a prospective, single-arm, multicenter
study of the BASILICA procedure, with inde-
pendent on-site source-data verification and
data monitoring, independent endpoint
adjudication, and central core laboratory
analysis of baseline and post-procedure im-
ages. The trial was designed by the in-
vestigators and sponsored by the senior
author (R.J.L.) on behalf of the National
Heart, Lung, and Blood Institute (NHLBI).
Sites were not reimbursed for research ac-
tivities. The U.S. Food and Drug Administra-
tion granted IDE for the study under the Early
Feasibility pathway. The Institutional Re-
view Board at each site and at the NHLBI
approved the study protocol. The NHLBI Data
Safety Monitoring Board provided study
oversight. The NHLBI was the data-
coordinating center. A Clinical Event Com-
mittee independently adjudicated the primary
endpoints, all strokes, and all deaths, and determined
relatedness to the BASILICA procedure and to TAVR.
The authors have full custody of the data and the
senior author had final responsibility for the decision
to submit for publication.
SUBJECTS. Between February 15, 2018, and July 31,
2018, 30 subjects with symptomatic severe aortic
stenosis or bioprosthetic aortic valve failure were
enrolled at 4 centers in the United States (see Figure 1
and the Online Appendix for study enrollment de-
tails). Adult patients were included if they were
considered to be at high or prohibitive risk for surgi-
cal aortic valve replacement on the basis of clinical
assessments by the institutional multidisciplinary
heart team and considered at high risk of developing
coronary artery obstruction from TAVR as determined
by a central eligibility committee (see Figure 1). Cor-
onary artery height, sinus width, VTC, sinotubular
junction height and diameter, leaflet length and
thickness, bioprosthetic valve type, prior coronaryor Edwards Lifesciences and Medtronic. Drs. Eng and
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y 20, 2019, accepted March 11, 2019.
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FIGURE 1 Trial Enrollment
Sixty patients were screened and 30 were enrolled. All patients completed follow-up. One patient declined 30-day computed tomography
(CT) and 1 died before 30 days. BASILICA ¼ bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery
obstruction during TAVR; STJ ¼ sinotubular junction; TAVR ¼ transcatheter aortic valve replacement; VTC ¼ virtual transcatheter heart valve
to coronary distance.
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J.M. Khanartery bypass grafts, and balloon valvuloplasty with
simultaneous aortography were all considered, where
appropriate, to determine coronary obstruction risk.
Patients with severe calcified masses on the target
aortic leaflets and those not expected to survive
beyond 12 months despite TAVR were excluded. The
complete list of inclusion and exclusion criteria is
provided in the Online Appendix. All subjects con-
sented to participate in writing.
BASILICA TECHNIQUE. The technique is described
elsewhere (10,11) and is demonstrated in the Central
Illustration and Online Video 1. Briefly, the BASILICA
target leaflet or leaflets are chosen depending on the
coronary artery at risk of obstruction. Fluoroscopic
projection angles for the target aortic leaflets are
planned on cardiac computed tomography (CT). The
BASILICA procedure is performed under general
anesthesia or moderate sedation. The procedure usesownloaded for Anonymous User (n/a) at MEDSTAR HEALTH VNA INC fr
For personal use only. No other uses without permission. Copyright
Transcatheter Electrosurgstandard cardiovascular catheterization equipment.
Two guiding catheters are used per target leaflet. For
single leaflet or solo BASILICA, no additional vascular
access is required beyond the 2 sheaths required for
TAVR deployment and angiography. For double
leaflet or doppio BASILICA, the sheath used for
angiography is upsized to 12- to 14-F to house 2 side-
by-side 6- to 8-F catheters. The guiding catheters are
positioned on either side of the aortic leaflet, with a
traversal guidewire (Astato XS 20, Asahi, Japan) in the
aortic root and snare (Amplatz Gooseneck, AGA
Medical Corporation, Minneapolis, Minnesota) in the
left ventricular outflow tract, respectively. The
guidewire is insulated in a microcatheter (Piggyback
Wire Convertor, Teleflex, Wayne, Pennsylvania) to
confine the electrical current to the tip, and electri-
fied using a radiofrequency generator (ForceFx Val-
leylab, Minneapolis, Minnesota) to perforate the baseom ClinicalKey.com by Elsevier on July 05, 2019.
 ©2019. Elsevier Inc. All rights reserved.
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CENTRAL ILLUSTRATION BASILICA Representative Example and Trial Results
Khan, J.M. et al. J Am Coll Cardiol Intv. 2019;12(13):1240–52.
A representative subject with failed Mitroflow valve and at high risk of coronary obstruction who underwent doppio bioprosthetic or native aortic scallop intentional
laceration to prevent iatrogenic coronary artery obstruction during TAVR (BASILICA) and transcatheter aortic valve replacement (TAVR) (Online Video 1). (A) The
guidewire traverses the right coronary cusp (RCC). (B) The guidewire traverses the left coronary cusp (LCC) into a snare in the left ventricular outflow tract. (C)
BASILICA guidewire loops are formed through the base of both right and left cusps, ready for radiofrequency-assisted laceration. (D) Aortic root angiography
demonstrates flow to both coronaries through the split Mitroflow leaflets after TAVR with a SAPIEN 3 valve. The RCC is highlighted in green, LCC highlighted in red,
noncoronary cusp highlighted in yellow, BASILICA catheters highlighted in blue, coronary arteries outlined by dashed lines, and arrow points indicate traversal target.
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TABLE 1 Baseline Characteristics (n ¼ 30)
Age, yrs 76 (69–82)
Female 24 (80)
Comorbidities
Prior stroke 7 (23)
Prior myocardial infarction 5 (17)
Coronary artery disease 19 (63)
Peripheral artery disease 7 (23)
Diabetes 12 (40)
End-stage kidney disease on dialysis 3 (10)
Severe pulmonary disease 12 (40)
Liver cirrhosis 2 (7)
Hypertension 26 (87)
Atrial fibrillation 11 (37)
Prior endocarditis 0 (0)
Prior rheumatic fever 1 (3)
Prior percutaneous revascularization 11 (37)
Prior coronary artery bypass surgery 7 (23)
$2 prior cardiac surgeries 4 (13)
Pacemaker or ICD 6 (20)
NYHA functional class III or IV 26 (87)
Aspirin or P2Y12 inhibitor 23 (77)
Oral anticoagulant 8 (27)
Frail 14 (47)
STS predicted risk of mortality 6 (3–15)





Aortic stenosis 24 (80)
Aortic regurgitation 1 (3)
Mixed 5 (17)
LVEF <30% 4 (13)
AV peak velocity, m/s 4 (4–5)
AV mean gradient, mm Hg 43 (37–53)
AVA, cm2 0.7 (0.6–0.8)
Values are median (interquartile range) or n (%).
AV ¼ aortic valve; AVA ¼ aortic valve area; ICD ¼ implantable cardioverter-
defibrillator; KCCQ ¼ Kansas City Cardiomyopathy Questionnaire; LVEF ¼ left
ventricular ejection fraction; NYHA¼ New York Heart Association; STS¼ Society of
Thoracic Surgeons; TAVR ¼ transcatheter aortic valve replacement.
TABLE 2 Procedure Characteristics
Valve type
SAPIEN 3 16 (53)
Evolut R 11 (37)
Evolut Pro 3 (10)
Valve nominal size
20 mm 4 (13)
23 mm 17 (57)
26 mm 6 (20)




Percutaneous axillary 1 (3)
Target cusp
Left solo 18 (60)
Right solo 5 (17)
Doppio 7 (23)
Sentinel cerebral protection 13 (43)
Balloon pre-dilation 5 (17)
Balloon post-dilation 7 (23)
Bioprosthetic valve fracture 3 (10)
General anesthesia 27 (90)
Moderate sedation 3 (10)
Total procedure time (access to hemostasis),
min
113 (98–162)
BASILICA time, solo (catheter
introduction to laceration), min
73 (58–88)
BASILICA time, doppio
(catheter introduction to laceration), min
123 (106–137)
Time from BASILICA to TAVR, min 9 (7–16)
Fluoroscopy time, min 75 (57–111)
Contrast volume, ml 143 (101–226)
Values are n (%) or median (interquartile range)
BASILICA ¼ bioprosthetic or native aortic scallop intentional laceration to pre-
vent iatrogenic coronary artery obstruction during TAVR; TAVR ¼ transcatheter
aortic valve replacement.
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J.M. Khanof the target leaflet. The guidewire is snared in the
left ventricular outflow tract and externalized to form
a loop through the leaflet, between the 2 guiding
catheters. The guidewire shaft is shaped to confine
electrical contact with leaflet tissue, and then further
electrified under tension to lacerate the leaflet down
the centerline. The split leaflet typically splays in
systole and coapts in diastole. The BASILICA system
is disconnected and removed from the body, and then
TAVR is performed as usual. The TAVR valve dis-
places the leaflets outwards but the split leaflets splay
away from the coronary ostia, maintaining coro-
nary flow.ownloaded for Anonymous User (n/a) at MEDSTAR HEALTH VNA INC fr
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Transcatheter ElectrosurgSTUDY ENDPOINTS. The prespecified primary
endpoint was procedure success, measured at exit
from the catheterization laboratory, and required all
the following: successful BASILICA traversal and
laceration of the intended leaflet(s); successful ac-
cess, delivery, and retrieval of the BASILICA device
system; successful TAVR device implantation;
absence of procedural mortality; absence of coronary
artery obstruction; and freedom from emergency
cardiac surgery or reintervention related to the
BASILICA TAVR procedure, including attempted im-
plantation of coronary stents to treat TAVR-induced
coronary artery obstruction. The prespecified pri-
mary safety endpoint was freedom from major
adverse clinical events according to Valve Academic
Research Consortium (VARC)-2 early safety at
30 days, which is a composite of all-cause mortality,
all stroke, life-threatening bleeding, acute kidneyom ClinicalKey.com by Elsevier on July 05, 2019.
 ©2019. Elsevier Inc. All rights reserved.
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TABLE 3 Coronary Obstruction Risk
Risk Prediction



















Coronary height, mm 7.2 (5.2–9.7) 10.4 (6.2–12.1) 9.8 (7.9–11.8) 11.7 (10.4–12.4) 6.3 (3.8–8.4) 5.6 (4.6–10.7)
Coronary height <10 mm 28 (76) 9 (24) 7 (50) 1 (8) 21 (91) 8 (73)
Sinus width, mm 25.9 (24.8–29.0) 27.9 (24.8–31.4) 26.5 (24.7–29.6) 28.4 (24.8–31.1) 25.5 (24.9–28.6) 27.9 (25.5–32.1)
Leaflet above coronary ostium 34 (92) 13 (57) 12 (86) 4 (33) 22 (96) 9 (82)
Leaflet above STJ 18 (49) 6 (26) 0 (0) 0 (0) 18 (78) 6 (55)
Calcium volume, mm3 94 (33–298) 127 (85–228) 57 (29–96) 118 (91–190) 136 (60–395) 164 (75–230)
VTC, mm 3.3 (2.7–4.0) 4.3 (3.4–5.2) 2.9 (2.4–3.7) 4.2 (3.4–4.8) 3.7 (2.9–4.1) 4.6 (3.6–5.3)
VTC <4 mm 27 (73) 9 (39) 13 (93) 5 (42) 14 (61) 4 (36)
VTC <3 mm 14 (38) 3 (13) 7 (50) 2 (17) 7 (30) 1 (9)
THV to STJ, mm 2.2 (0.5–3.1) 2.6 (1.1–4.0) 1.2 (0.1–2.2) 2.0 (0.5–2.8) 2.6 (1.6–3.4) 3.5 (2.5–5.8)
THV to STJ <3 mm 27 (73) 15 (65) 13 (93) 10 (83) 14 (61) 5 (46)
Post-procedure risk assessment
VTC, mm 3.3 (1.7–4.5) 3.6 (2.8–4.7) 2.3 (0.6–3.7) 3.2 (2.6–3.8) 3.6 (3.0–4.6) 4.7 (3.9–6.0)
VTC <4 mm 24 (69) 12 (57) 13 (93) 9 (75) 11 (52) 3 (33)
VTC <3 mm 14 (40) 7 (33) 9 (64) 6 (50) 5 (24) 1 (11)
THV to STJ, mm 1.4 (0–2.2) 1.3 (0–2.2) 0 (0–0.7) 0.4 (0–1.1) 1.8 (0.9–2.7) 2.1 (1.6–2.9)
THV to STJ <3 mm 28 (90) 16 (89) 11 (100) 10 (100) 17 (85) 6 (75)
Values are median (interquartile range) or n (%).
BASILICA ¼ bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction during TAVR; STJ ¼ sinotubular junction; THV ¼
transcatheter heart valve; VTC ¼ virtual transcatheter heart valve to coronary distance.
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1245injury (stage 2 or 3), coronary artery obstruction
requiring intervention, major vascular complications,
and valve-related dysfunction requiring repeat pro-
cedure. Secondary endpoints included hemodynamic
instability caused by BASILICA before TAVR, TAVR
thrombosis on follow-up CT or echocardiography,
hemolytic anemia, and BASILICA-related technical
failure, including embolism, mitral valve injury, off-
target traversal, and coronary artery injury. The
complete list of endpoints is provided in the
Online Appendix.
IMAGING. Transesophageal or transthoracic echocar-
diograms were performed at baseline, intra-procedure,
discharge, and 30-days. Contrast-enhanced electro-
cardiogram-gated multislice CT scans were performed
at baseline and post-procedure. Images were analyzed
by the NHLBI core laboratory using dedicated 4-
dimensional CT software, 3mensio version 9.1 (Pie
Medical, Maastricht, the Netherlands). The VTC was
measured using the Vancouver method (12). A virtual
valve cylinder with a diameter of the selected valve
being implanted was simulated in position and the
distance to the coronary ostia measured in the
short and long axes. For SAPIEN valves (Edwards
Lifesciences, Irvine, California), the nominal valve
diameter was used for the virtual valve (a 23 SAPIEN 3Downloaded for Anonymous User (n/a) at MEDSTAR
For personal use only. No other uses withou
J.M. Khan Transcvalve was simulated with a valve with diameter
23 mm). For Evolut R/Pro valves (Medtronic, Minne-
apolis, Minnesota), a “constrained” diameter was
used as follows: 20 mm, 23 mm, and 26 mm for 23, 26,
and 29 Evolut valves, respectively. Follow-up CT was
performed to measure observed valve to coronary
artery distances; and to evaluate coronary patency;
hypoattenuated leaflet thickening (HALT), defined as
an area of hypodensity on TAVR valve leaflets on CT;
and hypoattenuation affecting motion, defined as
reduced leaflet motion in the presence of HALT (13).
Leaflet calcium volumes were measured on contrast
CT using dedicated software (3mensio) after per-
forming automation-assisted segmentation of the
aortic valve leaflets, using established methodology (14).
STATISTICAL ANALYSIS. All analyses were based on
the intention-to-treat principle with data from all
enrolled patients. The sample size of 30 subjects was
not derived statistically. Baseline subject and proce-
dural characteristics were summarized as median and
interquartile range for continuous variables and
count and proportion for categorical variables.
McNemar’s test and paired t test were used to assess
the difference in the proportion of New York Heart
Association (NYHA) functional class and Kansas City
Cardiomyopathy Questionnaire (KCCQ) quality of life HEALTH VNA INC from ClinicalKey.com by Elsevier on July 05, 2019.
t permission. Copyright ©2019. Elsevier Inc. All rights reserved.
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FIGURE 2 Correlation Between Predicted and Observed Valve-to-Coronary Distance
(A) The overall correlation coefficient was 0.58, with (C) good correlation across left and right cusps. Observed virtual transcatheter heart
valve to coronary distance (VTC) was smaller than predicted (B) for SAPIEN 3 valves and (D) in native aortic stenosis. (B, D) There were few
outliers when using Evolut valves in surgical bioprostheses in which prediction underestimated VTC. The Bland-Altman plot demonstrates no
systematic difference (bias) between predicted and observed VTC. LCA ¼ left coronary artery; RCA ¼ right coronary artery.
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J.M. Khanmeasure between baseline and 30-day visits, respec-
tively. Pearson’s correlation and Bland-Altman plot
were used to assess the correlation and agreement
between predicted VTC on pre-procedure CT andownloaded for Anonymous User (n/a) at MEDSTAR HEALTH VNA INC fr
For personal use only. No other uses without permission. Copyright
Transcatheter Electrosurgobserved measurements on post-procedure CT. Sta-
tistical analyses were performed using R statistical
software 3.5.1 (R Foundation for Statistical
Computing, Vienna, Austria).om ClinicalKey.com by Elsevier on July 05, 2019.
 ©2019. Elsevier Inc. All rights reserved.
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TABLE 4 Clinical Outcomes
Primary efficacy endpoint (exit from catheter laboratory)* (n ¼ 30)
Successful BASILICA traversal and laceration 28 (93)
Immediate survival 30 (100)
Successful first TAVR device implantation 30 (100)
Coronary obstruction 0 (0)
Freedom from emergency surgery or reintervention
related to BASILICA or TAVR
30 (100)
Technical success (all of above) 28 (93)
Primary safety endpoint (30 days)* (n ¼ 30)
All death 1 (3)
Cardiovascular 1 (3)
Noncardiovascular 0
All stroke 3 (10)
Disabling 1 (3)
Nondisabling 2 (7)
Life threatening bleeding 2 (7)
Clearly related to BASILICA 0
Potentially related to BASILICA 0
Not related to BASILICA 2 (7)
Major vascular complication 6 (20)
Clearly related to BASILICA 0
Potentially related to BASILICA 0
Not related to BASILICA 6 (20)
AKI stage 2/3 1 (3)
Coronary artery obstruction 0 (0)
Valve-related dysfunction requiring repeat procedure 0 (0)
VARC-2 early safety (all of above) 21 (70)
Secondary endpoints (30 days) (n ¼ 30)
Secondary myocardial infarction 1 (3)
Major cardiac structural complication 0 (0)
Hemolytic anemia 0 (0)
Endocarditis 0 (0)
New pacemaker 2 (7)
Need for second valve 0 (0)
PVL > mild 0 (0)
Cardiac tamponade 0 (0)
Nontarget BASILICA traversal (left atrial entry) 1 (3)
Hemodynamic instability from laceration requiring vasopressors 2 (7)
Embolic debris recovered if cerebral protection used 6/13 (46)
Coronaries obstructed on follow-up CT 0/28 (0)
30-day mean gradient >20 mm Hg 9/28 (32)
HALT on follow-up CT 3/28 (11)
HAM on follow-up CT 1/28 (4)
Values are n (%) or n/N (%). *Clinical Event Committee adjudicated.
AKI ¼ acute kidney injury; ICA ¼ bioprosthetic or native aortic scallop intentional laceration;
CT ¼ computed tomography; HALT ¼ hypoattenuated leaflet thickening; HAM ¼ hypoattenuation
affecting motion; PVL ¼ paravalvular leak; VARC ¼ Valve Academic Research Consortium.
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SUBJECT AND PROCEDURE DETAILS. Baseline sub-
ject characteristics are shown in Table 1. Subjects
were typically elderly, with high surgical risk and
comorbidity, and in NYHA functional class III or IV. Of
note, 80% were women, and 23% had a prior stroke.
43% had native aortic stenosis and 57% had bio-
prosthetic aortic valve failure. Procedure character-
istics are shown in Table 2. SAPIEN 3 valves were used
in 53% and Evolut R/Pro in 47%. TAVR access was
transfemoral in 77%, transcaval 20%, and percuta-
neous axillary in 3%. The bioprosthetic valve frame
was intentionally fractured (15) with high-pressure
balloon inflation in 10%. A Sentinel device (Claret
Medical, Santa Rosa, California) was used for cerebral
protection in 43% and embolic debris was recovered
in 46% of those cases, though no systematic inspec-
tion technique was mandated. General anesthesia
and transesophageal echocardiography were used in
90% and moderate sedation without transesophageal
echocardiography in 10%.
CORONARY OBSTRUCTION RISK. The target
BASILICA leaflet was solo in 77% of subjects (left only
in 60%, right only in 17%) and doppio (both leaflets)
in 23%. The risk profile of the target leaflets and
associated coronary arteries compared with the
nontarget control leaflets is shown in Table 3. Indi-
vidual risk for each patient is presented in Online
Table 1. A total of 95% of target leaflets fit at least 2
of 3 best-available CT risk criteria for coronary
obstruction—namely coronary height <10 mm, sinus
width <30 mm, and VTC <4 mm (4,5). The predicted
VTC on pre-procedure CT and observed transcatheter
heart valve-to-coronary ostia measurements on post-
procedure CT correlated well overall (Figure 2).
Observed valve-to-coronary distance tended to be
smaller than predicted VTC in SAPIEN 3 valves and in
native annuli.
PROCEDURE OUTCOMES. The adjudicated endpoints
are shown in Table 4. The primary endpoint of pro-
cedure success was met in 93% of subjects. Leaflet
traversal was successful in 35 of 37 (95%) of target
leaflets. Laceration was successful in all leaflets tra-
versed. All subjects survived their procedure with
successful implantation of the first TAVR device.
There were no cases of coronary obstruction. There
were no cases requiring reintervention or surgery. In
the 2 cases in which leaflet traversal was not suc-
cessful, coronary stents were pre-positioned, of
which 1 was deployed after TAVR and the other
removed due to low probability of obstruction on
angiographic assessment after TAVR. We attribute theDownloaded for Anonymous User (n/a) at MEDSTAR
For personal use only. No other uses withou
J.M. Khan Transc2 traversal failures to confluent leaflet calcification at
the crossing target at the nadir of the leaflet.
Figure 3 and Online Video 2 show a manually
segmented post-procedure CT of a typical subject,
demonstrating split native leaflets parting away from
otherwise threatened left and right coronary ostia. HEALTH VNA INC from ClinicalKey.com by Elsevier on July 05, 2019.
t permission. Copyright ©2019. Elsevier Inc. All rights reserved.
atheter Electrosurgery 135
FIGURE 3 Three-dimensional CT Reconstruction After
Doppio Native BASILICA
Native leaflets (LCC in red, RCC in green) and coronary arteries
(blue) are manually segmented and colorized on a CT acquired
after BASILICA and TAVR. Both left and right coronary
leaflets are seen split and parted away from the coronary ostia.
(Online Video 2) The leaflet configuration suggests that both
coronary ostia would have obstructed without BASILICA.
Abbreviations as in Figures 1 and 2.
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J.M. KhanThe primary endpoint of early safety was met in
70% of subjects at 30 days (Table 4). This was mostly
driven by 6 TAVR-related major vascular complica-
tions: 1 retroperitoneal bleed from femoral access; 1
transcaval bleed requiring covered stent placement,
both of which qualified as VARC-2 life-threatening
bleeds; 2 groin hematomas; 1 groin bleed without
hematoma; and 1 ischemic limb requiring femoral
artery thromboendarterectomy.
There was 1 death in a subject who developed a
severe inflammatory response at induction of anes-
thesia despite a technically successful procedure,
leading to multiple organ failure on a background of
multiple brain metastases. Care was withdrawn and
the subject died on post-procedure day 18.
There was 1 (3%) disabling stroke and 2 (7%) non-
disabling strokes, detailed in Table 5. Two of the 3
subjects had baseline central neurological pathology,
including the subject that died, making the clinical
and radiological diagnosis ambiguous. Cerebral pro-
tection was used in 1 and no debris was recovered.
OTHER CLINICAL ENDPOINTS. Mean arterial pres-
sures for each subject at baseline, before and afterownloaded for Anonymous User (n/a) at MEDSTAR HEALTH VNA INC fr
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Figure 1. Transient hypotension after laceration was
seen in 2 subjects. This resolved promptly with TAVR.
There was 1 off-target guidewire traversal into the left
atrium. The guidewire was withdrawn and traversal
reattempted without clinical sequelae. One subject
went into ventricular fibrillation after left leaflet
guidewire traversal requiring cardioversion. No sub-
ject had greater than mild paravalvular leak. Two
subjects had permanent pacemaker implantation.
Mean aortic valve gradient fell from 44  16 mm Hg to
18  7 mm Hg at 30 days. Gradients were similar be-
tween bioprosthetic and native valve TAVR subjects.
A total of 29% had severe patient-prosthesis mismatch
(indexed effective orifice area <0.65 cm2/m2), and
38% had moderate prosthesis-patient mismatch
(indexed effective orifice area 0.65 to 0.85 cm2/m2).
There was improvement in subject NYHA func-
tional class and KCCQ quality of life scores (16)
(Figure 4). At 30-day visit, the median KCCQ sum-
mary score was 52.9 (interquartile range: 42.5 to
76.8) with 14% subjects in NYHA functional class III
to IV, compared with a median KCCQ of 23.4 (inter-
quartile range: 15.6 to 39.6) and 87% subjects in
NYHA functional class III to IV at baseline (both
p < 0.0001). HALT was seen in 3 (11%) subjects on
follow-up CT, all in SAPIEN 3 valves, and on the
noncoronary leaflet in all. One of these subjects had
hypoattenuation affecting motion. No HALT was
seen on TAVR leaflets adjacent to leaflets split by
BASILICA.
DISCUSSION
The purpose of this IDE trial was to determine feasi-
bility, early safety, and efficacy of TAVR with
BASILICA in subjects who might obstruct their coro-
nary arteries with stand-alone TAVR. BASILICA-TAVR
met the composite primary endpoint of procedure
success in 93%. Crucially, despite the high predicted
risk, 100% of subjects were free of coronary artery
obstruction after TAVR, with no evidence of coronary
obstruction on angiography, CT, electrocardiogram,
or echocardiogram, or clinically at 30 days.
Guidewire traversal failed in 2 leaflets. These
cases demonstrate that confluent heavy leaflet
calcification at the nadir of the target aortic leaflets
may be an obstacle to leaflet traversal using radi-
ofrequency energy. This is similar to the experience
using guidewire electrification in transcaval access
for TAVR (17,18). In all cases where leaflet traversal
was successful, laceration was able to be
performed.om ClinicalKey.com by Elsevier on July 05, 2019.
 ©2019. Elsevier Inc. All rights reserved.
ery 136
TABLE 5 Procedural Stroke
Subject 1 Subject 2 Subject 3
Neurological symptoms
and sequelae
Mild bilateral hand weakness,
resolved at 30 days
Confounded by baseline central
and peripheral neuropathy;
subjective left leg weakness,









MRI MRI-DWI multiple small bilateral
foci of diffusion restriction
MRI-DWI multiple small bilateral
foci of diffusion restriction
MRI-DWI confounded by multiple
brain metastases and global
ischemia
Setting Mitroflow stenosis, doppio
BASILICA LþR




TAVR valve SAPIEN 3 SAPIEN 3 Evolut R
Pre-dilatation/post-dilatation No/no Yes/yes No/yes
Calcium volume of BASILICA leaflet LCC 182, RCC 215 LCC 95 LCC 93
Sentinel cerebral protection used;
debris retrieved
No; N/A Yes; no debris No; N/A
HALT on CT No Yes No
DWI ¼ diffusion-weighted imaging; L ¼ left; LCC ¼ left coronary cusp; MRI ¼ magnetic resonance imaging; N/A ¼ not applicable; R ¼ right; RCC ¼ right coronary cusp; other
abbreviations as in Table 4.
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1249Three (10%) subjects had neurological events (3%
disabling stroke). The neurological event rate from
TAVR in contemporary adjudicated trials in
intermediate-risk subjects was 6.4% (3.2% disablingFIGURE 4 Symptom and Quality of Life Improvement
There was an improvement in New York Heart Association (NYHA) funct
score at 30 days compared with baseline. Error bars represent the inter
Downloaded for Anonymous User (n/a) at MEDSTAR
For personal use only. No other uses withou
J.M. Khan Transcstroke) in the PARTNER 2 (Placement of Aortic
Transcatheter Valves) trial (1) and 4.5% (1.2%
disabling stroke) in SURTAVI (Surgical Replacement
and Transcatheter Aortic Valve Implantation) trialional class and Kansas City Cardiomyopathy Questionnaire (KCCQ)
quartile range.
 HEALTH VNA INC from ClinicalKey.com by Elsevier on July 05, 2019.
t permission. Copyright ©2019. Elsevier Inc. All rights reserved.
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J.M. Khan(2), and in high-risk subjects in the SENTINEL
(Cerebral Protection in Transcatheter Aortic Valve
Replacement) trial was 5.6% with cerebral protection
and 9.1% without (19). Whether there is an excess risk
of stroke from BASILICA cannot be determined from
this small sample size of high- and extreme-risk
subjects, 23% of whom had a previous stroke and
23% of whom had severe vascular disease requiring
alternative TAVR access. Two of the 3 subjects
experiencing stroke had ambiguous findings related
to baseline neurological comorbidity including a
central demyelinating syndrome and metastatic brain
cancer. Embolic stroke from BASILICA may theoreti-
cally be caused by multiple catheter manipulations
and leaflet laceration releasing calcific debris. Stroke
risk for BASILICA-TAVR needs to be assessed in larger
prospective trials and registries.
Hemodynamic instability was uncommon but
tolerated after BASILICA (7%) and resolved promptly
with TAVR. Another concern is the VARC-2 major
vascular complication rate (20%), which was higher
than seen in contemporary registries—4.1% in for
SAPIEN 3 in the SOURCE 3 trial (20) and 6.5% for
Evolut R in the FORWARD trial (21). This may reflect
the smaller anatomies in patients at risk of coronary
obstruction, with increased the risk of vascular com-
plications. All were independently adjudicated as
related to TAVR and not related to BASILICA. Small
anatomies are also reflected in the high post-
procedural gradients and higher rates of severe and
moderate prosthesis-patient mismatch compared
with those recently reported from the TVT (Trans-
catheter Valve Therapy) registry (12% and 25%,
respectively) (22) but similar to those seen in the
Valve-in-Valve registry (23). Overall, the results of
this early feasibility study suggest an acceptable early
safety profile for BASILICA in high-risk subjects.
Subclinical leaflet thrombosis rates (11%) were
similar to those in observational registries (13% in
the RESOLVE (Assessment of Transcatheter and
Surgical Aortic Bioprosthetic Valve Thrombosis and
Its Treatment With Anticoagulation) and SAVORY
(Subclinical Aortic Valve Bioprosthesis Thrombosis
Assessed With 4D CT) registries (24) and clinical
trials (14% in Low Risk TAVR trial) (3). Interestingly,
no HALT was seen in TAVR leaflets adjacent to
lacerated aortic leaflets. This generates a testable
hypothesis that BASILICA might reduce subclinical
leaflet thrombosis by promoting sinus washout and
reducing stasis (25).
There is an unmet clinical need for high surgical
risk patients at risk of coronary obstruction fromownloaded for Anonymous User (n/a) at MEDSTAR HEALTH VNA INC fr
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Transcatheter ElectrosurgTAVR. Coronary protection with pre-positioned
guidewires and coronary stents is potentially haz-
ardous (7). “Snorkel” stents, implanted to create a
channel between TAVR valve and coronary sinus, are
at risk of deformation and thrombosis due to constant
mechanical pressures from the TAVR valve and poor
blood flow in the obstructed neosinus. Future coro-
nary access may be compromised, and patients are
committed to long-term thromboprophylaxis and
potential late bleeding complications. Furthermore,
absence of coronary obstruction while a guidewire is
down the coronary artery may be falsely reassuring,
and the coronary artery may obstruct once the leaflet
is unpinned after guidewire withdrawal. Addition-
ally, coronary obstruction may occur remotely from
the index procedure (7).
PROCEDURE LIMITATIONS. High-quality CT image
acquisition is required to assess for a calcium-free
target at the base of the leaflet for guidewire
traversal. If there appears to be confluent leaflet cal-
cium, there may be a low likelihood of success, and if
BASILICA is attempted, we recommend it is only tried
briefly and by an experienced operator.
Careful procedure planning and image-guided
execution is required to align the laceration in front
of the coronary artery ostium. If the laceration is not
aligned, obstruction may occur from a portion of the
leaflet.
The poor correlation between predicted and post
hoc observed VTC probably reflects unpredictable
TAVR implantation characteristics (e.g., device se-
lection, implantation depth, canting angle, and de-
vice flaring), as well as variable surgical bioprosthesis
characteristics (leaflet material, frame geometry, and
frame expansion after TAVR).
STUDY LIMITATIONS. Further study is required to
enhance the specificity of coronary obstruction risk
prediction. Coronary obstruction is a rare complication
and it is possible that some of the subjects undergoing
BASILICA may not have obstructed their coronary ar-
teries with standalone TAVR. Indeed, 1 subject did not
obstruct their coronary artery after failed BASILICA.
Acknowledging these limitations, all subjects were at
high risk of coronary obstruction from TAVR by
currently available criteria, as determined by the
central eligibility committee based on pre-procedural
CT imaging including simulation of the transcatheter
heart valve and assessing the relation to the coronary
arteries and aortic sinuses. Indeed, the predicted risk
correlated well with observed measurements on
follow-up CT. In this study, the coronary obstructionom ClinicalKey.com by Elsevier on July 05, 2019.
 ©2019. Elsevier Inc. All rights reserved.
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PERSPECTIVES
WHAT IS KNOWN? Coronary artery obstruction from the re-
sidual diseased aortic leaflets is a rare and devastating compli-
cation of TAVR. BASILICA is a transcatheter technique that slices
the aortic valve leaflets to prevent coronary obstruction, with
proof of principal demonstrated in animal and first-in-human
studies.
WHAT IS NEW? The BASILICA IDE clinical trial demonstrated
feasibility in native and bioprosthetic aortic valves, with an
acceptable safety profile, and appeared effective in preventing
coronary artery obstruction in subjects at high risk.
WHAT IS NEXT? This early feasibility study should instigate
larger prospective studies to further assess the safety of
BASILICA as an adjunct to TAVR. BASILICA may be offered to
enable TAVR in patients at risk of coronary artery obstruction at
experienced centers.
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1251risk appeared to be underestimated in SAPIEN 3 valves
and native annuli. In a few cases of Evolut valves
implanted into bioprostheses, expansion of the valve
was less than predicted.
No control arm was possible in this study as TAVR-
related coronary obstruction has a high mortality and
these subjects had no suitable alternatives that could
provide clinical equipoise for a randomized
comparison.
This study was designed to test early feasibility.
Whether there are excess cardiovascular events
related to BASILICA need to be addressed in larger
studies.
FUTURE DIRECTIONS. Further registry data are
required to increase the sensitivity and specificity of
coronary artery obstruction risk prediction, including
analysis of high-quality pre- and post-procedure CT.
This trial should inform further study. We do not
believe that we have equipoise to compare BASILICA
against alternatives such as snorkel stenting. One
possible investigation might be a comparison of
BASILICA and TAVR against surgical aortic valve
replacement among patients at high or extreme sur-
gical risk.
Dedicated catheter tools may make BASILICA into a
relatively easy and swift adjunct to TAVR. At present,
the BASILICA procedure is a novel technique and
should be limited to high-volume centers and be
performed with appropriate education and
proctoring.
The method may be used to lacerate bicuspid
aortic leaflets (Bi-SILiCA [Bicuspid Scallop Inten-
tional Laceration to Circularize the Annulus]) and
may enhance transcatheter heart valve circularity
and improve TAVR outcomes in this difficult cohort
of patients. We have reported this technique previ-
ously (26) and it needs to be evaluated in a pro-
spective trial.
CONCLUSIONS
In subjects at high risk of coronary artery obstruction
from TAVR, BASILICA demonstrated feasibility in
both native and surgical bioprosthetic valves in a
prospective, independently adjudicated, IDE early
feasibility trial. Hemodynamic compromise was rare,
and resolved with TAVR. Safety was acceptable and
needs to be confirmed in larger studies. BASILICA
appears effective in preventing coronary obstruction
from TAVR in subjects at high risk.Downloaded for Anonymous User (n/a) at MEDSTAR
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The BASILICA Trial: A prospective multi-centre cohort study of intentional leaflet 
laceration before transcatheter aortic valve implantation (TAVI) to prevent 
coronary obstruction 
Study selection criteria 
Inclusion Criteria  
• Adults age ≥ 21 years  
• High or extreme risk of surgical aortic valve replacement according to the local 
multidisciplinary heart team  
• Undergoing TAVI for valve-in-valve or native aortic valve failure (“on-label” 
TAVI)  
• Deemed likely to suffer coronary artery obstruction from TAVI according to 
multidisciplinary heart team  
• Concurrence of the study eligibility committee  
Exclusion criteria  
• Subjects unable to consent to participate, unless the subject has a legally 
authorized representative  
• Excessive target aortic leaflet calcification or masses on baseline CT  
• Survival despite successful procedure expected < 12 months  
• Planned concurrent valve intervention in the same setting (such as 
transcatheter mitral valve therapy or paravalvular leak therapy)  
• Subjects unwilling to participate or unwilling to return for study follow-up 
activities.  
• Pregnancy or intent to become pregnant prior to completion of all protocol 
follow-up procedures  
Trial endpoints 
Primary efficacy endpoint  
The primary efficacy endpoint is procedure success (measured at exit from the 
catheterization laboratory). All of the following must be present:  
• Successful BASILICA traversal and laceration of the intended aortic leaflet; and  
• Absence of procedural mortality; and  
• Successful access, delivery, and retrieval of the BASILICA device system; and  
• Successful TAVI device implantation; and  
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• Absence of acute life-threatening ostial coronary artery obstruction (by 
immediate hemodynamics, by angiography, and by iFR <0.89 if obtained)  
• Freedom from emergency cardiac surgery or reintervention related to the 
BASILICA TAVI procedure, including attempted implantation of coronary artery 
stents to treat TAVI-induced coronary artery obstruction.  
Additional details about primary endpoint  
Valve post-dilatation is not considered unplanned re-intervention. When pre-
positioned coronary artery stents are not able to be retrieved, they may be 
implanted without impacting the primary endpoint.  
Primary safety endpoint  
The primary safety endpoint is freedom from major adverse clinical events 
(MACE) according to VARC-2 at 30days: 
• All-cause mortality 
• All stroke (disabling and non-disabling) 
• Life-threatening bleeding 
• Acute kidney injury—Stage 2 or 3 (including renal replacement therapy) 
• Coronary artery obstruction requiring intervention 
• Major vascular complication 
• Valve-related dysfunction requiring repeat procedure (BAV, TAVI, or SAVR) 
Additional endpoints 
• Technical success, defined as clinical success irrespective of coronary artery 
stenting  
• Clinical success without stroke, as determined by site physicians  
• Technical success of BASILICA only (delivery and removal of BASILICA catheter 
equipment, traversal, and laceration of intended aortic leaflet)  
• Coronary artery obstruction measured as instantaneous wave-free pressure 
ratio (iFR) or related measurements using a solid-state pressure-transducer 
guidewire, if measured  
• Survival to discharge, to 30d, and to 12mo  
• Neurological events as reported by the site clinicians  
• Access and vascular complications  
• Peri-procedural and spontaneous acute myocardial infarction  
• Pericardial effusion or tamponade  
J.M. Khan Transcatheter Electrosurgery 142
• VARC-2 bleeding complications  
• Acute kidney injury  
• Freedom from hemolytic anemia related to BASILICA TAVI  
• BASILICA Device or Procedure related technical failure: acute embolism, mitral 
valve injury, traversal into left atrium, coronary artery injury induced by 
BASILICA, etc.  
• Rotational orientation of transcatheter heart valve commissures with regard to 
coronary artery ostia  
• Hemodynamic instability caused by BASILICA before TAVI  
• TAVI thrombosis on CT or echocardiography during follow-up  
• Endocarditis during follow-up  
• Outcomes for laceration of native versus surgical aortic valves, for single versus 
double scallop laceration, and for procedures with versus without bioprosthesis 
intentional overexpansion  
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Enrolling Sites 






Atlanta Vasilis Babaliaros 10 Subjects 
University of 
Washington 
Seattle Danny Dvir 10 Subjects 
Henry Ford 
Hospital Systems 
Detroit Adam Greenbaum 





Washington DC Toby Rogers 3 subjects 
Supplement Table 6 Coronary obstruction risk factors and BASILICA technical 
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Supplement Figure 5 Procedure Hemodynamics 
Mean arterial pressures for each patient is shown at baseline, before and after (solo 
or doppio) laceration, and after TAVI for native and bioprosthetic valves. Small 
decrements in mean arterial pressures were seen more often in native aortic valves. 
Only two subjects required transient increase in vasopressor support prior to TAVI. 
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Chapter Summary 
BASILICA is a technique developed using transcatheter electrosurgery tools. Using 
guidewires, microcatheters, guiding catheters and non-ionic 5% dextrose infusion, 
charge is concentrated to first perforate the base of the aortic valve leaflet then 
lacerate the leaflet from base to tip. The split leaflet splays away from the coronary 
artery ostium when a transcatheter valve is implanted, maintaining flow to the 
coronary arteries.  
Benchtop tests were performed on bioprosthetic aortic valves with bovine 
pericardial leaflets. The valves were submerged in a saline bath and traversed and 
cut with an electrified guidewire, demonstrating feasibility of transcatheter 
electrosurgery in these valves, and confirming leaflet splay after transcatheter valve 
implantation within the bioprosthetic valves. The procedure was tested in five 
anaesthetized pigs demonstrating central base to tip laceration in all animals. An 
important lesson about snaring high in the LVOT to prevent inadvertent mitral 
chordae laceration was learnt, as well as careful guidewire positioning for traversal. 
BASILCA was performed on a compassionate basis in seven patients with aortic 
valve failure in either native or bioprosthetic valves who were at prohibitive 
surgical risk. All had prohibitive risk of coronary artery obstruction from TAVI as 
predicted on pre-procedure CT. All patients had successful leaflet traversal and 
laceration, with no resulting coronary artery obstruction or stroke. No patient had 
hemodynamic compromise from BASILICA. In this early experience, back-up stents 
were pre-positioned in the coronary artery in case of obstruction. None were 
required for coronary obstruction, but one was deployed as it could not be retrieved 
past the transcatheter valve.  
The procedure was then investigated in the prospective single arm NHLBI BASILICA 
IDE trial, with independent end point adjudication and core laboratory analysis of 
images. 30 subjects at high or prohibitive risk for surgical aortic valve replacement 
and high risk of coronary artery obstruction from TAVR were enrolled. BASILICA 
traversal and laceration was successful in 28 out of 30 patients. No patient had 
coronary artery obstruction of required re-intervention. There was one death and 
one disabling stroke at 30 days.  
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In developing this novel procedure and investigating it in a carefully designed 
clinical trial, the hypothesis that aortic valve leaflets can be precisely lacerated using 
transcatheter electrosurgery, and that controlled laceration may prevent blood flow 
obstruction following transcatheter valve implantation has been demonstrated. 
Accordingly, the second specific aim of this thesis has been addressed.    
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CHAPTER 5. FUTURE DIRECTIONS 
LAMPOON has been demonstrated when using a transcatheter aortic valve (Sapien 
3, Edwards Lifesciences) in the mitral position, anchored in native annular 
calcification or a surgical bioprostheses. Its compatibility with dedicated mitral 
devices remains untested. Many dedicated transcatheter mitral valves in their 
current iteration have a complete outer fabric covering which would not allow 
blood flow despite anterior mitral leaflet laceration. However, dynamic left 
ventricular outflow tract obstruction from systolic anterior motion of the mitral 
valve leaflet may be prevented by LAMPOON.  
LAMPOON has been demonstrated in an anaesthetized pig predicted to have LVOT 
obstruction following Tendyne valve implantation(104). The Tendyne bioprosthetic 
mitral valve system is a tri-leaflet pericardial valve mounted in a coaxial dual-frame 
covered stent, fixed using an adjustable apical tether. The naïve pig had SAM after 
initial Tendyne valve implantation with an LVOT gradient of 26mmHg. Following 
retrieval of the Tendyne valve, LAMPOON was performed and the valve re-
implanted. There was no SAM and the LVOT gradient reduced to 3mmHg [Figure 
39].  
LAMPOON with Tendyne valve implantation was performed in a patient on 
compassionate basis(104). The patient had risk factors for developing SAM and 
LVOT obstruction following Tendyne valve implantation based on his long anterior 
mitral valve leaflet, redundant chordae and acute aorto-mitral angulation. 
LAMPOON was performed and the Tendyne valve implanted without SAM or LVOT 
obstruction [Figure 39].  
Like splitting a sail, splitting the anterior leaflet may prevent Bernoulli forces from 
dragging the leaflet towards the septum, which in turn could obstruct outflow and 
impair prosthetic sealing. However, LAMPOON can only alleviate LVOT obstruction 
from a reduced neo-LVOT, caused by valves that protrude towards the septum, in 
transcatheter valves with uncovered stent cells across the LVOT.  
BASILICA has been performed in native valves and in bioprosthetic surgical valves. 
The effectiveness of BASILICA in failed transcatheter heart valves, where there is 
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excess leaflet material and an enclosing cage, remains untested. It is possible more 
extensive leaflet excision is required in these cases. Benchtop experiments with 
some common transcatheter heart valves demonstrate variability in leaflet splay, 
partly due to the external cage restricting leaflet splay and partly due to increased 
leaflet redundancy in second generation valve designs [Figure 40].  
LAMPOON and BASILICA are performed using marketed devices off-label. Dedicated 
catheters and guidewires should simplify the procedure. Dedicated electrosurgery 
equipment may also reduce the variability in current losses in the present set-up. In 
its current form, transcatheter electrosurgery has been used to make simple linear 
cuts. Dedicated cutting and capture devices, and improved imaging, may enable 
more complex percutaneous resections and manipulations.  
One relatively simple application is to enable TMVI after mitral valve repair. Edge-
to-edge mitral valve repair with an Alfieri Stitch or MitraClip device may prohibit 
future transcatheter mitral valve replacement. Cutting the Alfieri stitch or MitraClip 
away from its anterior leaflet attachment has been demonstrated to create a single 
orifice where TMVI can be performed(121). The clip or stitch may be accessed 
antegrade via a transseptal approach or retrograde from the femoral arteries. 
Catheters are positioned in each mitral valve orifice and guidewire is passed from 
one and snared from the other. The Flying V is positioned along the anterior mitral 
valve leaflet edge of the clip or stitch, which is lacerated during 1-5s of 
radiofrequency energy application at 70W with a continuous dextrose infusion. The 
clip or stitch remains on the posterior mitral valve leaflet and TMVR is performed, 
pinning the liberated device to the posterior ventricular wall. 
Finally, data on both LAMPOON and BASILICA are now being collected as part of the 
STS/ACC TVT Registry in the United States, which will provide real world data on a 
larger number of patients.  
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FIGURE 39 LAMPOON in Tendyne 
A) Transthoracic echocardiogram of Tendyne implantation without LAMPOON in a 
pig demonstrating SAM causing LVOT obstruction and anterior PVL. B) Following 
LAMPOON, SAM, LVOT obstruction, and PVL are abolished. Transthoracic (C) and 
transesophageal (D) echocardiogram following LAMPOON and Tendyne valve 
implantation in a patient showing a split anterior leaflet and no SAM. E) CT with 
motion artefact in diastole with long anterior mitral leaflet with close 
approximation to the interventricular septum and acute aorto-mitral angulation. F) 
Post procedure CT in systole with no evidence of LVOT obstruction. LV=Left 
Ventricle; LA=Left Atrium; Ao=Aorta 
  
J.M. Khan Transcatheter Electrosurgery 151
FIGURE 40 Splay characteristics after benchtop BASILICA and TAVR-in-TAVR in 
four common TAVR devices  
The orifices created by BASILICA-splayed leaflets are depicted in red. The figure 
shows that early-generation TAVR devices (Sapien XT and Lotus) exhibited wider 
splay angles (50±11 vs 17±5 degrees, Student t-test p<0.01) and slit width (9±2 vs 
5±2, p=0.05) after BASILICA in vitro than newer-generation TAVR devices (Sapien 3 
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CHAPTER 6. SUMMARY AND CONCLUSIONS 
This thesis has attempted to achieve the specific aims set out. It demonstrates that 
the mitral and aortic valve leaflets can be precisely lacerated using transcatheter 
electrosurgery in animals and subsequently in patients. This laceration prevented 
obstruction in the left ventricular outflow tract in the case of LAMPOON and 
coronary artery obstruction in the case of BASILICA in patients predicted to be at 
high risk of obstruction.  
Previous applications of transcatheter electrosurgery were limited to making 
pinhole perforations with the tip of an insulated guidewire. For more extensive 
tissue laceration, controlled targeted directional radiofrequency delivery is 
required, with greater care to avoid charring and coagulation during longer and 
higher energy applications. Simulation and benchtop experiments for transcatheter 
electrosurgery tissue laceration demonstrated feasibility of this technique. Selective 
denudation of the kinked inner surface of a guidewire with catheter insulation and 
blood displacement with non-ionic flush was demonstrated to be optimal for charge 
concentration for cutting.  
For the development of two novel procedures, the technique was investigated in 
anesthetised pigs. Reproducible midline laceration was demonstrated in these 
experiments, in line with the left ventricular outflow tract in the case of LAMPOON 
and coronary artery ostia in the case of BASILICA.  
Both procedures were translated into clinical care in selected high-risk patients 
with no other options on a compassionate basis.  
Both procedures were studied prospectively in patients in FDA approved 30 patient 
early feasibility clinical trials.  
In the LAMPOON trial, eligible patients were suitable for transcatheter mitral valve 
replacement except for prohibitive risk LVOT obstruction as predicted by CT. 
LAMPOON traversal and laceration was successful in all patients. LVOT obstruction 
was seen in three patients who were at risk from LVOT obstruction from the 
transcatheter heart valve skirt, which is an important exclusion criterion, and one 
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patient with a mid-leaflet laceration. The other patients did not demonstrate LVOT 
obstruction despite the high predicted risk without LAMPOON. 
In the BASILICA trial, eligible patients were suitable for transcatheter aortic valve 
implantation except for the prohibitive risk of coronary artery obstruction as 
predicted by CT. BASILICA traversal and laceration was successful in 93% of 
patients. No patient developed coronary artery obstruction despite the high 
predicted risk without BASILICA.  
These techniques enabled transcatheter valve replacement in otherwise ineligible 
patients. These patients all high risk of mortality with valve replacement surgery 
and so had no other options for treatment. LAMPOON and BASILICA have been 
included in the STS/ACC TVT Registry in the United States, which will provide 
valuable data in a large number of patients in the real-world setting.  
Transcatheter electrosurgery takes us one step closer to bespoke “transcatheter 
surgery” for patients.  
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